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GENERAL INTRODUCTION 
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General background 
Communication between cells in the brain involves the release of 
neurotransmitters, which bind to specific receptors on the target cells. 
Neurotransmitters are released by neurons and enable the transmission of a 
signal from one neuron to another neuron or to non-neuronal cells such as 
glia cells. Most connections between these cells are mediated by so-called 
synapses. Over the past few decades, more than 100 neurotransmitters 
(and neuromodulators) have been identified in the human brain, which 
interact with an even larger number of receptor subtypes. Two of these 
neurotransmitters are the monoamines dopamine (DA) and serotonin (5-
HT). Although the actual number of dopaminergic and serotonergic neurons 
is small, they are involved in a variety of physiological, behavioral, cognitive 
and emotional processes. Moreover, DA and 5-HT have been implicated in 
the pathogenesis of neurological and psychiatric disorders such as 
depression, schizophrenia, anxiety, addiction and Parkinson’s disease and 
most drugs used for the treatment of these syndromes involve the 
modulation of these neurotransmitter systems. However, their exact role in 
health and disease is not completely known. 
 
Imaging techniques such as positron emission tomography (PET), single 
photon emission computed tomography (SPECT) and functional magnetic 
resonance imaging (fMRI) provide a useful method to obtain insight in the 
living brain. With these imaging methods, information can be obtained on 
biological parameters such as receptor density, neurotransmitter 
concentration or neuronal activation. These techniques can be used to 
study the (dys)function of neurotransmitter systems and may enable the 
measurement of pharmacokinetic (e.g. receptor occupancy) and 
pharmacodynamic (functional) aspects of (psychopharmacological) drugs. 
Several studies have reported correlations between these biological 
parameters and cognitive functioning or subjective effects such as anxiety, 
depression or euphoria. These findings may improve the knowledge of the 
neural mechanisms underlying (drug-induced) changes in behavior. 
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This thesis focuses on the examination of PET methods that are used to 
measure drug-induced changes in extracellular 5-HT and DA transmission. 
The first studies concentrate on methods that are used to assess changes 
in 5-HT and DA concentration. In the last study we have investigated the 
effect of a dopaminergic drug challenge on regional brain activation. In 
future studies such measurements may be used to obtain information on the 
mechanism of action or therapeutic potential of drugs in development. In 
addition, these methods may be useful to assess dopaminergic or 
serotonergic abnormalities in psychiatric patients. 
 
Below, a short introduction will be given of the dopaminergic and 
serotonergic neurotransmitter systems. Emphasis will be placed on the 
dopaminergic D2 receptor and serotonergic 5-HT1A receptor, since these 
receptors have been imaged in our studies. Subsequently, the PET 
technology and modeling methods will be described. Finally, some 
examples will be given of human studies that have used PET to study 
dopaminergic and serotonergic neurotransmitter function, often through the 
administration of psychopharmacological challenges.  
The dopaminergic system 
History 
It was previously believed that DA was only a precursor of another 
neurotransmitter, noradrenaline. In the late 1950s however, it was shown 
that DA was concentrated in other areas of the brain than noradrenaline, 
which led to the conclusion that DA is a neurotransmitter in itself. Soon, the 
involvement of DA in motor behavior, especially in Parkinson’s disease, was 
discovered. Subsequently, its role in normal brain function and psychiatric 
disorders, such as schizophrenia was revealed (Svensson and Mathe 
2002). 
Anatomy 
The dopaminergic neurons that innervate the forebrain are located in two 
nuclei in the brainstem, the substantia nigra (SN) and ventral tegmental General introduction 
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area (VTA). The dopaminergic neurons in the SN project primarily to the 
dorsal striatum (nigrostriatal pathway) whereas the neurons of the VTA 
project most strongly to the limbic and cortical areas such as the nucleus 
accumbens, septum, amygdala, hippocampus, olfactory bulb, prefrontal and 
cingulate cortex (mesolimbocortical system) (Majovski et al. 1981; 
Svensson and Mathe 2002; Wise 2004). A third group of dopaminergic 
neurons are localized in the hypothalamus and project to the pituitary gland 
(tuberoinfundibilar hypophyseal system) (Figure 1). 
Physiology 
DA is formed by the hydroxylation and decarboxylation of the amino acid 
tyrosine (Wurtman et al. 1980). It is synthesized in the cytoplasm and 
thereafter transported into the secretory compartment for regulated 
exocytotic release. After release, the action of the transmitter is terminated 
by reuptake
 in the presynaptic nerve terminals via the DA transporter (DAT). 
Thereafter, the transmitter may be stored in the synaptic vesicles for future 
use, or metabolized and inactivated by oxidation
  by monoamine oxidase 
(MAO). DA may also be taken up by glial cells, followed
 by O-methylation by 
catechol-O-methyltransferase (COMT) and/or
 oxidation by MAO (Brannan et 
al. 1995; Karhunen et al. 1995; Paterson et al. 1995). 
 
The impulse activity of dopaminergic neurons can be characterized by two 
different modes of firing (Svensson and Mathe 2002): a single spike mode 
and a bursting mode. Burst firing consists of a transient high frequency 
discharge of multiple action potentials and induces massive synaptic DA 
release, which is rapidly removed by reuptake in the cell. In contrast, spike-
like firing is a relatively regular, low frequency firing pattern and modulates 
tonic extrasynaptic DA levels that are less influenced by reuptake (Floresco 
et al. 2003; Svensson and Mathe 2002). 
Receptors 
Five distinct DA receptors have been isolated, which, on the basis of their 
biochemical and pharmacological properties, can be subdivided into two 
subfamilies: D1-like (D1 / D5) and D2-like (D2, D3, and D4). D1 receptors are 
distributed in the striatum and also in cortical areas. The D2 receptors are 
mainly found in the striatum, including the nucleus accumbens and to a Chapter 1 
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lesser extent in cortical areas, the amygdala, hippocampus and thalamus. 
D3 receptors are preferentially found in the nucleus accumbens and Islands 
of Celleja. The D4 receptors are highly expressed in limbic cortical areas, 
the amygdala, hippocampus, hypothalamus and low levels are found in the 
striatum. D5 receptors are found on thalamic, hypothalamic and 
hippocampal neurons. The D2 receptors are located postsynaptically in the 
terminal fields and also serve as autoreceptors in these areas and on the 
VTA and SN neurons (Svensson and Mathe 2002; Vallone et al. 2000). 
Function 
The dopaminergic system is involved in the regulation of movement, 
cognitive functions such as attention, stress and the rewarding and 
reinforcing effects of certain stimuli (Le Moal and Simon 1991; Spanagel 
and Weiss 1999; Ungless 2004; Wise 2004), and has also been implicated 
in the pathogeneses and treatment of a variety of psychiatric disorders, 
such as schizophrenia, Parkinson’s disease, depression and addiction 
(Kapur and Mamo 2003; Leenders 2002; Naranjo et al. 2001; Volkow et al. 
2002a). Most knowledge has been obtained on the function of D1 and D2 
receptors. Interactions between these receptors have been implicated in the 
regulation of voluntary movements and probably also in reward processing 
and cognitive function (Ikemoto et al. 1997; Vallone et al. 2000). 
The serotonergic system  
History 
The pharmacological effects of 5-HT were first described during the 1930s 
and in 1949 the structure of 5-HT was reported. Shortly thereafter, 5-HT 
was found to be present in different regions of the mammalian brain which 
led to the proposal of 5-HT as a neurotransmitter (Jacobs and Azmitia 
1992). 
Anatomy 
The majority of serotonergic cell bodies that innervate the brain are located 
in the raphe nuclei in the brainstem: the dorsal raphe (DRN) and median General introduction 
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raphe (MRN). The serotonergic neurons project to large parts of the brain. 
The DRN projects preferentially to the cortex and striatum, whereas the 
MRN innervates structures such as the septum, hypothalamus and dorsal 
hippocampus. Several brain structures like the amygdala and ventral 
hippocampus are innervated by the DRN as well as the MRN (Jacobs and 
Azmitia 1992; Pineyro and Blier 1999) (Figure 1). 
Physiology 
5-HT is formed by the hydroxylation and decarboxylation of the essential 
amino acid tryptophan (Wurtman et al. 1980). It is predominantly 
synthesized in the cytoplasm of the nerve terminals and thereafter 
accumulated into a secretory compartment for regulated exocytotic release. 
After release, the action of the neurotransmitter is terminated by an efficient 
transporter (SERT). The SERT is mainly located on serotonergic axons and, 
possibly, a small proportion is present on glia cells. After reuptake in the 
neuron, 5-HT is degraded by monoamine oxidase or stored in the synaptic 
vesicles for future use (Pineyro and Blier 1999; Shih et al. 1999; Svensson 
and Mathe 2002; Zhou et al. 1998). 
 
Most serotonergic neurons fire with a spontaneous, slow, regular discharge 
pattern. The activity is at its highest during active waking and low during 
sleep (Jacobs and Azmitia 1992; Pineyro and Blier 1999; Svensson and 
Mathe 2002). More recent, a subpopulation of serotonergic neurons was 
found that displays repetitive burst firing activity which may result in 
facilitation of synaptic 5-HT release (Gartside et al. 2000). 
Receptors 
Over the last 20 years, the serotonergic receptors have been classified into 
seven receptor families on the basis of their structural and functional 
properties: 5-HT1-5-HT7. These receptor types comprise a large number of 
different subtypes: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 
5-HT2C, 5-HT3, 5-HT4, 5-HT5A, 5-HT5B, 5-HT6, and 5-HT7. The 5-HT1A 
receptor is located presynaptically in the raphe nuclei and postsynaptically 
in the terminal areas such as the frontal cortex, hippocampus, amygdala, 
thalamus, hypothalamus, and septum and is barely detectable in the 
striatum and cerebellum. In the raphe nuclei the 5-HT1A receptor acts as an Chapter 1 
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autoreceptor, and regulates the release of 5-HT. The other receptor 
(sub)types are also distributed in highly distinct brain areas, such that 
individual brain regions express their own patterns of serotonergic receptor 
subtypes (Barnes and Sharp 1999; Saxena et al. 1998a). 
Function 
The serotonergic system is involved in the control of mood and numerous 
behavioral, cognitive and physiological processes. It is also implicated in 
psychiatric disorders such as depression and anxiety (Barnes and Sharp 
1999; Jacobs and Azmitia 1992; Pineyro and Blier 1999. The 5-HT1A 
receptor has a role in processes such as sexual behavior, sleep, 
aggression, learning and memory and homeostatic mechanisms (Barnes 
and Sharp 1999). Several studies also report the possible involvement of 
this receptor in psychiatric and neurodegenerative disorders (Bantick et al. 
2001, Hjorth et al. 2000, Oosterink et al. 1998). 
 
 
 
 
Figure 1: Dopaminergic and serotonergic pathways in the human brain. AMG: 
amygdala, CAU: caudate nucleus, CG: cingulate cortex, CRB: cerebellum, CTX: 
cortical regions, CVO: circumventricular organs, HIP: hippocampus, HYP: 
hypothalamus, NAC: nucleus accumbens, OLF: olfactory bulb, PAG: 
periaqueductal grey, PFC: prefrontal cortex, PIT: pituitary gland, PUT: putamen, 
RN: raphe nuclei, SEP: septum, SN: substantia nigra, SPC: spinal cord, THA: 
thalamus, VTA: ventral tegmental area. Adapted from Manter and Gatz’s 
Essentials of Clinical Neuroanatomy and Neurophysiology, 10th edition, FA 
Davis Company, Philadelphia, 2003. General introduction 
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Receptor characteristics 
G-protein coupled receptors 
The D2 and 5-HT1A receptors are both coupled to so-called G-proteins. The 
G-proteins are membrane associated proteins which, after activation, 
transmit the signal into the cell. This process finally generates the cellular 
response. Those molecules that produce cellular responses after binding to 
the receptor are called agonists. These include the neurotransmitter itself 
and drugs which mimick the activity of the natural neurotransmitters at the 
receptor. Antagonists are molecules that block the action of agonists. Both 
the neurotransmitter itself and receptor-binding drugs can behave as either 
agonists or antagonists. The interaction of agonists with G-protein coupled 
receptors has been described by the ternary complex model. This model 
involves the interaction between a ligand (agonist or antagonist) and its 
receptor, and may be described using the law of mass action: Receptor + 
Ligand ↔ Receptor-Ligand complex. The law of mass action predicts the 
fraction of receptors that are bound as a function of ligand concentration. In 
the ternary complex model, agonists have a higher affinity for the 
receptor/G-protein complex, compared to the uncoupled receptor. This 
leads to the formation of the ternary complex, consisting of the 
agonist/receptor/G-protein. The intracellular effect is exerted after formation 
of this ternary complex. The observation that G-proteins can induce cellular 
responses without agonist binding to the receptor (constitutive activity) led 
to the extended ternary complex model. In this model the receptors can 
spontaneously convert between the active and inactive conformations and 
the different ligand receptor G-protein interactions are in equilibrium. The 
activated receptor is able to couple to the G-protein and constitutive activity 
is caused by the active receptor G-protein complex. Agonists preferentially 
bind to the active conformation, thereby stabilizing both the active receptor 
conformation and the active receptor G-protein complex. This leads to an 
increase in the cellular activity. The cellular activation is prevented by 
antagonists since these molecules have an equal affinity for the different 
receptor states. In addition to G-protein coupling and inducing cellular 
responses, receptors have been found to demonstrate other functions such 
as internalization. This may be coupled to receptor activation, but ligands Chapter 1 
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may also induce such receptor processes without cellular activation 
(Kenakin 2002; Lefkowitz et al. 1993). 
 
Usually, in PET research the data are described by receptor high and low 
affinity conformational states. It is assumed that the high affinity state is the 
active receptor that can either be coupled or uncoupled to the G-protein and 
the low affinity state is the inactive receptor. Antagonists will bind with equal 
affinity to either state whereas agonists will preferentially bind to the high 
affinity state (Gozlan et al. 1995, Khawaja 1995, Mongeau et al. 1992, 
Nénonéné et al. 1994, Watson et al. 2000; Wreggett and Seeman 1984). 
The 5-HT1A and D2 receptor 
As indicated above, the 5-HT1A and D2 receptors can exist in high and low 
affinity conformational states. The affinity of DA for the D2 receptor in the 
high affinity state is approximately 10 nM and for the low affinity state 
between 100 and 1000 nM (Fisher et al. 1995; Sasaki et al. 2002). The 
affinity of 5-HT for the 5-HT1A receptor in the high affinity state is 
approximately 5 nM and for the low affinity state around 250 nM (Watson et 
al. 2000). The 5-HT1A and D2 receptors are located both within the synapse 
and extrasynaptically (Azmitia et al. 1996, Riad et al. 2000; Yung et al. 
1995). It has been suggested that the extrasynaptic receptors are activated 
by the low, ambient concentration of the neurotransmitter, which is 
permanently maintained in the extracellular space (Riad et al. 2000; Yung et 
al. 1995). To act effectively at a distance and at low concentration, the 
neurotransmitter requires high affinity receptors. Therefore it can be 
assumed that in the extrasynaptic compartment, a large proportion of 
receptors is in the high affinity state (Vizi 2000; Zoli et al. 1999). In contast, 
the neurotransmitter concentration is much higher in the intrasynaptic 
space, especially immediately after release (Fisher et al. 1995; Vizi 2000). 
Therefore it is supposed that intrasynaptically the proportion of high affinity 
receptors is relatively low (Vizi 2000). General introduction 
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PET 
General 
The first PET camera was built in the 1970s and during the following 
decades, there has been a rapid increase in the number of PET studies. 
Using PET, information can be obtained on biological parameters such as 
receptor density, neurotransmitter release, regional cerebral blood flow 
(rCBF) and glucose metabolism. The last two parameters serve as an index 
for neuronal activation. All these processes are visualized by injecting tracer 
amounts of molecules labeled with short-lived radioisotopes (radiotracer, or 
radioligand in the case of receptor binding studies). After injection, the 
radiotracer accumulates in the tissue to be studied and the distribution of 
the radiotracer is recorded with a PET camera, as follows: The radioactive 
atoms of the radiotracer decay by emission of a positron (anti-electron). 
After emission, the positron immediately annihilates with a nearby electron. 
During this process, the mass of both particles is converted into energy, 
which is emitted as two gamma rays, in opposite directions. These gamma 
rays are detected by the PET camera that consists of a ring of detectors 
positioned around the subject. The camera only registers gamma ray pairs 
that are detected at the same time by two opposing detectors (Figure 2). 
Using advanced electronic equipment and software, this information is 
translated into a three dimensional image showing the location of the 
labeled molecule in the body (brain) as a function of time. Using various 
mathematical models, quantitative measures of the biological parameter of 
interest can be extracted from the PET radioactivity measurements. Several 
radiotracers have been developed for the imaging of receptors, 
neurotransmitter transporters, enzymes and other molecular targets. Three 
commonly used radioisotopes are 
18F, 
11C and 
15O with half-lives of 110, 20 
and 2 minutes respectively. In our study we have used the radiotracers 
[
18F]-MPPF, [
11C]-raclopride and [
15O]-H2O. [
18F]-MPPF is a reversible 
antagonist to the 5-HT1A receptor with an affinity (KD) of approximately 2.8 
nM (Costes et al. 2002). Raclopride is a reversible antagonist to the D2 
receptor and has an affinity of around 1.2 nM (Kohler et al. 1985). [
15O]-H2O 
is used to measure changes in rCBF (see figure 3 for an example of a [
18F]-
MPPF, [
11C]-raclopride and [
15O]-H2O scan). 
 Chapter 1 
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Figure 2: Schematic representation of a PET camera with positron electron 
annihilation. Adapted from http://bioteach.ubc.ca. 
 
 
Figure 3: Examples of [
18F]-MPPF, [
11C]-raclopride and [
15O]-H2O uptake in 
horizontal sections of the human brain. General introduction 
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PET modeling 
Mathematical modeling of PET measurements is needed to relate the 
observed radioactivity to properties of the biological parameters under 
investigation. Most studies in this thesis involve measurements of receptor 
binding. Therefore the following description is focused on models that are 
used to obtain information on receptor characteristics and the interaction of 
the receptor with the radioligand. One of the most used outcome 
parameters in PET receptor binding studies is the so called binding potential 
(BP). The BP corresponds to the ratio of Bmax (total receptor concentration) 
over KD (the equilibrium dissociation constant) and can be derived from the 
Michaelis-Menten equilibrium equation, which is functionally identical to the 
law of mass action. At equilibrium, the association and dissociation of the 
ligand from the receptor are equal, which implies:  
kon*L*R = koff*LR, 
where kon is the association rate constant, koff the dissociation rate from the 
receptor and L, R and LR the free concentration of the radioligand, available 
receptors and ligand receptor complex respectively. In a more 
pharmacologic notation LR is denoted as B, the total receptor concentration 
as  Bmax, the koff/kon ratio as KD and R as Bmax - B. Substitution and 
rearrangement leads to the following equation:  
L K
L B
B
D +
=
* max  
At tracer doses, L is much smaller than KD and the equation simplifies to:  
D K
L B
B
* max =  
or:  
BP
K
B
L
B
D
= =
max  
Thus, at equilibrium and at tracer doses, the BP is equal to the ratio of 
specifically bound ligand to free ligand. In experiments where ligand binding Chapter 1 
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achieves equilibrium during scanning, the BP can be derived directly from 
the PET measurements. In these experiments, the activity in a reference 
region is used to measure free radioligand binding. The reference region 
does not contain specific binding and it is assumed that the nonspecifically 
bound and free ligand concentrations are identical to those in the receptor 
containing region. The nonspecific binding is usually in rapid equilibrium 
with the free compartment and is therefore not distinguished from the free 
radioligand concentration. 
 
In most studies, however, the ligand is administered as a single bolus and 
no true equilibrium is achieved. In these studies, the receptor parameters 
are calculated from the derivation of rate constants which can be estimated 
from the dynamic data. These calculations are based on models that 
describe the ligand distribution using the standard three compartment model 
(two tissue model). In this model, the compartments correspond to 
physiologically separate pools of ligand concentration. The first 
compartment (Cp) defines the radioligand concentration in arterial plasma, 
the second compartment (Cf) the free and nonspecifically bound ligand 
concentration in brain tissue and the third compartment (Cb) the specifically 
bound ligand (receptor compartment). The exchange of the radioligand 
between the different compartments can be described using first order rate 
constants, as long as the radioligand is administered at tracer doses and 
steady-state of the tissue under investigation is maintained. K1 is the 
delivery rate constant from Cp to Cf, k2 defines the rate constant of return of 
Cf to Cp,  k3 is the rate constant of transfer from Cf to Cb and k4 is the 
constant of return from Cb to Cf (Figure. 4). 
 
 
Figure 4: Schematic representation of a compartment model.  General introduction 
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Mathematically, the compartment model can be described as a system of 
linear constant coefficient differential equations. The solution to these 
equations can be written as the "convolution integral" of the input with a 
tissue specific function using the model parameters (rate constants). These 
parameters can then be estimated from the measured PET signal and 
measurements of the input (e.g. plasma). The rate constants can be related 
to the receptor characteristics in the following way:  
() B B k k on − = max 3 *  
off k k = 4  
At tracer doses B << Bmax which leads to the following equation: 
BP
K
B
k
k
D
= =
max
4
3  
When the KD does not change over experiments, the BP is proportional to 
Bmax and as such a desirable outcome measure in receptor binding studies 
(Laruelle et al. 2003; Mintun et al. 1984; Slifstein and Laruelle 2001). 
 
In this thesis, changes in neuronal activity are measured using [
15O]-H2O. 
With this radiotracer, (changes in) rCBF can be quantified. Changes in 
blood flow are coupled to neuronal activity in the following way: An increase 
in brain activity leads to increases in energy consumption. The main energy 
substrate for the brain is glucose, which is delivered through the blood. It 
appears that an increased need for energy per se does not drive the blood 
flow response. A variety of chemical modulators have been proposed to be 
involved in the regulation of blood flow changes. Nevertheless, increases in 
rCBF are found to be coupled to increases in energy demand and thus to 
neuronal activity (Herscovitch 2001). The method that is used to measure 
rCBF is based on a single tissue compartment model (including two 
compartments: blood and tissue). [
15O]-H2O diffuses freely through the body 
and the distribution of this radiotracer is therefore dependent on the local 
blood flow. Chapter 1 
  15 
Other imaging techniques 
Apart from PET, other imaging techniques exist that are used to study 
(drug-induced) changes in neurotransmitter function. The techniques that 
are used in or referred to in this thesis include autoradiography, and in vivo 
methods such as SPECT and fMRI. In autoradiography experiments, the 
distribution of the radiotracer is visualized by exposure of tissue sections to 
a photographic film or plate. The SPECT method is comparable to PET, but 
instead of using positron (dual gamma ray) emitters as in PET, it uses single 
gamma ray emitters. PET has a much higher sensitivity and spatial 
resolution compared to SPECT due to the use of electronic collimation. 
Especially fMRI is increasingly used to study brain function. This technique 
uses the blood oxygen level dependent (BOLD) effect as an indirect 
measure of rCBF, thereby also enabling non-invasive measurements of 
changes in brain activation. Compared to PET, fMRI has a much higher 
temporal and somewhat higher spatial resolution. In addition, fMRI does not 
require the administration of radioactive compounds, thereby enabling 
multiple repeated measurements in individual subjects. However, the signal 
to noise ratio is relatively low since the BOLD response is small and 
variable. To improve the statistical strength of the data, the effect of 
cognitive, motor or sensory stimuli is usually measured using a repetitive 
on-off stimulation pattern. Due to the relatively long duration of the drug 
signal, the generally used design of rapidly alternating periods of rest and 
activation is not appropriate to study acute drug effects. Therefore 
alternative means of signal detection are needed, such as the use of an 
input function based on the drug pharmacokinetics (Bloom et al. 1999; 
Vaidya 2002; Wise et al. 2002) or pharmacodynamics (Anderson et al. 
2002; Vollm et al., 2004) or parametric contrast agents that enhance the 
sensitivity of the signal (Salmeron and Stein 2002). The methods to 
measure acute drug effects are currently under development. In addition, 
fMRI is increasingly used to study the interaction of a drug with task-related 
changes in the fMRI signal. General introduction 
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PET and pharmacological challenges 
PET, especially in combination with a pharmacological challenge, has been 
broadly applied to study neurotransmitter function in healthy subjects or 
patients. Moreover, this method has been widely used in order to assess the 
mechanism of action of psychotropic drugs. The pharmacological challenge 
strategy involves the acute administration of a test compound (drug).  From 
the observed drug-induced changes, information can be obtained on the 
process under investigation. In the studies in this thesis, information on 
dopaminergic or serotonergic transmission and neuronal activation is 
obtained from drug-induced changes in radioligand distribution and rCBF 
respectively. Below, these methods will be described shortly and some 
examples will be given of other studies that have used comparable 
methods. Most studies have used acute drug challenges, some studies, 
however, were performed during chronic treatment. In addition, receptor 
density studies are discussed that do not involve administration of 
pharmacological compounds. Since these methods are commonly used in 
psychiatric research, we decided to include a few examples of these studies 
as well. Functional imaging methods, such as [
15O]-H2O PET, enable the 
investigation of drug-induced effects on task-related changes in brain 
activation. In this thesis we did not study the interaction between drug and 
task effects. However, since this paradigm is also widely applied, a number 
of studies that investigated drug effects on task-related changes in brain 
activation will also be discussed. 
Receptor binding studies 
Receptor density 
Using specific radioligands, the regional distribution of the receptor can be 
measured as well as disease or medication related changes in receptor 
density. These data may provide information on the involvement of a 
receptor in the pathogenesis and treatment of psychiatric disorders. 
Alterations in dopaminergic transmission have been implicated in 
schizophrenia, Parkinson’s disease, addiction and attention deficit 
hyperactivity disorder (ADHD). The idea of dopaminergic dysfunction is 
supported by findings of abnormal D2 receptor densities in drug addicts 
(Martinez et al. 2004; Volkow et al. 2001), schizophrenic patients (Soares Chapter 1 
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and Innis 1999; Talvik et al. 2003) and changes in D2 or DAT binding in 
patients with Parkinson’s disease (Kaasinen et al. 2000; Laihinen et al. 
1995; Nurmi et al. 2000) and ADHD (Jucaite et al. 2005). 
 
The role of the serotonergic system in depression is indicated by studies 
that have shown alterations in 5-HT1A, 5-HT2 and SERT density in untreated 
and treated patients (Bhagwagar et al. 2004; Biver et al. 1997; Drevets et al. 
1999, Massou et al. 1997; Meltzer et al. 2004; Messa et al. 2003; Meyer et 
al. 2001a, 2004; Rabiner et al. 2004; Sargent et al. 2000; Yatham et al. 
2000; Zanardi et al. 2001). Reduced 5-HT1A receptor binding is also found in 
panic disorder (Neumeister et al. 2004). 
Drug occupancy 
The relationship of pharmacokinetic and pharmacodynamic parameters of a 
drug with behavior and therapeutic efficacy can be evaluated in PET 
occupancy studies. The pharmacokinetics of the drug can directly be 
measured using radiotracers that are positron emitting analogues of the 
drug itself. For example, [
11C]-labeled clozapine was demonstrated to enter 
the brain and at tracer doses to have a selective accumulation in striatum 
and frontal cortex (Lundberg et al. 1989). The procedure of labeling drugs 
however, is complex and time consuming, and may have other 
disadvantages (Fowler et al. 1999). Therefore, in most cases, established 
PET radioligands are used that occupy the same receptor as the drug of 
interest. The drug induced change in ligand binding is obtained as a 
measure of drug occupancy. Specifically, this method may be used to relate 
the receptor occupancy of the drug to dose, plasma drug levels and 
treatment response, thereby providing information on therapeutic doses and 
frequency of administration (Gefvert et al. 1998; Grunder et al. 1997; 
Learned-Coughlin et al. 2003; Nordstrom et al. 1992; Rabiner et al. 
2002a,b). At this moment the occupancy of antipsychotics (drugs that are 
used in the treatment of schizophrenia) at the D2 receptor is most 
investigated (Talbot and Laruelle 2002). It has been found that all 
antipsychotic drugs bind to the D2 receptor. Most PET studies have shown 
therapeutic effects at striatal occupancies between 65 to 80% and 
extrapyramidal side-effects at higher doses (Kapur and Seeman 2001; 
Nyberg et al. 1998; Nyberg and Farde 2000; Seeman 2002), although it is 
unknown whether these findings apply to all antipsychotic drugs (Gefvert et General introduction 
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al. 2001; Yokoi et al. 2002). Furthermore, it has been shown that drugs that 
are effective in ADHD occupy the DAT (DA transporter), thereby increasing 
the concentration of DA (Volkow et al. 1998a). 
 
It has been found that at therapeutic doses, the binding of selective 
serotonin reuptake inhibitors (SSRIs) is high (Meyer et al. 2001b; Suhara et 
al. 2003). These drugs are used to treat patients with depression, but are 
not always effective. It has been suggested that the efficacy of SSRIs can 
be augmented by co-administration of a 5-HT1A antagonist. However, PET 
data indicate that at the investigated doses the 5-HT1A occupancy was too 
low to be effective (Martinez et al. 2001; Rabiner et al. 2001). Data have 
shown that antidepressants also occupy 5-HT2 receptors (Meyer et al. 1999) 
and interaction with this receptor may be involved in the therapeutic activity 
of these drugs (Loo et al. 2003; Meyer et al. 2003).  
Measurement of changes in neurotransmitter release 
In order to study the (dys)function of neurotransmitter systems, it is 
important to quantify changes in the levels of these neurotransmitters in the 
living brain. Abnormalities in dopaminergic and serotonergic transmission 
have widely been studied using neuroendocrine challenge tests (Insel and 
Siever 1981; Power and Cowen 1992). This method however, only reflects 
functioning of the hypothalamo-hypophysial system, but does not 
necessarily assess neurotransmission in other brain regions. The combined 
use of radiolabeled ligands with a dopaminergic or serotonergic challenge 
may provide information on neurotransmitter release in specific regions of 
the brain. The approach is based on the assumption that an injected 
radiolabeled ligand competes for the same receptor as the endogenous 
transmitter. So, increases in neurotransmitter release result in a decreased 
binding of the radioligand and decreased neurotransmitter release induces 
an increase in ligand binding. The changes in ligand binding are used as a 
measure of the change in neurotransmitter levels. The concept of assessing 
the synaptic level of neurotransmitters was initially proposed by Friedman et 
al. (1984). Their study showed that binding of antipsychotic drugs to the D2 
receptor could best be described if competition with the endogenous 
neurotransmitter was included in the calculations. The idea of competition 
between D2 receptor ligands and endogenous DA was mentioned again a Chapter 1 
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few years later by Seeman et al. (1989) and during the following decades 
this method has been widely applied to study changes in neurotransmitter 
release in animals and humans.  
Studies in animals and healthy volunteers 
Most “competition studies” have studied DA release and used D2 
radioligands such as [
11C]-raclopride (Laruelle 2000). It has been shown 
that changes in ligand binding are correlated to extracellular DA levels as 
measured with microdialysis (Breier et al. 1997; Laruelle et al. 1997), 
although extracellular levels do not always reflect intrasynaptic processes 
(Tsukada et al. 2000a,b). The DA competition studies mainly involved 
measurements of drug-induced increases in DA concentration using the 
psychostimulants amphetamine, cocaine and methylphenidate. Most 
experiments investigated the role of the dopaminergic system in reward 
processing. After dopaminergic drug challenges, correlations have been 
found between (drug-related) subjective effects, such as euphoria, and 
reductions in D2 ligand binding. Furthermore, the extent of increase in DA 
concentration is found to be related to personality (novelty seekers) (Leyton 
et al. 2002). 
 
Ligand binding is not only affected by these drugs but also by cognitive or 
physiological challenges. A study by Koepp et al. (1998a) was the first that 
used this technique to investigate the effect of subjective experiences on D2 
ligand binding. They found a reduction in ligand binding during a video 
game indicating an increase of DA levels during reward learning and 
novelty. Other studies have shown effects of memory tasks (Aalto et al. 
2005), transcranial magnetic stimulation (Strafella et al. 2003), monetary 
rewards (Zald et al. 2004) or stress (Pruessner et al. 2004) on DA release. 
Moreover, it has been shown that merely the expectation of a reward can 
induce reductions in ligand binding, indicating an increase in DA levels (de 
la Fuente-Fernandez et al. 2002; Kaasinen et al. 2004). Thus, this PET 
method has been successfully used to study the dopaminergic system. 
 
Only a few studies have evaluated the use of ligands to study other 
neurotransmitter systems such as the noradrenergic (Tyacke et al. 2005), 
cholinergic (Carson et al. 1998; Nishiyama et al. 2001; Skaddan et al. 2002) 
or opioid system (Koepp et al. 1998b; Zubieta et al. 2003). The first results General introduction 
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of these studies are promising, although further research is needed. In 
contrast, results from studies using serotonergic ligands do not always 
agree. These studies have mainly used 5-HT1A ligands such as [
18F]-MPPF 
and [
11C]-WAY-100635 and have been performed in rats and human 
subjects. Physiological changes in 5-HT levels did not induce measurable 
effects in humans (Rabiner et al. 2002c) and studies in rat, using the 5-HT 
releasing agent and reuptake inhibitor fenfluramine, have shown that larger 
increases in 5-HT levels were not always effective either (Hume et al. 2001; 
Maeda et al. 2001). In contrast to these negative results, some rat studies 
have shown an effect of 5-HT increases on 5-HT1A ligand binding (Hume et 
al. 2001; Zimmer et al. 2002). Using the 5-HT2 antagonists [
18F]-altanserin 
and [
11C]-MDL 100907, no displacement was seen after citalopram (an 
SSRI) or fenfluramine-induced increases in 5-HT levels respectively (Hirani 
et al. 2003; Pinborg et al. 2004). Binding of the SERT ligand [
11C]-DASB is 
found to be decreased after increases in 5-HT (Ginovart et al. 2003). 
However, ligand binding was not affected after a decrease in 5-HT 
concentration (Talbot et al. 2005). Currently, the reason for these 
inconsistent results is unknown. 
Patient studies 
Several studies have used the above mentioned “competition method” to 
study dopaminergic function in patients. Increased amphetamine-induced 
DA release is found in schizophrenic patients (Breier et al. 1997) and in 
patients with Tourette syndrome (Singer et al. 2002). An attenuation of DA 
transmission is reported in Parkinson’s patients during sequential finger 
movements (Goerendt et al. 2003). Levodopa, a drug used for the treatment 
of Parkinson’s disease, is found to increase dopaminergic transmission (de-
la-Fuente-Fernandez et al. 2004; Tedroff et al. 1996). Studies in cocaine 
addicts revealed reduced DA release in the striatum and increased, craving 
related, DA release in the thalamus (Volkow et al. 1997a). Results from 
subjects with ADHD suggest abnormal low extracellular DA concentration in 
these subjects (Rosa-Neto et al. 2002). It is shown that oral doses of 
methylphenidate, the drug that is used to treat ADHD, lead to an increase in 
DA concentration (Volkow et al. 2002b). Chapter 1 
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Activation studies 
PET provides the possibility to measure (changes in) neuronal activation. It 
uses measurements of rCBF or glucose utilization as an index of neural 
activity (Herscovitch 2001). These methods enable the investigation of drug-
induced effects on (task related changes in) brain activation. Glucose 
metabolism is measured using [
18F]-fluoro-2-deoxyglucose (FDG). This 
method requires a relatively long period of FDG uptake by the brain 
(approximately 30 minutes). The method is therefore not useful to detect 
short lasting changes in brain activation but better suited for studying brain 
activity in disease states or chronic effects of drugs. In contrast, due to the 
short duration of the [
15O]-H2O scan (1-4 minutes), the [
15O]-H2O method is 
most appropriate for studies requiring multiple measurements in one 
session.  
Drug effects 
Several studies have investigated the effect of dopaminergic and 
serotonergic challenges on brain activation, in healthy subjects and in 
psychiatric patients. 
 
Studies that investigated the effects of increases in DA levels have mainly 
used psychostimulants such as amphetamine, cocaine or methylphenidate. 
Administration of these compounds is shown to induce widespread changes 
in cortical, subcortical, limbic and cerebellar activation. (Ernst et al. 1997; 
London et al. 1990; Volkow et al. 1997b, 1998b; Vollenweider et al. 1998; 
Wolkin et al. 1987). The extent and direction of these changes is suggested 
to be related to the state of the dopaminergic system, in addition to 
methodological factors such as the timing of the challenge (Volkow et al. 
1997b). A region that showed consistent increases after methylphenidate 
administration is the cerebellum. In subjects with ADHD, a relatively low 
resting activity in this region correlates with greater improvement after 
treatment with methylphenidate. In cocaine abusers increases in the 
cerebellum, anterior cingulate and thalamus were shown after 
methylphenidate administration. In addition, drug-induced changes in the 
striatum and orbitofrontal cortex were found to correlate with craving 
(Volkow et al. 1999a). In patients with schizophrenia, treatment with 
antipsychotics was accompanied by changes in striatal, frontal cortex, General introduction 
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anterior cingulate and cerebellar activation (Holcomb et al. 1996; Miller et al. 
1997). 
 
Results from studies in healthy volunteers using serotonergic challenges 
such as fenfluramine or SSRIs show changes in a discrete network of brain 
regions. Most studies found relative decreases in activation in the thalamus 
and (medial) temporal cortex, including the hippocampus and amygdala, 
and increases in frontal areas, including the anterior cingulate (Cook et al. 
1994; Geday et al. 2005; Kapur et al. 1994; Mann et al. 1996; Meyer et al. 
1996; Smith et al. 2002a). These areas show abnormal activation patterns 
in depressed patients, and in most studies a reversal of pretreatment 
abnormalities in brain activity is seen after SSRI treatment. These studies 
also found evidence for a role for the anterior cingulate in the pathology and 
treatment of depression (Brody et al. 1999; Kegeles et al. 2003; Mayberg et 
al. 2000; Oquendo et al. 2003; Smith et al. 2002b). Studies in patients with 
impulsive-aggressive personality disorder (Siever et al. 1999) and panic 
disorder (Meyer et al. 2000) reported abnormal fenfluramine-induced 
changes in frontal regions and the parietal-superior temporal cortex 
respectively. In patients with obsessive compulsive disorder (OCD) 
increased baseline activity is found in the cingulate cortex, orbitofrontal 
cortex, caudate nuclei and thalamus when compared to healthy controls and 
SSRI-related clinical improvement is shown to be correlated with a decrease 
in these regions (Perani et al. 1995; Saxena et al. 1998b, 1999, 2002). 
Drug interaction with task 
Using a verbal fluency task, Fletcher et al. (1996) reported a failure of task-
related anterior cingulate activation in schizophrenic subjects compared to 
healthy controls. Comparable findings were reported in a study that used a 
decision task (Lahti et al. 2004). In these studies, the impaired activation 
was reversed by acute administration of the DA agonist apomorphine and 
after treatment with clozapine respectively (Fletcher et al. 1996; Lahti et al. 
2004). A study in drug addicts using a cognitive task (Stroop task), showed 
a negative correlation between the amount of cocaine used and the task-
related activation in the anterior cingulate cortex (Bolla et al. 2004). Cools et 
al. (2002) studied the effects of L-dopa treatment in Parkinson’s patients 
and suggest that L-dopa improves cognitive deficits in Parkinson's disease Chapter 1 
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by inducing relative blood flow changes in the right dorsolateral prefrontal 
cortex. 
 
The effect of a decrease in 5-HT levels on cognitive function in depressed 
patients was studied by Smith et al. (1999). They reported an attenuation of 
the task (verbal fluency) related activation in the anterior cingulate after this 
challenge, which was correlated to an increase in depressive symptoms. 
 
These examples illustrate the possibilities of PET in psychiatric research 
and drug development. The different findings have provided useful 
knowledge on the involvement of the dopaminergic and serotonergic 
systems in the pathogenesis and treatment of psychiatric disorders. The use 
of PET is still expanding and a large amount of research is directed to the 
development of new radiotracers and methods which may provide further 
insight in these processes. 
Scope of the thesis 
Measurement of drug-induced changes in 5-HT release 
The results of receptor binding and activation studies add to the evidence 
that the serotonergic system is involved in psychiatric disorders such as 
depression and anxiety. As mentioned earlier, information on abnormal 
serotonergic transmission has largely been obtained from neuroendocrine 
challenge studies (Power and Cowen 1992). This method reflects 
functioning of the hypothalamo-hypophysial system, but does not 
necessarily assess neurotransmission in other brain regions. The combined 
use of radiolabeled ligands with a serotonergic challenge may extend the 
knowledge on serotonergic dysfunction in psychiatric disorders by enabling 
measurement of 5-HT release in specific brain regions. Successful use of 
this method requires a serotonergic receptor ligand that is sensitive to 
changes in endogenous 5-HT concentration. One of the aims of this thesis 
was to investigate if the binding of the 5-HT1A receptor antagonist [
18F]-
MPPF is sensitive to changes in 5-HT levels. As described above, previous 
studies which investigated the effect of alterations in 5-HT concentration on General introduction 
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the binding of serotonergic ligands were not always successful. In some 
studies significant changes in ligand binding were observed after the 
administration of a serotonergic challenge (Ginovart et al. 2003; Hume et al. 
2001; Zimmer et al. 2002), whereas in other studies no measurable effects 
were found (Hirani et al. 2003; Hume et al. 2001; Maeda et al. 2001; 
Pinborg et al. 2004; Rabiner et al. 2002c; Talbot et al. 2005). The reason for 
these inconsistent findings is unknown but may be related to differences in 
study method, species, the ligand used or specific properties of the 
serotonergic system. In this thesis, the effect of different serotonergic 
challenges on the binding of [
18F]-MPPF was studied in human subjects, 
rats and monkeys. In a previous study in anesthetized rats the effect of 
fenfluramine-induced increases in 5-HT levels on the binding of [
18F]-MPPF 
was studied using a using a ß+ radiosensitive probe (Zimmer et al. 2002). 
The authors reported a dose-related decrease of [
18F]-MPPF binding in the 
hippocampus. This probe, however, is an invasive instrument and also 
sensitive to methodological errors (Ginovart et al. 2004). In addition, it has 
been shown that ligand binding may be affected by the use of anesthetics 
(Ginovart et al. 2002; Harada et al. 2004; Hassoun et al. 2003; Momosaki et 
al. 2004; Seeman and Kapur 2003; Tsukada et al. 2002). For this reason, 
we decided to perform all our experiments in conscious animals. In the first 
study, described in chapter 2, the effect of alterations in 5-HT levels on 
[
18F]-MPPF binding was studied in healthy human subjects, using PET. 
Changes in 5-HT levels were achieved by influencing its synthesis through 
tryptophan depletion and infusion. These treatments are thought to induce 
relatively small changes in 5-HT levels. In the next study, described in 
chapter 3, the effects of larger increases in 5-HT were investigated in rats. 
5-HT levels were increased by administration of either fenfluramine or a 
combination of citalopram with ketanserin. Microdialysis studies have shown 
that both treatments induce marked increases in extracellular 5-HT 
concentrations. [
18F]-MPPF binding was assessed using ex-vivo 
autoradiography, however the animals were awake at the time of drug 
administration and [
18F]-MPPF injection. In these human and rat studies, 
[
18F]-MPPF was administered using a double bolus protocol with separate 
injections of the ligand during the different conditions. However using this 
method the results may be affected by drug-induced changes in blood flow. 
Therefore we decided to use a bolus with constant infusion protocol in the Chapter 1 
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next study, as described in chapter 4. Using this protocol, equilibrium 
levels of the radioligand were attained in blood and brain (Carson 2000). 
During equilibrium, there is no net transfer of the radioligand across the 
blood-brain barrier, thereby minimizing possible effects of drug-induced 
changes in blood flow on ligand binding (Laruelle 2000). A drug challenge 
can be administered during the equilibrium period, enabling measurement of 
baseline and drug-induced changes in ligand binding in the same 
experiment. Using this protocol, we studied the effect of fenfluramine-
induced increases in 5-HT on [
18F]-MPPF binding in conscious monkeys. 
Measurement of drug-induced changes in DA release 
As stated earlier, the “competition method” has successfully been used to 
study changes in DA release, using D2 antagonists such as [
11C]-raclopride. 
A second aim of this thesis was to introduce this method in our center in 
order to study possible dopaminergic abnormalities in psychiatric disorders, 
such as depression. Previous studies have mainly focused on serotonergic 
dysfunction in this disorder. However, data from several studies point to a 
possible role of the dopaminergic system in depression (Ebert et al. 1996; 
Klimke et al. 1999; Shah et al. 1997). In chapter 5 the effect of the DA 
reuptake blocker methylphenidate on the binding of the D2 receptor ligand 
[
11C]-raclopride was studied in healthy volunteers. Previous studies have 
investigated the effect of methylphenidate using double bolus injections of 
the radioligand. We decided to use a bolus with constant infusion protocol in 
order to exclude possible effects of drug-induced changes in blood flow on 
ligand binding. We also assessed the subjective state of the volunteer 
before and after methylphenidate administration, since previous studies 
reported correlations between subjective effects and changes in ligand 
binding (Drevets et al. 2001; Laruelle et al. 1995; Leyton et al. 2002; 
Martinez et al. 2003; Volkow et al. 1994, 1999b). The aim of our study was 
to investigate if the results from the combined use of a relatively low dose of 
methylphenidate with a [
11C]-raclopride constant infusion protocol comply 
with results from previous dopaminergic competition studies. Once the 
suitability of this method is established in healthy volunteers, it may be 
applicable to study dopaminergic abnormalities in psychiatric patients. General introduction 
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Measurement of drug-induced changes in brain 
activation 
The “competition method”, used in the previous chapters, enables the 
assessment of regional changes in neurotransmitter release. However, this 
method does not provide information on postsynaptic effects (neuronal 
activation). Information on neuronal activation can be obtained using [
15O]-
H2O or FDG PET, as mentioned previously. In this thesis, we wished to 
investigate the usefulness of methylphenidate as a dopaminergic probe in 
such studies. In chapter 6 we studied the effects of this drug on neuronal 
activation and subjective experiences in healthy volunteers. Previous 
studies that investigated the effects of dopaminergic drugs on brain activity 
have mainly used FDG PET (Ernst et al. 1997; London et al. 1990; Volkow 
et al. 1997b, 1998b, Vollenweider et al. 1998; Wolkin et al. 1987). As 
mentioned earlier, compared to FDG, the temporal resolution of [
15O]-H2O 
PET is much higher. We were interested in effects of methylphenidate at 
different time-points, therefore we decided to use [
15O]-H2O instead of FDG 
PET in our study. Scans were made at ten minutes after drug 
administration, which is the time of the peak in subjective effects, and at 30 
minutes after administration, the time of the peak in DA concentration. If 
methylphenidate is found to induce changes in brain regions that are known 
to be involved in dopaminergic (dys)function, this method may also be 
useful to study dopaminergic functional abnormalities in psychiatric patients. Chapter 1 
  27 
References 
 
Aalto S, Bruck A, Laine M, Nagren K, Rinne JO (2005). Frontal and temporal 
dopamine release during working memory and attention tasks in healthy 
humans: a positron emission tomography study using the high-affinity dopamine 
D2 receptor ligand [11C]FLB 457. J Neurosci 25:2471-2477. 
 
Anderson IM, Clark L, Elliott R, Kulkarni B, Williams SR, Deakin JF (2002). 5-
HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans 
with fMRI. Neuroreport 13: 1547-1551. 
 
Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM (1996). Cellular 
localization of the 5-HT1A receptor in primate brain neurons and glial cells. 
Neuropsychopharmacology 14: 35-46. 
 
Bantick RA, Deakin JF, Grasby PM (2001). The 5-HT1A receptor in 
schizophrenia: a promising target for novel atypical neuroleptics? J 
Psychopharmacol 15: 37-46. 
 
Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their 
function. Neuropharmacology 38: 1083-1152. 
 
Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ (2004). 
Persistent reduction in brain serotonin1A receptor binding in recovered 
depressed men measured by positron emission tomography with [11C]WAY-
100635. Mol Psychiatry 9: 386-392. 
 
Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J (1997). 
Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-
insular cortex. Br J Psychiatry 171: 444-448. 
 
Bloom AS, Hoffmann RG, Fuller SA, Pankiewicz J, Harsch HH, Stein EA 
(1999). Determination of drug-induced changes in functional MRI signal using a 
pharmacokinetic model. Hum Brain Mapp 8: 235-244. 
 
Bolla K, Ernst M, Kiehl K, Mouratidis M, Eldreth D, Contoreggi C, Matochik J, 
Kurian V, Cadet J, Kimes A, Funderburk F, London E (2004). Prefrontal cortical 
dysfunction in abstinent cocaine abusers. J Neuropsychiatry Clin Neurosci 16: 
456-464. 
 
Brannan T, Prikhojan A, Martinez-Tica J, Yahr MD (1995). In vivo comparison of 
the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and 
dopamine metabolism. J Neural Transm Park Dis Dement Sect 10:79-89.  
 General introduction 
  28 
Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de-Bartolomeis A et 
al (1997). Schizophrenia is associated with elevated amphetamine-induced 
synaptic dopamine concentrations: evidence from a novel positron emission 
tomography method. Proc Natl Acad Sci USA 49: 2569-2574. 
 
Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, 
Huang SC, Wu HM, Maidment K, Baxter LR Jr (1999). Brain metabolic changes 
in major depressive disorder from pre- to post-treatment with paroxetine. 
Psychiatry Res 91: 127-139. 
 
Carson RE, Kiesewetter DO, Jagoda E, Der MG, Herscovitch P, Eckelman WC 
(1998). Muscarinic cholinergic receptor measurements with [18F]FP-TZTP: 
control and competition studies. J Cereb Blood Flow Metab 18: 1130-1142. 
 
Carson RE (2000). PET physiological measurements using constant infusion. 
Nucl Med Biol 27: 657-660. 
 
Cook EH Jr, Metz J, Leventhal BL, Lebovitz M, Nathan M, Semerdjian SA, 
Brown T, Cooper MD (1994). Fluoxetine effects on cerebral glucose 
metabolism. Neuroreport 5: 1745-1748. 
 
Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM (2002). 
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role 
of the prefrontal cortex revealed by PET. Brain 125: 584-594. 
 
Costes N, Merlet I, Zimmer L, Lavenne F, Cinotti L, Delforge J, Luxen A, Pujol 
JF, Le-Bars D (2002). Modeling [18 F]MPPF positron emission tomography 
kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration 
with multiinjection. J Cereb Blood Flow Metab 22: 753-765. 
 
De la Fuente Fernandez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth 
TJ, Stoessl AJ (2002). Dopamine release in human ventral striatum and 
expectation of reward. Behav Brain Res 136: 359-363. 
 
De la Fuente Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, 
Ruth TJ, Stoessl AJ (2004). Levodopa-induced changes in synaptic dopamine 
levels increase with progression of Parkinson's disease: implications for 
dyskinesias. Brain 127: 2747-2754. 
 
Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier 
C, Mathis C (1999). PET imaging of serotonin 1A receptor binding in 
depression. Biol Psychiatry 46: 1375-1387. 
 
Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, 
Mathis CA (2001). Amphetamine-induced dopamine release in human ventral 
striatum correlates with euphoria. Biol Psychiatry 49: 81-96. 
 Chapter 1 
  29 
Ebert D, Feistel H, Loew T, Pirner A (1996). Dopamine and depression--striatal 
dopamine D2 receptor SPECT before and after antidepressant therapy. 
Psychopharmacology 126: 91-94. 
 
Ernst M, Zametkin AJ, Matochik J, Schmidt M, Jons PH, Liebenauer LL, Hardy 
KK, Cohen RM (1997). Intravenous dextroamphetamine and brain glucose 
metabolism. Neuropsychopharmacology 17: 391-401. 
 
Fisher RE, Morris ED, Alpert NM, Fischman AJ (1995). In vivo imaging of 
neuromodulatory synaptic transmission using PET: A review of relevant 
neurophysiology. Human Brain Mapping 3: 24-34. 
 
Fletcher PC, Frith CD, Grasby PM, Friston KJ, Dolan RJ (1996). Local and 
distributed effects of apomorphine on fronto-temporal function in acute 
unmedicated schizophrenia. J Neurosci 16: 7055-7062. 
 
Floresco SB, West AR, Ash B, Moore H, Grace AA (2003). Afferent modulation 
of dopamine neuron firing differentially regulates tonic and phasic dopamine 
transmission. Nat Neurosci 6:968-973. 
 
Fowler JS, Volkow ND, Wang GJ, Ding YS, Dewey SL (1999). PET and drug 
research and development. J Nucl Med 40: 1154-1163. 
 
Friedman AM, DeJesus OT, Revenaugh J, Dinerstein RJ (1984). 
Measurements in vivo of parameters of the dopamine system. Ann Neurol 15 
Suppl: S66-76. 
 
Gartside SE, Hajos-Korcsok E, Bagdy E, Harsing LG Jr, Sharp T, Hajos M 
(2000). Neurochemical and electrophysiological studies on the functional 
significance of burst firing in serotonergic neurons. 
Neuroscience 98:295-300. 
  
Geday J, Hermansen F, Rosenberg R, Smith DF (2005). serotonin modulation 
of cerebral blood flow measured with positron emission tomography (PET) in 
humans. Synapse. 2005 Mar 15;55(4):224-9. 
 
Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R 
(1998). Time course of central nervous dopamine-D2 and 5-HT2 receptor 
blockade and plasma drug concentrations after discontinuation of quetiapine 
(Seroquel) in patients with schizophrenia. Psychopharmacology 135: 119-126. 
 
Gefvert O, Lundberg T, Wieselgren IM, Bergstrom M, Langstrom B, Wiesel F, 
Lindstrom L (2001). D(2) and 5HT(2A) receptor occupancy of different doses of 
quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 11:105-
110. 
 General introduction 
  30 
Ginovart N, Hassoun W, Le-Cavorsin M, Veyre L, Le-Bars D, Leviel V (2002). 
Effects of amphetamine and evoked dopamine release on [11C]raclopride 
binding in anesthetized cats. Neuropsychopharmacology 27(1): 72-84. 
 
Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S (2003). [11C]-DASB, a 
tool for in vivo measurement of SSRI-induced occupancy of the serotonin 
transporter: PET characterization and evaluation in cats. Synapse 47: 123-133. 
 
Ginovart N, Sun W, Wilson AA, Houle S Kapur S (2004). Quantitative validation 
of an intracerebral beta-sensitive microprobe system to determine in vivo drug-
induced receptor occupancy using [11C]raclopride in rats. Synapse 52: 89-99. 
 
Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ (2003). 
Dopamine release during sequential finger movements in health and 
Parkinson's disease: a PET study. Brain 126: 312-325. 
 
Gozlan H, Thibault S, Laporte AM, Lima L, Hamon M (1995). The selective 5-
HT1A antagonist radioligand [
3H]WAY 100635 labels both G-protein-coupled and 
free 5-HT1A receptors in rat brain membranes. Eur J Pharmacol 288: 173-186. 
 
Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, 
Szymanski S, Wilson PD, Howard DR, Wong DF (1997). Time course of 5-
HT2A receptor occupancy in the human brain after a single oral dose of the 
putative antipsychotic drug MDL 100,907 measured by positron emission 
tomography. Neuropsychopharmacology 17: 175-185. 
 
Harada N, Ohba H, Fukumoto D, Kakiuchi T, Tsukada H (2004). Potential of 
[(18)F]beta-CFT-FE (2beta-carbomethoxy-3beta-(4-fluorophenyl)-8-(2-
[(18)F]fluoroethyl)nortropane) as a dopamine transporter ligand: A PET study in 
the conscious monkey brain. Synapse 54(1):37-45. 
 
Hassoun W, Le-Cavorsin M, Ginovart N, Zimmer L, Gualda V, Bonnefoi F, 
Leviel V (2003). PET study of the [11C]raclopride binding in the striatum of the 
awake cat: effects of anaesthetics and role of cerebral blood flow. Eur J Nucl 
Med Mol Imaging 30(1): 141-148. 
 
Herscovitch P (2001). Can [15O]water be used to evaluate drugs? J Clin 
Pharmacol Suppl: 11S-20S. 
 
Hirani E, Sharp T, Sprakes M, Grasby P, Hume S (2003). Fenfluramine evokes 
5-HT2A receptor-mediated responses but does not displace [11C]MDL 100907: 
small animal PET and gene expression studies. Synapse 50: 251-260. 
 
Hjorth S, Bengtsson HJ, Kullberg A, Carlzon D, Peilot H, Auerbach SB (2000). 
Serotonin autoreceptor function and antidepressant drug action. J 
Psychopharmacol 14: 177-185. 
 Chapter 1 
  31 
Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA 
(1996). Functional sites of neuroleptic drug action in the human brain: PET/FDG 
studies with and without haloperidol. Am J Psychiatry 153: 41-49. 
 
Hume S, Hirani E, Opacka-Juffry J, Myers R, Townsend C, Pike V, Grasby P 
(2001). Effect of 5-HT on binding of [
11C] WAY 100635 to 5-HTIA receptors in rat 
brain, assessed using in vivo microdialysis and PET after fenfluramine. 
Synapse 41: 150-159. 
 
Ikemoto S, Glazier BS, Murphy JM, McBride WJ (1997). Role of dopamine D1 
and D2 receptors in the nucleus accumbens in mediating reward. J Neurosci 
17:8580-8587. 
 
Insel TR, Siever LJ (1981). The dopamine system challenge in affective 
disorders: a review of behavioral and neuroendocrine responses. J Clin 
Psychopharmacol 1: 207-213. 
 
Jacobs BL, Azmitia EC (1992). Structure and function of the brain serotonin 
system. Physiol Rev 72: 165-229. 
 
Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L (2005). Reduced midbrain 
dopamine transporter binding in male adolescents with attention-
deficit/hyperactivity disorder: association between striatal dopamine markers 
and motor hyperactivity. Biol Psychiatry 57:229-238. 
 
Kaasinen V, Nagren K, Hietala J, Oikonen V, Vilkman H, Farde L, Halldin C, 
Rinne JO (2000). Extrastriatal dopamine D2 and D3 receptors in early and 
advanced Parkinson's disease. Neurology 54: 1482-1487. 
 
Kaasinen V, Aalto S, Nagren K, Rinne JO (2004). Expectation of caffeine 
induces dopaminergic responses in humans.  Eur J Neurosci 19: 2352-2356. 
 
Kapur S, Meyer J, Wilson AA, Houle S, Brown GM (1994). Modulation of 
cortical neuronal activity by a serotonergic agent: a PET study in humans. Brain 
Res 646: 292-294. 
 
Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) 
receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J 
Psychiatry  158: 360-369. 
 
Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role 
for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 
1081-1090. 
 
Karhunen T, Tilgmann C, Ulmanen I, Panula P (1995). Catechol-O-
methyltransferase (COMT) in rat brain: immunoelectron microscopic study with 
an antiserum against rat recombinant COMT protein. Neurosci Lett 187:57-60. 
 General introduction 
  32 
Kegeles LS, Malone KM, Slifstein M, Ellis SP, Xanthopoulos E, Keilp JG, 
Campbell C, Oquendo M, Van-Heertum RL, Mann JJ (2003). Response of 
cortical metabolic deficits to serotonergic challenge in familial mood disorders. 
Am J Psychiatry 160: 76-82. 
 
Kenakin T (2002). Efficacy at G-protein-coupled receptors. Nat Rev Drug 
Discov 1: 103-110. 
 
Khawaja X (1995). Quantitative autoradiographic characterisation of the binding 
of [
3H]WAY-100635, a selective 5-HT1A receptor antagonist. Brain Res 673: 
217-225. 
 
Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W (1999). 
Dopamine D2 receptor binding before and after treatment of major depression 
measured by [123I]IBZM SPECT. Psychiatry Res 90: 91-101. 
 
Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, 
Brooks DJ, Bench CJ, Grasby PM (1998a). Evidence for striatal dopamine 
release during a video game. Nature 393: 266-268. 
 
Koepp MJ, Richardson MP, Brooks DJ, Duncan JS (1998b). Focal cortical 
release of endogenous opioids during reading-induced seizures. Lancet 352: 
952-955. 
 
Kohler C, Hall H, Ogren SO, Gawell L (1985). Specific in vitro and in vivo 
binding of 3H-raclopride. A potent substituted benzamide drug with high affinity 
for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34: 2251-2259. 
 
Lahti AC, Holcomb HH, Weiler MA, Medoff DR, Frey KN, Hardin M, Tamminga 
CA (2004). Clozapine but not haloperidol Re-establishes normal task-activated 
rCBF patterns in schizophrenia within the anterior cingulate cortex. 
Neuropsychopharmacology 29: 171-178. 
 
Laihinen AO, Rinne JO, Nagren KA, Lehikoinen PK, Oikonen VJ, Ruotsalainen 
UH, Ruottinen HM, Rinne UK (1995). PET studies on brain monoamine 
transporters with carbon-11-beta-CIT in Parkinson's disease. J Nucl Med 36: 
1263-1267. 
 
Laruelle M, Abi-Dargham A, van-Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi 
SS, Baldwin RM,  Charney DS, Hoffer PB, Kung HF, Innis RB (1995). SPECT 
imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 
36: 1182-1190. 
 
Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin 
RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997). 
Microdialysis and SPECT measurements of amphetamine-induced dopamine 
release in nonhuman primates. Synapse 25: 1-14. 
 Chapter 1 
  33 
Laruelle M (2000). Imaging synaptic neurotransmission with in vivo binding 
competition techniques: a critical review. J Cereb Blood Flow Metab 20: 423-
451. 
 
Laruelle M, Slifstein M, Huang Y (2003). Relationships between radiotracer 
properties and image quality in molecular imaging of the brain with positron 
emission tomography. Mol Imaging Biol 5: 363-375. 
 
Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, 
Langstrom B (2003). In vivo activity of bupropion at the human dopamine 
transporter as measured by positron emission tomography. Biol Psychiatry 54: 
800-805. 
 
Leenders KL (2002). Disease process and drug treatments in Parkinson's 
disease. Eur Neuropsychopharmacol 12: 575-580. 
 
Lefkowitz RJ, Cotecchia S, Samama P, Costa T (1993). Constitutive activity of 
receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol 
Sci 14: 303-307. 
 
Le-Moal M, Simon H (1991). Mesocorticolimbic dopaminergic network: 
functional and regulatory roles. Physiol Rev 71: 155-234. 
 
Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A (2002). 
Amphetamine-induced increases in extracellular dopamine, drug wanting, and 
novelty seeking: a PET/[11C]raclopride study in healthy men. 
  Neuropsychopharmacology 27: 1027-1035. 
 
London ED, Cascella NG, Wong DF, Phillips RL, Dannals RF, Links JM, 
Herning R, Grayson R, Jaffe JH, Wagner HN Jr (1990). Cocaine-induced 
reduction of glucose utilization in human brain. A study using positron emission 
tomography and [fluorine 18]-fluorodeoxyglucose. Arch Gen Psychiatry 47: 567-
574. 
 
Loo H, Dalery J, Macher JP, Payen A (2003). Pilot study comparing in blind the 
therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 
5HT2c receptors antagonist, in the treatment of major depressive disorders. 
Encephale 29:165-171. 
 
Lundberg T, Lindstrom LH, Hartvig P, Eckernas SA, Ekblom B, Lundqvist H, 
Fasth KJ, Gullberg P, Langstrom B (1989). Striatal and frontal cortex binding of 
11-C-labelled clozapine visualized by positron emission tomography (PET) in 
drug-free schizophrenics and healthy volunteers. Psychopharmacology 99: 8-
12. 
 
Maeda J, Suhara T, Ogawa M, Okauchi T, Kawabe K, Zhang MR, Semba J, 
Suzuki K (2001). In vivo binding properties of [carbonyl-
11C]WAY-100635: effect 
of endogenous serotonin. Synapse 40: 122-129. General introduction 
  34 
 
Majovski LV, Jacques S, Hartz G, Fogwell LA (1981). Dopaminergic (DA) 
systems: their role in pathological neurobehavioral symptoms. Neurosurgery 
9:751-757. 
 
Mann JJ, Malone KM, Diehl DJ, Perel J, Nichols TE, Mintun MA (1996). 
Positron emission tomographic imaging of serotonin activation effects on 
prefrontal cortex in healthy volunteers. J Cereb Blood Flow Metab 16: 418-426. 
 
Martinez D, Hwang D, Mawlawi O, Slifstein M, Kent J, Simpson N, Parsey RV, 
Hashimoto T, Huang Y, Shinn A, Van-Heertum R, Abi-Dargham A, Caltabiano 
S, Malizia A, Cowley H, Mann JJ, Laruelle M (2001). Differential occupancy of 
somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-
occupancy study with [11C]WAY 100635 and positron emission tomography in 
humans. Neuropsychopharmacology 24: 209-229. 
 
Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, 
Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M (2003). Imaging 
human mesolimbic dopamine transmission with positron emission tomography. 
Part II: amphetamine-induced dopamine release in the functional subdivisions 
of the striatum. J Cereb Blood Flow Metab 23: 285-300. 
 
Martinez D, Broft A, Foltin RW, Slifstein M, Hwang DR, Huang Y, Perez A, 
Frankle WG, Cooper T, Kleber HD, Fischman MW, Laruelle M (2004). Cocaine 
dependence and d2 receptor availability in the functional subdivisions of the 
striatum: relationship with cocaine-seeking behavior. 
Neuropsychopharmacology 29: 1190-1202. 
 
Massou JM, Trichard C, Attar-Levy D, Feline A, Corruble E, Beaufils B, Martinot 
JL (1997). Frontal 5-HT2A receptors studied in depressive patients during 
chronic treatment by selective serotonin reuptake inhibitors. 
Psychopharmacology 133: 99-101. 
 
Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, 
Jerabek PA (2000). Regional metabolic effects of fluoxetine in major 
depression: serial changes and relationship to clinical response. Biol Psychiatry 
48: 830-843. 
 
Meltzer CC, Price JC, Mathis CA, Butters MA, Ziolko SK, Moses-Kolko E, 
Mazumdar S, Mulsant BH,  Houck PR, Lopresti BJ, Weissfeld LA, Reynolds CF 
(2004). Serotonin 1A receptor binding and treatment response in late-life 
depression. Neuropsychopharmacology 29: 2258-2265. 
 
Messa C, Colombo C, Moresco RM, Gobbo C, Galli L, Lucignani G, Gilardi MC, 
Rizzo G, Smeraldi E, Zanardi R, Artigas F, Fazio F (2003). 5-HT(2A) receptor 
binding is reduced in drug-naive and unchanged in SSRI-responder depressed 
patients compared to healthy controls: a PET study. Psychopharmacology 167: 
72-78. Chapter 1 
  35 
 
Meyer JH, Kapur S, Wilson AA, DaSilva JN, Houle S, Brown GM (1996). 
Neuromodulation of frontal and temporal cortex by intravenous d-fenfluramine: 
an [15O]H2O PET study in humans. Neurosci Lett 207: 25-28. 
 
Meyer JH, Cho R, Kennedy S, Kapur S (1999). The effects of single dose 
nefazodone and paroxetine upon 5-HT2A binding potential in humans using 
[18F]-setoperone PET. Psychopharmacology 144: 279-281. 
 
Meyer JH, Swinson R, Kennedy SH, Houle S, Brown GM (2000). Increased left 
posterior parietal-temporal cortex activation after D-fenfluramine in women with 
panic disorder. Psychiatry Res 98: 133-143. 
 
Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-
Tari S, Mayberg HS, Kennedy SH (2001a). The effect of paroxetine on 5-
HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J 
Psychiatry 158: 78-85. 
 
Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S 
(2001b). Occupancy of serotonin transporters by paroxetine and citalopram 
during treatment of depression: a [(11)C]DASB PET imaging study. Am J 
Psychiatry 158: 1843-1849. 
 
Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson 
AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P (2003). 
Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. 
Am J Psychiatry 160:90-99.   
 
Meyer JH, Houle S, Sagrati S, Carella A, Hussey DF, Ginovart N, Goulding V, 
Kennedy J, Wilson AA (2004). Brain serotonin transporter binding potential 
measured with carbon 11-labeled DASB positron emission tomography: effects 
of major depressive episodes and severity of dysfunctional attitudes. Arch Gen 
Psychiatry 61: 1271-1279. 
 
Miller DD, Andreasen NC, O'Leary DS, Rezai K, Watkins GL, Ponto LL, Hichwa 
RD (1997). Effect of antipsychotics on regional cerebral blood flow measured 
with positron emission tomography. Neuropsychopharmacology 17: 230-240. 
 
Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984). A 
quantitative model for the in vivo assessment of drug binding sites with positron 
emission tomography. Ann Neurol 15: 217-227. 
 
Momosaki S, Hatano K, Kawasumi Y, Kato T, Hosoi R, Kobayashi K, Inoue O, 
Ito K (2004). Rat-PET study without anesthesia: Anesthetics modify the 
dopamine D(1) receptor binding in rat brain. Synapse 54(4): 207-213.  
 General introduction 
  36 
Mongeau R, Welner SA, Quirion R, Suranyi-Cadotte BE (1992). Further 
evidence for differential affinity states of the serotonin1A receptor in rat 
hippocampus. Brain Res 590: 229-238. 
 
Naranjo CA, Tremblay LK, Busto UE (2001). The role of the brain reward 
system in depression. Prog Neuropsychopharmacol Biol Psychiatry 25: 781-
823. 
 
Nénonéné EK, Radja F, Carli M, Grondin L, Reader TA (1994). Heterogeneity of 
cortical and hippocampal 5-HT1A receptors: a reappraisal of homogenate 
binding with 8-[3H]hydroxydipropylaminotetralin. J Neurochem 62: 1822-1834. 
 
Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, 
Eckelman W, Herscovitch P, Charney DS, Drevets WC (2004).Reduced 
serotonin type 1A receptor binding in panic disorder. J Neurosci 24:589-591. 
 
Nishiyama S, Tsukada H, Sato K, Kakiuchi T, Ohba H, Harada N, Takahashi K 
(2001). Evaluation of PET ligands (+)N-[11C]ethyl-3-piperidyl benzilate and 
(+)N-[11C]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: A 
PET study with microdialysis in comparison with (+)N-[11C]methyl-3-piperidyl 
benzilate in the conscious monkey brain. Synapse 40: 159-169. 
 
Nordstrom AL, Farde L, Halldin C (1992). Time course of D2-dopamine receptor 
occupancy examined by PET after single oral doses of haloperidol. 
Psychopharmacology 106: 433-438. 
 
Nurmi E, Ruottinen HM, Kaasinen V, Bergman J, Haaparanta M, Solin O, Rinne 
JO (2000). Progression in Parkinson's disease: a positron emission tomography 
study with a dopamine transporter ligand [18F]CFT. Ann Neurol 47: 804-808. 
 
Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L (1998). Implications of brain 
imaging for the management of schizophrenia. Int Clin Psychopharmacol 13 
Suppl 3: S15-20. 
 
Nyberg S, Farde L (2000). Non-equipotent doses partly explain differences 
among antipsychotics - implications of PET studies. Psychopharmacology 148: 
22-23. 
 
Oosterink BJ, Korte SM, Nyakas C, Korf J, Luiten PG (1998). Neuroprotection 
against N-methyl-D-aspartate-induced excitotoxicity in rat magnocellular 
nucleus basalis by the 5-HT1A receptor agonist 8-OH-DPAT. Eur J Pharmacol 
358: 147-152. 
 
Oquendo M A, Placidi GP, Malone KM, Campbell C, Keilp J, Brodsky B, 
Kegeles LS, Cooper TB, Parsey RV, van-Heertum RL, Mann JJ (2003). 
Positron emission tomography of regional brain metabolic responses to a 
serotonergic challenge and lethality of suicide attempts in major depression. 
Arch Gen Psychiatry 60: 14-22. Chapter 1 
  37 
 
Paterson IA, Davis BA, Durden DA, Juorio AV, Yu PH, Ivy G, Milgram W, 
Mendonca A, Wu P, Boulton AA (1995). Inhibition of MAO-B by (-)-deprenyl 
alters dopamine metabolism in the macaque (Macaca facicularis) brain. 
Neurochem Res 20:1503-1510.  
 
Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S, Bellodi L, 
Smeraldi E, Fazio F (1995). [18F]FDG PET study in obsessive-compulsive 
disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry 
166: 244-250. 
 
Pinborg LH, Adams KH, Yndgaard S, Hasselbalch SG, Holm S, Kristiansen H, 
Paulson OB, Knudsen GM (2004). [18F]altanserin binding to human 5HT2A 
receptors is unaltered after citalopram and pindolol challenge. J Cereb Blood 
Flow Metab 24: 1037-1045. 
 
Pineyro G, Blier P (1999). Autoregulation of serotonin neurons: role in 
antidepressant drug action. 
Pharmacol Rev 51:533-591. Review. 
 
Power AC, Cowen PJ (1992). Neuroendocrine challenge tests: assessment of 
5-HT function in anxiety and depression. Mol Aspects Med 13: 205-220. 
 
Pruessner JC, Champagne F, Meaney MJ, Dagher A (2004). Dopamine release 
in response to a psychological stress in humans and its relationship to early life 
maternal care: a positron emission tomography study using [11C]raclopride. J 
Neurosci 24: 2825-2831. 
 
Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ, 
Grasby PM (2001). Pindolol augmentation of selective serotonin reuptake 
inhibitors: PET evidence that the dose used in clinical trials is too low. Am J 
Psychiatry 158: 2080-2082. 
 
Rabiner EA, Wilkins MR, Turkheimer F, Gunn RN, de-Haes JU, de-Vries M, 
Grasby PM (2002a). 5-Hydroxytryptamine1A receptor occupancy by novel full 
antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-
piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-
3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-
pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron 
emission tomography study in humans. J Pharmacol Exp Ther 301: 1144-1150. 
 
Rabiner EA, Gunn RN, Wilkins MR, Sedman E, Grasby PM (2002b). Evaluation 
of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET 
study with [11C]WAY-100635 and [11C]raclopride. J Psychopharmacol 16: 195-
199. 
 
Rabiner EA, Messa C, Sargent PA, Husted-Kjaer K, Montgomery A, Lawrence 
AD, Bench CJ, Gunn RN, Cowen P, Grasby PM (2002c). A database of General introduction 
  38 
[(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: 
normative data and relationship to methodological, demographic, physiological, 
and behavioral variables. Neuroimage 15(3): 620-632. 
 
Rabiner EA, Bhagwagar Z, Gunn RN, Cowen PJ, Grasby PM (2004). 
Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in 
depressed patients: effect of treatment or an endophenotype of depression? 
Neuropsychopharmacology 29: 1688-1698. 
 
Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X, el-Mestikawy S, 
Hamon M, Descarries L (2000). Somatodendritic localization of 5-HT1A and 
preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. 
J Comp Neurol 417: 181-194. 
 
Rosa-Neto P, Lou H, Cumming P, Pryds O, Gjedde A (2002). Methylphenidate-
evoked potentiation of extracellular dopamine in the brain of adolescents with 
premature birth: correlation with attentional deficit. Ann NY Acad Sci 965: 434-
439. 
 
Salmeron BJ, Stein EA (2002). Pharmacological applications of magnetic 
resonance imaging. Psychopharmacol-Bull 36: 102-129. 
 
Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, MessaC, MeyerJ, Gunn RN, 
Grasby PM, Cowen PJ (2000). Brain serotonin1A receptor binding measured by 
positron emission tomography with [
11C]WAY-100635: effects of depression and 
antidepressant treatment.  Arch Gen Psychiatry 57: 174-180. 
 
Sasaki T, Ishiwata K, Murata T, Senda M (2002). Demonstration of competition 
between endogenous dopamine and [11C]raclopride binding in in vitro brain 
slices using a dynamic autoradiography technique. Synapse 44: 42-50. 
 
Saxena PR, De Vries P, Villalon CM (1998a). 5-HT1-like receptors: a time to bid 
goodbye. 
Trends Pharmacol Sci 19:311-316. 
 
Saxena S, Brody AL, Schwartz JM, Baxter LR (1998b). Neuroimaging and 
frontal-subcortical circuitry in obsessive-compulsive disorder. Brit J Psychiat 
173: 26-38. 
 
Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps 
ME, Baxter LR Jr (1999). Localized orbitofrontal and subcortical metabolic 
changes and predictors of response to paroxetine treatment in obsessive-
compulsive disorder.   Neuropsychopharmacology 21: 683-693. 
 
Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, 
Huang SC, Wu HM, Baxter LR Jr (2002). Differential cerebral metabolic 
changes with paroxetine treatment of obsessive-compulsive disorder vs major 
depression. Arch Gen Psychiatry 59:250-261.   Chapter 1 
  39 
 
Seeman P, Guan HC, Niznik HB (1989). Endogenous dopamine lowers the 
dopamine D2 receptor density as measured by [3H]raclopride: implications for 
positron emission tomography of the human brain. Synapse 3: 96-97. 
 
Seeman P (2002). Atypical antipsychotics: mechanism of action. Can J 
Psychiatry 47: 27-38. 
 
Seeman P, Kapur S (2003). Anesthetics inhibit high-affinity states of dopamine 
D2 and other G-linked receptors. Synapse 50(1): 35-40. 
 
Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP (1997). Clinical and 
psychometric correlates of dopamine D2 binding in depression. Psychol Med 
27: 1247-1256. 
 
Shih JC, Chen K, Ridd MJ (1999). Monoamine oxidase: from genes to behavior. 
Annu Rev Neurosci 22:197-217. Review. 
 
Siever LJ, Buchsbaum MS, New AS, Spiegel-Cohen J, Wei T, Hazlett EA, Sevin 
E, Nunn M, Mitropoulou V (1999). d,l-fenfluramine response in impulsive 
personality disorder assessed with [18F]fluorodeoxyglucose positron emission 
tomography. Neuropsychopharmacology 20: 413-423. 
 
Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, Zhou Y, 
Grace AA, Wong DF (2002). Elevated intrasynaptic dopamine release in 
Tourette's syndrome measured by PET. Am J Psychiatry 159: 1329-1336. 
 
Skaddan MB, Jewett DM, Sherman PS, Kilbourn MR (2002). (R)-N-
[11C]methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET 
studies of the muscarinic acetylcholine receptor. Synapse 45: 31-37. 
 
Slifstein M, Laruelle M (2001). Models and methods for derivation of in vivo 
neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl 
Med Biol 28: 595-608. 
 
Smith KA, Morris JS, Friston KJ, Cowen PJ, Dolan RJ (1999). Brain 
mechanisms associated with depressive relapse and associated cognitive 
impairment following acute tryptophan depletion. Br J Psychiatry 174: 525-529. 
 
Smith GS, Ma Y, Dhawan V, Gunduz H, Carbon M, Kirshner M, Larson J, Chaly 
T, Belakhleff A, Kramer E, Greenwald B, Kane JM, Laghrissi-Thode F, Pollock 
BG, Eidelber D (2002a). Serotonin modulation of cerebral glucose metabolism 
measured with positron emission tomography (PET) in human subjects. 
Synapse 45: 105-112. 
 
Smith GS, Kramer E, Hermann CR, Goldberg S, Ma Y, Dhawan V, Barnes A, 
Chaly T, Belakhleff A, Laghrissi-Thode F, Greenwald B, Eidelberg D, Pollock General introduction 
  40 
BG (2002b). Acute and chronic effects of citalopram on cerebral glucose 
metabolism in geriatric depression. Am J Geriatr Psychiatry 10: 715-723. 
 
Soares JC, Innis RB (1999). Neurochemical brain imaging investigations of 
schizophrenia. Biol Psychiatry 46: 600-615. 
 
Spanagel R, Weiss F (1999). The dopamine hypothesis of reward: past and 
current status. Trends Neurosci 22: 521-527. 
 
Strafella AP, Paus T, Fraraccio M, Dagher A (2003). Striatal dopamine release 
induced by repetitive transcranial magnetic stimulation of the human motor 
cortex. Brain 126: 2609-2615. 
 
Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo 
Y (2003). High levels of serotonin transporter occupancy with low-dose 
clomipramine in comparative occupancy study with fluvoxamine using positron 
emission tomography. Arch Gen Psychiatry 60: 386-391. 
 
Svensson TH, Mathe AA (2002). Monoaminergic transmitter systems. In: D 
'haenen H, den Boer JA, Willner P, editors. Biological Psychiatry. New York: 
John Wiley & Sons Ltd. pp: 45-66.  
 
Talbot PS, Laruelle M (2002). The role of in vivo molecular imaging with PET 
and SPECT in the elucidation of psychiatric drug action and new drug 
development. Eur Neuropsychopharmacol 12: 503-511. 
 
Talbot PS, Frankle WG, Hwang DR, Huang Y, Suckow RF, Slifstein M, Abi-
Dargham A, Laruelle M (2005). Effects of reduced endogenous 5-HT on the in 
vivo binding of the serotonin transporter radioligand 11C-DASB in healthy 
humans. Synapse 55:164-175. 
 
Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L (2003). Decreased 
thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a 
PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6: 361-370. 
 
Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, LangstromB 
(1996). Levodopa-induced changes in synaptic dopamine in patients with 
Parkinson's disease as measured by [11C]raclopride displacement and PET. 
Neurology 46: 1430-1436. 
 
Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D, Kakiuchi T 
(2000a). Ketamine decreased striatal [(11)C]raclopride binding with no 
alterations in static dopamine concentrations in the striatal extracellular fluid in 
the monkey brain: multiparametric PET studies combined with microdialysis 
analysis. Synapse 37: 95-103. 
 
Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T (2000b). Cholinergic 
neuronal modulation alters dopamine D2 receptor availability in vivo by Chapter 1 
  41 
regulating receptor affinity induced by facilitated synaptic dopamine turnover: 
positron emission tomography studies with microdialysis in the conscious 
monkey brain. J Neurosci 20: 7067-7073. 
 
Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF 
(2002). Comparative effects of methamphetamine and nicotine on the striatal 
[(11)C]raclopride binding in unanesthetized monkeys. Synapse 45(4): 207-212. 
 
Tyacke RJ, Robinson ES, Lalies MD, Hume SP, Hudson AL, Nutt DJ (2005). 
Estimation of endogenous noradrenaline release in rat brain in vivo using 
[3H]RX 821002. Synapse 55:126-132. 
 
Ungless MA (2004). Dopamine: the salient issue. Trends Neurosci. 27:702-706. 
 
Vaidya CJ (2002). Application of pharmacological fMRI to developmental 
psychiatric disorders. Developmental Science 5: 310-317. 
 
Vallone D, Picetti R, Borrelli E (2000). Structure and function of dopamine 
receptors. Neurosci Biobehav Rev 24:125-132. Review. 
 
Vizi ES (2000). Role of high-affinity receptors and membrane transporters in 
nonsynaptic communication and drug action in the central nervous system. 
Pharmacol Rev 52: 63-89. 
 
Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman 
J, Angrist B, Pappas N, MacGregor R, Burr G, Cooper T, Wolf A (1994). 
Imaging endogenous dopamine competition with [11C]raclopride in the human 
brain. Synapse 16: 255-262. 
 
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, 
Dewey SL, Pappas N (1997a). Decreased striatal dopaminergic responsiveness 
in detoxified cocaine-dependent subjects. Nature 386: 830-833. 
 
Volkow ND, Wang GJ, Fowler JS, Logan J, Angrist B, Hitzemann R, Lieberman 
J, Pappas N (1997b). Effects of methylphenidate on regional brain glucose 
metabolism in humans: relationship to dopamine D2 receptors. Am J Psychiatry 
154: 50-55. 
 
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, 
Pappas N (1998a). Dopamine transporter occupancies in the human brain 
induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155: 
1325-1331. 
 
Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Gatley J, Ding YS, Wong C, 
Pappas N (1998b). Differences in regional brain metabolic responses between 
single and repeated doses of methylphenidate. Psychiatry Res 83: 29-36. 
 General introduction 
  42 
Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, 
Ding YS, Pappas N (1999a). Association of methylphenidate-induced craving 
with changes in right striato-orbitofrontal metabolism in cocaine abusers: 
implications in addiction. Am J Psychiatry 156: 19-26. 
 
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, Hitzemann R, 
Pappas NR (1999b) Reinforcing effects of psychostimulants in humans are 
associated with increases in brain dopamine and occupancy of D(2) receptors. 
J Pharmacol Exp Ther 291: 409-415. 
 
Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M, Logan J, 
Franceschi D, Gatley J, Hitzemann R, Gifford A, Wong C, Pappas N (2001). 
Low level of brain dopamine D2 receptors in methamphetamine abusers: 
association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158: 
2015-2021. 
 
Volkow ND, Fowler JS, Wang GJ (2002a). Role of dopamine in drug 
reinforcement and addiction in humans: results from imaging studies. Behav 
Pharmacol 13: 355-366. 
 
Volkow ND, Wang GJ, Fowler JS, Logan J (2002b). Franceschi,-D; Maynard,-L; 
Ding,-Y-S; Gatley,-S-J; Gifford,-A; Zhu,-W; Swanson,-J-M Relationship between 
blockade of dopamine transporters by oral methylphenidate and the increases 
in extracellular dopamine: therapeutic implications. Synapse 43: 181-187. 
 
Vollenweider FX, Maguire RP, Leenders KL, Mathys K, Angst J (1998). Effects 
of high amphetamine dose on mood and cerebral glucose metabolism in normal 
volunteers using positron emission tomography (PET). Psychiatry Res 83: 149-
162. 
 
Vollm BA, de-Araujo IE, Cowen PJ, Rolls ET, Kringelbach ML, Smith KA, 
Jezzard P, Heal RJ, Matthews PM (2004). Methamphetamine activates reward 
circuitry in drug naive human subjects. Neuropsychopharmacology 29: 1715-
1722. 
 
Watson J, Collin L, Ho M, Riley G, Scott C, Selkirk JV, Price GW (2000). 5-HT1A 
receptor agonist-antagonist binding affinity difference as a measure of intrinsic 
activity in recombinant and native tissue systems. Br J Pharmacol. 130: 1108-
1114. 
 
Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, Rapeport G, 
Tracey I (2002). Combining fMRI with a pharmacokinetic model to determine 
which brain areas activated by painful stimulation are specifically modulated by 
remifentanil. Neuroimage 16: 999-1014. 
 
Wise RA (2004). Dopamine, learning and motivation. Nat Rev Neurosci 5: 483-
494. 
 Chapter 1 
  43 
Wolkin A, Angrist B, Wolf A, Brodie J, Wolkin B, Jaeger J, Cancro R, Rotrosen J 
(1987). Effects of amphetamine on local cerebral metabolism in normal and 
schizophrenic subjects as determined by positron emission tomography. 
Psychopharmacology-(Berl) 92: 241-246. 
 
Wreggett KA, Seeman P (1984). Agonist high- and low-affinity states of the D2-
dopamine receptor in calf brain. Partial conversion by guanine nucleotide. Mol 
Pharmacol 25: 10-17. 
 
Wurtman RJ, Hefti F, Melamed E (1980). Precursor control of neurotransmitter 
synthesis. Pharmacol Rev 32:315-335. 
 
Yatham LN, Liddle PF, Shiah IS, Scarrow G, Lam RW, Adam MJ, Zis AP, Ruth 
TJ (2000). Brain serotonin2 receptors in major depression: a positron emission 
tomography study. Arch Gen Psychiatry 57: 850-858. 
 
Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, 
Suri A, Bramer S, Wong DF (2002). Dopamine D2 and D3 receptor occupancy 
in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): 
a study using positron emission tomography and [11C]raclopride. 
Neuropsychopharmacology 27:248-259. 
 
Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, Levey AI (1995). 
Immunocytochemical localization of D1 and D2 dopamine receptors in the basal 
ganglia of the rat: light and electron microscopy. Neuroscience 65: 709-730. 
 
Zald DH, Boileau I, El-Dearedy W, Gunn R, McGlone F, Dichter GS, Dagher A 
(2004). Dopamine transmission in the human striatum during monetary reward 
tasks. J Neurosci 24: 4105-4112. 
 
Zanardi R, Artigas F, Moresco R, Colombo C, Messa C, Gobbo C, Smeraldi E, 
Fazio F (2001). Increased 5-hydroxytryptamine-2 receptor binding in the frontal 
cortex of depressed patients responding to paroxetine treatment: a positron 
emission tomography scan study. J Clin Psychopharmacol 21: 53-58. 
 
Zhou FC, Tao-Cheng JH, Segu L, Patel T, Wang Y (1998). Serotonin 
transporters are located on the axons beyond the synaptic junctions: anatomical 
and functional evidence. Brain Res 805:241-254. 
 
Zimmer L, Mauger G, Le-BarsD, Bonmarchand G, Luxen A, Pujol JF (2002). 
Effect of endogenous serotonin on the binding of the 5-HT1A PET ligand 18F-
MPPF in the rat hippocampus: kinetic beta measurements combined with 
microdialysis. J Neurochem 80(2): 278-286. 
 
Zoli M, Jansson A, Sykova E, Agnati LF, Fuxe K (1999). Volume transmission in 
the CNS and its relevance for neuropsychopharmacology. Trends Pharmacol 
Sci 20: 142-150. 
 General introduction 
  44 
Zubieta JK, Ketter TA, Bueller JA, Xu Y (2003). Kilbourn,-M-R; Young,-E-A; 
Koeppe,-R-A Regulation of human affective responses by anterior cingulate and 
limbic mu-opioid neurotransmission. Arch Gen Psychiatry 60: 1145-1153. 
  
  45 
CHAPTER 2 
5-HT1A RECEPTOR IMAGING IN THE 
HUMAN BRAIN:  
EFFECT OF TRYPTOPHAN DEPLETION 
AND INFUSION ON [
18F]-MPPF BINDING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joanna I. Udo de Haes
1, Fokko J. Bosker
1, Aren van Waarde
2, Jan Pruim
2, 
Antoon T.M. Willemsen
2, Willem Vaalburg
2, Johan A. den Boer
1 
1Department of Biological Psychiatry, University Medical Center Groningen, 
2PET center, 
University Medical Center Groningen 
Published in Synapse 46 (2002): 108-115 
 5-HT1A receptor imaging in the human brain 
  46 
Abstract 
The 5-HT1A receptor has been implicated in a variety of physiological 
processes, psychiatric disorders and neurodegenerative disorders. [
18F]-
MPPF is a useful radioligand for quantitative imaging of 5-HT1A receptors in 
human subjects. Previous studies have shown that the binding of some 
radioligands is sensitive to changes in neurotransmitter concentration, 
whereas in other cases, binding is not affected. In the present study we 
investigated if [
18F]-MPPF binding to the 5-HT1A receptor is sensitive to 
changes in 5-HT. Changes in 5-HT levels were achieved by influencing its 
synthesis through tryptophan depletion, including a tryptophan-free amino 
acid drink 4.5 hour prior to the PET scan and tryptophan infusion (10 mg/ml, 
50 mg/kg, 30 minutes, starting 60 minutes prior to the PET scan). Binding of
 
[
18F]MPPF in the brain of 6 healthy, male volunteers was compared in these 
two conditions. Mean BPs in the medial temporal cortex, cortical regions 
and raphe nucleus did not significantly differ between the two conditions. 
The results of the study show that, under the experimental conditions used, 
[
18F]-MPPF binding was not affected. It is hypothesized that the increases in 
5-HT levels needed to produce a measurable effect on [
18F]-MPPF binding 
would be significantly greater than that possible with tryptophan 
manipulation. Therefore, in pathological conditions, where such large 
increases in 5-HT levels are not expected, [
18F]-MPPF seems a useful 
ligand to measure 5-HT1A receptor distribution without interference of 
endogenous 5-HT. Chapter 2 
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Introduction 
The 5-HT1A receptor is distributed widely throughout the brain with the 
highest densities in the hippocampal formation, neocortex and raphe 
nucleus (Hall et al. 1997). The 5-HT1A receptor is implicated in a variety of 
physiological processes (Barnes and Sharp 1999) such as sexual behavior, 
sleep, learning and memory and homeostatic mechanisms. Several studies 
also report the possible involvement of this receptor in psychiatric and 
neurodegenerative disorders (Bantick et al. 2001; Hjorth et al. 2000; 
Oosterink et al. 1998). 
 
The study of receptors in the living human brain has become possible by 
means of Positron Emission Tomography (PET). Recently, two independent 
PET studies reported a decrease of 5-HT1A receptor binding in depressed 
patients, using the radioligand [
11C]-WAY-100635, a selective 5-HT1A 
receptor antagonist (Drevets et al. 1999; Sargent et al. 2000). [
18F]-MPPF  
(4-(2'-methoxyphenyl)-1-[2'-(N-2"-pyridinyl)-p-
[
18F]fluorobenzamido]ethylpiperazine) is another selective 5-HT1A receptor 
antagonist. It can be prepared in high yields, and due to the relatively long 
half-life of 
18F, this radioligand can be distributed to PET centers that do not 
have access to onsite radiotracer production facilities (Passchier et al. 
2001). Previous studies in animals and healthy volunteers have shown that 
[
18F]-MPPF displays a regional radioactivity uptake in good correlation with 
known 5-HT1A receptor distribution and density (Ginovart et al. 2000; Le 
Bars et al. 1998; Passchier et al. 2000; Passchier et al. 2001; Plenevaux et 
al. 2000; Shiue et al. 1997). 
 
For an optimal use of [
18F]-MPPF in clinical studies, it is important to 
investigate whether the binding of the ligand is sensitive to changes in 
extracellular serotonin (5-hydroxytryptamine, 5-HT) concentration. Previous 
studies have shown that the binding of some radioligands is sensitive to 
changes in neurotransmitter concentration, whereas in other cases, binding 
is not affected (Laruelle 2000). The binding of the D2 receptor ligand 
[
11C]raclopride, for instance, is found to be sensitive to changes in 
dopamine release. The binding is decreased by elevation of extracellular 5-HT1A receptor imaging in the human brain 
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dopamine concentration and increased after a reduction of dopamine levels 
(Ginovart et al. 1997; Volkow et al. 1994). These alterations in ligand 
binding are interpreted as changes in availability of the receptor after 
neurotransmitter release. 
 
It has been hypothesized that for a tracer to be sensitive to changes in 
neurotransmitter concentration, it should reversibly bind to the receptor and 
rapidly clear from tissue to blood (Endres and Carson 1998). Because [
18F]-
MPPF dissociates relatively fast from the receptor, the binding could be 
sensitive to changes in brain 5-HT (Passchier et al. 2000). 
 
If [
18F]-MPPF appears to be sensitive to changes in 5-HT levels, it may be 
used to measure alterations of neurotransmitter release associated with 
psychiatric disorders such as depression (Blier and de-Montigny 1994). On 
the other hand, when changes in neurotransmitter levels do not  affect [
18F]-
MPPF binding, the ligand is suitable to detect differences in receptor 
distribution irrespective of endogenous 5-HT levels. 
 
In human subjects, the effect of changes in brain 5-HT levels can be studied 
by varying plasma tryptophan levels. Tryptophan is the precursor of 5-HT. 
Because brain 5-HT synthesis depends on the availability of this precursor, 
changes in plasma tryptophan lead to dose related alterations in brain 5-HT 
levels and 5-HT turnover (Fernstrom and Wurtman 1971; Moja et al. 1989). 
A decrease in tryptophan levels can be induced by tryptophan depletion, 
consisting of a low tryptophan diet followed by a tryptophan-free amino acid 
drink (Delgado et al. 1990; Young et al. 1985). A reduction in total and free 
plasma tryptophan levels of around 90 % is achieved within 5 hours after 
administration of the amino acid drink (Delgado et al. 1990). Moreover, 
studies in healthy volunteers show that cerebrospinal fluid (CSF) levels of 
the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA) are decreased 
after tryptophan depletion, indicating that 5-HT function indeed is reduced 
by this method (Carpenter et al. 1998; Williams et al. 1999). Plasma 
tryptophan levels can be increased by means of tryptophan infusion. A 
study by Young and Gauthier (1981) in human volunteers showed that CSF 
5-HIAA levels increased after tryptophan administration, indicating 
increased 5-HT synthesis, release and metabolism. In addition, Chapter 2 
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microdialysis studies in rats showed that 5-HT levels in the brain indeed are 
affected by changes in plasma tryptophan levels (Stancampiano et al. 1997; 
Westerink and de Vries 1991). 
 
In the present study, the sensitivity of [
18F]-MPPF binding to changes in 5-
HT in human subjects was investigated by comparing [
18F]-MPPF binding 
potential (BP) after tryptophan depletion and tryptophan infusion. In order to 
induce maximal differences in receptor availability, PET scans were 
performed in both conditions in the same subject. 
Materials and methods 
General design 
Binding of
 [
18F]-MPPF was compared in two conditions, separated by 7 to 
10 days. In one condition, 5-HT synthesis was decreased by tryptophan 
depletion consisting of a low tryptophan diet and a tryptophan–free amino 
acid drink 4.5 hour before the PET scan (see below). In the other condition, 
5-HT synthesis was increased by tryptophan infusion, starting at 60 minutes 
before the PET scan (see below). Each volunteer was studied in both 
conditions, thereby eliminating inter-individual variation. The sequence of 
the tryptophan depletion and infusion condition was randomly assigned. The 
starting time of all [
18F]-MPPF PET scans was between 13.30 p.m. and 
16.00 p.m.  Blood samples were taken for tryptophan analyses and the 
Profile of Mood States (POMS) (McNair et al. 1971) was used to record 
adverse reactions. Subjects were asked to refrain from alcohol use on the 
evening before the PET scan and from caffeine containing products on the 
day of the PET scan. After the PET scan, food and drink intake was no 
longer restricted. 
Subjects 
The study was approved by the medical ethics committee of the University 
Medical Center Groningen. Six healthy male volunteers were included (age 
range: 19 to 62 years) after written informed consent had been obtained. 
Only male volunteers were included to avoid possible effects of the 5-HT1A receptor imaging in the human brain 
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menstrual cycle on 5-HT1A  receptor density. Suitability to participate in the 
study was determined by an independent physician after a medical 
examination including an ECG and blood laboratory tests. The subjects 
were non-smoking, without history of neurodegenerative or psychiatric 
disorders and did not use psychoactive drugs or corticosteroids. 
Radiochemistry 
[
18F]-MPPF was prepared by nucleophilic [
18F] fluorination of the appropriate 
nitro precursor  (see Shiue et al. 1997 for a comparable method). Thereafter 
it was formulated into saline  containing 10% ethanol. Levels of nitro 
precursor were < 1 mg/L. The radiochemical purity was greater than 95% 
and the specific activity > 10 TBq/mmol at the time of injection. 
PET protocol 
The PET scans were performed in 3D acquisition mode using a Siemens 
ECAT Exact HR+ camera, giving 63 slices with a center to center distance 
of 2.425 mm. Before the start of the PET scan, the volunteers were 
positioned in the camera and their heads were fixed using a head restraint. 
A transmission scan was obtained using 
68Ge/
68Ga-rod-sources for 
attenuation correction of the dynamic PET scan. After the transmission 
scan, [
18F]-MPPF (110 – 160 MBq) was administered as a 60 s injection in a 
vein in one of the lower forearms. Twenty-one consecutive frames were 
acquired over a period of 60 minutes. [
15O]-H2O (500 MBq) was injected to 
assess regional cerebral blood flow. Data were acquired over a period of 3.5 
minutes. 
Regions of interest 
The image obtained from the [
15O]-H2O scan was used to obtain anatomical 
information to draw regions of interest. The regions were manually drawn in 
the transaxial orientation using a contour tool (Clinical Applications 
Programming Package, Siemens/CTI, Knoxville, TN). The areas were 
located using a stereotaxic atlas (Talairach and Tournoux 1989). Regions of 
interest (ROIs) were defined for the medial temporal cortex (MTC) including 
the hippocampus, frontal cortex, cingulate cortex, insular cortex, lateral 
temporal cortex, raphe nucleus and cerebellum. The ROI for the raphe Chapter 2 
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nucleus was directly drawn on the binding potential (BP) image (see below). 
Each ROI was drawn in 3 (MTC, raphe nucleus and cerebellum) or 5 (all 
other areas) consecutive planes and the data were pooled over the planes 
so that the mean value for the whole region was obtained. Right and left 
regions of bilateral ROI’s were averaged. 
Binding potential calculation 
Binding potentials (BPs) were calculated using a simplified reference tissue 
model on a pixel by pixel basis, with the cerebellum as reference region 
(Gunn et al. 1997). The same ROI boundaries were used to analyze the two 
scans of each subject after realignment of the two [
18F]-MPPF BP images to 
the corresponding [
15O]-H2O scan, by means of statistical parametric 
mapping (SPM 99) (Frackowiak et al. 1997). 
Tryptophan depletion 
Tryptophan depletion consisted of a 24-hour low tryptophan diet (diet 
available on request) followed at the next morning by a tryptophan-free 
amino acid drink, in fasting condition. The amino acid drink was composed 
of 15 amino acids as described by Young et al. (1985). Just before 
administration, 300 ml cooled tap water was added and the mixture was 
flavored with artificial fruit flavor. The drink was administered approximately 
4.5 hour before the [
18F]-MPPF PET scan and consumed over a period of 
20 minutes. The subjects remained in a quiet room during the following 
hours. They were allowed to drink water but could not eat food or take other 
drinks until the end of the PET scan. Approximately one hour before start of 
the PET scan, the subjects were transported to the PET centre. Blood 
samples for tryptophan determinations were taken through an indwelling 
intravenous catheter just before administration of the amino acid drink (t = - 
270 minutes),  and 180 minutes (t = - 180), 120 minutes (t = - 120) and 60 
minutes (t = - 60) before the PET scan, at the start of the [
18F]-MPPF PET 
scan (t = 0) and at the end of the [
18F]-MPPF PET scan (t = 60). The 
samples were immediately placed on ice. POMS rating scales were 
completed just prior to plasma sampling.  5-HT1A receptor imaging in the human brain 
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Tryptophan infusion 
Tryptophan infusions were prepared by dissolving 10 g of tryptophan in 
1000 ml of a 0.74% NaCl solution with NaOH added to bring the solution to 
a pH level between 7.3 and 7.5. The solution was sterilized by passage 
through a 0.2 µm filter. The solution was tested for pyrogenicity and sterility 
before use. A dose of 50 mg/kg tryptophan was infused over 30 minutes 
through an indwelling intravenous catheter, starting 60 minutes before the 
[
18F]-MPPF PET scan. Blood samples for tryptophan determinations were 
taken just prior to the start of the infusion (t = - 60), at the end of the infusion 
(t = - 30), at the start of the [
18F]-MPPF PET scan (t = 0), 30 minutes after 
start of the PET scan ( t = 30) and at the end of the PET scan (t = 60). The 
samples were immediately placed on ice. POMS rating scales were 
completed just prior to plasma sampling. 
Tryptophan analysis 
Free tryptophan was isolated using a method by Eynard et al. (1993). Free 
and total tryptophan levels were then determined by high performance liquid 
chromatography (Kema et al. 2001). 
Statistical analyses 
BPs in the two conditions were compared using the Wilcoxon signed rank 
test. Spearman correlation’s were used to assess if BP changes between 
the two conditions were correlated to changes in cerebellar activity (AUC in 
cerebellum corrected for injected radioactivity), age or sequence of 
experimental condition. 
Results 
Tryptophan challenges 
Tryptophan depletion 
The amino acid drink was consumed completely by five of the volunteers. 
Volunteer 3 could only drink one third of the mixture because of the 
unpalatable taste. Mean plasma total and free tryptophan levels of all 6 Chapter 2 
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subjects were reduced compared to baseline levels (67 % and 62 % 
respectively) (Figure 1). The plasma total and free tryptophan levels of the 
subject who did not consume the whole drink were reduced by 30 % and 48 
% respectively. Approximately 1 to 1.5 hours after intake of the amino acid 
drink some of the subjects experienced nausea,  abdominal fullness and 
light drowsiness as shown by the POMS ratings. No significant changes in 
mood were picked up by the POMS. 
Tryptophan infusion 
Tryptophan infusion caused an increase in total and free tryptophan levels 
compared to baseline (1021 % and 3986 % respectively) (Figure 1). Some 
of the volunteers reported slight dizziness after the infusion, as shown by 
the POMS ratings. 
[
18F]-MPPF binding 
Distribution 
After administration of [
18F]-MPPF, the distribution of radioactivity was in 
agreement with previous results and with known 5-HT1A  receptor 
localization, with the highest uptake in the MTC and low uptake in the 
cerebellum (Ginovart et al. 2000; Le Bars et al. 1998; Passchier et al. 2000; 
Passchier et al. 2001; Plenevaux et al. 2000; Shiue et al. 1997). 
Binding potentials in the two conditions 
BPs were calculated for the MTC, frontal cortex, cingulate cortex, insular 
cortex, lateral temporal cortex and raphe nucleus. Signifcant differences 
between the two conditions were not observed for the mean BPs in the 
various regions (Figure 2). The mean BP changes in the combined cortical 
regions, were in the same direction as changes in the individual cortical 
areas. Therefore, for further analysis, BP data for the frontal cortex, 
cingulate cortex, insular cortex and lateral temporal cortex were combined. 
After tryptophan infusion, compared to tryptophan depletion, the mean 
change in BP was – 0.6 % in the MTC (range – 14 % to + 16.6 %), + 1.9 % 
in the cortical regions (range – 11.6 % to + 22.1 %) and – 16.6 % in the 
raphe nucleus (range –75.3 to + 37.0 %) (table I). There was no correlation 
between changes in BP in the different regions and changes in cerebellar 
radioactivity, age or sequence of condition. 5-HT1A receptor imaging in the human brain 
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Figure 1: Mean (SD) plasma tryptophan levels (total and free) after tryptophan 
depletion and infusion. 
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Figure 2: Individual and mean (dotted line) BPs after tryptophan depletion and 
tryptophan infusion in the cortical regions, medial temporal cortex and raphe. 
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Table I: Individual and mean BPs after tryptophan depletion and infusion for the 
combined cortical areals, medial temporal cortex (MTC) and raphe nucleus. 
 
Volunteer Region  Depletion Infusion  %  Change 
1  Cortical  areas  0.94 0.97 +3.2 
  MTC  2.07 2.02 -2.4 
  Raphe  0.59 0.31 -47.5 
2  Cortical  areas  0.86 0.76 -11.6 
  MTC  2.15 1.85 -14.0 
  Raphe  0.77 0.19 -75.3 
3  Cortical  areas  0.80 0.75 -6.3 
  MTC  1.90 1.86 -2.1 
  Raphe  0.68 0.73 +7.4 
4  Cortical  areas  0.86 1.05 +22.1 
  MTC  1.69 1.97 +16.6 
  Raphe  0.54 0.74 +37.0 
5  Cortical  areas  0.73 0.70 -4.1 
  MTC  1.99 1.84 -7.5 
  Raphe  0.76 0.43 -43.4 
6  Cortical  areas  0.87 0.94 +8.1 
  MTC  1.85 1.96 +5.9 
  Raphe  0.54 0.66 +22.2 
Mean (SD)  Cortical areas  0.84 (0.07)   0.86 (0.14)  +1.9 (12.1) 
  MTC  1.94 (0.17)  1.92 (0.08)  -0.6 (10.7) 
  Raphe  0.65 (0.11)  0.51 (0.23)  -16.6 (44.9) 
 
Discussion 
The aim of this study was to investigate if [
18F]-MPPF binding to the 5-HT1A 
receptor is sensitive to changes in 5-HT concentration in human subjects. 
Therefore, [
18F]-MPPF binding was investigated after tryptophan depletion 
and tryptophan infusion, since changes in plasma tryptophan levels have 
been found to induce changes in brain 5-HT levels (Fernstrom and Wurtman 
1971; Moja et al. 1989). The results of the study show that, under these 
experimental conditions, [
18F]-MPPF binding was not affected by the Chapter 2 
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changes in 5-HT concentration. In the raphe nucleus the mean BP 
decreased by 16.6 % after tryptophan infusion, which could be interpreted 
as competition between [
18F]-MPPF and 5-HT. However, when looking at 
the data more carefully, it appears that a decrease is only seen in half of the 
subjects. In the other three subjects, BPs were slightly increased after 
tryptophan infusion compared to tryptophan depletion. Moreover, because 
of the large variability in BPs, probably caused by the small size of the raphe 
nucleus, it is very hard to draw any conclusions from these data. 
 
Recently, a few PET studies were performed in which the sensitivity of 5-HT 
ligands to changes in 5-HT levels was investigated. Using [
18F]altanserin, it 
was shown that ligand binding to the 5-HT2 receptor was decreased after 
administration of the 5-HT reuptake inhibitor clomipramine (Larisch et al. 
2000). Studies using 5-HT1A receptor radioligands however, did not show 
consistent results. After administration of the 5-HT releaser and reuptake 
inhibitor fenfluramine (10 mg/kg i.p.), a decrease in [
11C]-WAY-100635 BP 
was seen in the hippocampus of the rat but not in the prefrontal cortex or 
raphe nucleus (Hume et al. 2001). In contrast, using the same radioligand, 
Maeda et al. (2001) did not find an effect of fenfluramine (10 mg/kg i.p.) in 
the hippocampus of the rat. Recently a study was performed, using a ß
+ 
radiosensitive probe, to investigate changes in [
18F]-MPPF binding in vivo 
after different doses of fenfluramine. The authors reported a dose related 
decrease of [
18F]-MPPF binding in the hippocampus of the rat (Zimmer et al. 
2001). Rabiner et al. (2000) investigated the binding of [
11C]-WAY-100635 
in the prefrontal cortex and MTC of human volunteers after either tryptophan 
depletion or tryptophan infusion compared to baseline. They did not find 
consistent changes in the expected direction after these challenges. 
 
These discrepancies may be related to differences in the timing and extent 
of the alterations in 5-HT levels. In the studies of Hume et al. (2001), Maeda 
et al. (2001) and Zimmer et al. (2001), changes in extracellular 5-HT were 
estimated via microdialysis. Hume et al. showed that fenfluramine treatment 
resulted in a 15-fold increase in extracellular 5-HT levels in the 
hippocampus, whereas the increase in the prefrontal cortex was only 5-fold. 
In the study of Zimmer et al., the maximum increase in 5-HT was also 15-
fold, whereas the maximum 5-HT increase at the time of the PET scan in 5-HT1A receptor imaging in the human brain 
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the study of Maeda et al. was not more than 5-fold. Studies in rats indicate 
that decreases in extracellular 5-HT after tryptophan depletion, as used in 
the present study and the study of Rabiner et al. (2000), are only 50% 
(Stancampiano et al. 1997) and maximal increases in 5-HT after tryptophan 
infusion are only 2-fold (Wurtman and Fernstrom 1975; Young and Gauthier 
1981). Thus far, the data from animal studies indicate that substantial 
increases in 5-HT are needed to measure changes in ligand binding to the 
5-HT1A receptor. 
 
When exploring this issue in further detail, it is important to consider that the 
5-HT1A receptor can exist in a high and low affinity state (Gozlan et al. 1995; 
Khawaja 1995; Mongeau et al. 1992; Nénonéné et al. 1994; Watson et al. 
2000). The proportion of 5-HT1A receptors in the high affinity state may 
depend on the brain area examined (Khawaja 1995). Antagonists, such as 
[
18F]-MPPF and [
11C]-WAY-100635 will bind with equal affinity to either state 
whereas agonists such as 5-HT will preferentially bind to the high affinity 
state (Gozlan et al. 1995; Khawaja 1995; Mongeau et al. 1992; Nénonéné et 
al. 1994; Watson et al. 2000). It can be argued that changes in 5-HT will 
therefore mainly effect [
18F]-MPPF and [
11C]-WAY-100635 binding at the 
receptors in the high affinity state. Consequently, changes in binding can 
only be detected when a large enough proportion of 5-HT1A receptors is in 
the high agonist affinity state, or alternatively, when 5-HT increases are 
sufficiently large to also affect ligand binding to receptors in the low agonist 
affinity state. 
 
Of relevance in this respect could be that 5-HT1A receptors are located both 
within the synapse and extrasynaptically (Azmitia et al. 1996; Riad et al. 
2000). It has been suggested that extrasynaptic 5-HT1A receptors are 
activated by the low, ambient concentration of 5-HT, which is permanently 
maintained in the extracellular space, thereby enabling the widespread 
effects of 5-HT in global physiological processes, behavioral and therapeutic 
effects (Riad et al. 2000). Following this idea, regulation through 
extrasynaptic 5-HT1A receptors is optimal when extracellular 5-HT levels are 
in the range of the KD. The microdialysis studies by Hume et al. (2001) and 
Maeda et al. (2001) indicate that, even following fenfluramine 
administration, extracellular 5-HT levels are in the range of 6 - 35 nM, which Chapter 2 
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is at least a factor 10 below the affinity of 5-HT for the low agonist affinity 
state (Gozlan et al. 1995; Khawaja et al. 1995; Nénonéné et al. 1994; 
Watson et al. 2000). Taken together, we expect the major part of 
extracellular 5-HT1A receptors to be in the high agonist affinity state. Can 
our results and those of the before-mentioned studies, be explained in terms 
of competition at the extrasynaptic receptors? Using the law of mass action:  
] 5 [
] 5 [ * max
HT K
HT B
B
D +
=  
and assuming a 5-HT concentration equal to the KD, a two-fold increase or 
decrease in 5-HT concentration, as used in the current study, would result in 
an increase or decrease of 5-HT occupancy from 50% of Bmax to 67% or 
33% of Bmax, respectively. A 5-fold increase as found in the studies of 
Maeda et al. (2001) and Hume et al. (2001) would result in an increase in 
occupancy from 50% of Bmax to 83% of Bmax. Such changes seem large 
enough to induce changes in ligand binding. This is at variance with the 
present study wherein we could not demonstrate significant changes in 
[
18F]-MPPF binding. A reasonable explanation could be that the proportion 
of extrasynaptic receptors is low and most 5-HT1A receptors are thus 
located intrasynaptically. 
 
Can our results be explained in terms of competition at intrasynaptic 5-HT1A 
receptors? According to Maeda et al. (2001) and Hume et al. (2001), 
baseline 5-HT levels are considerably lower than those of dopamine. This 
may partly explain the differences in sensitivity to neurotransmitter changes 
between D2 and 5-HT1A ligands. Moreover, a large part of the 5-HT1A 
receptors may be in the low agonist affinity state (Nénonéné et al. 1994). To 
measure competition at this receptor state, large increases in 5-HT may be 
necessary. Arguably, manipulation of 5-HT synthesis by tryptophan 
depletion or infusion, may be too subtle to achieve this. 
 
The question is, how to induce sufficiently large increases in 5-HT in human 
subjects? It can be argued that a decrease in BP in the current study may 
have been seen after a higher dose of tryptophan. However, previous 
experiments in rats and human subjects indicate that 5-HT synthesis is not 5-HT1A receptor imaging in the human brain 
  60 
further increased at tryptophan doses exceeding 50 mg/kg. In the present 
study tryptophan was infused over 30 minutes, starting 60 minutes prior to 
the PET scan. Rat experiments showed that brain levels of 5-HT are 
maximally increased within the first 30-60 minutes of tryptophan injection 
(Sharp et al. 1992). 
 
Future studies in humans should explore other methods to increase 5-HT, 
for example by interfering with its release and reuptake. In the animal 
studies of Zimmer et al. (2001) and Hume et al. (2001), detectable 
decreases in radioligand binding were seen after administration of 
fenfluramine. Fenfluramine both releases 5-HT and blocks the reuptake 
sites of 5-HT, which may increase 5-HT in the synapse to levels sufficiently 
high for competition at the low affinity state. Unfortunately, safety 
considerations, preclude the use of comparable fenfluramine doses in man. 
Maybe, strategies based on reuptake inhibition combined with autoreceptor 
blockade, offer an alternative. 
 
To summarize, the results of the present study with [
18F]-MPPF complement 
recent studies in rat and man, using [
11C]-WAY-100635, and suggest that 
under baseline conditions only a few percent of the intrasynaptic 5-HT1A 
receptor population is occupied by 5-HT. In order to attain measurable 
competition between [
18F]-MPPF and 5-HT, large increases in 5-HT are 
necessary. 
 
Therefore, in pathological conditions, where such large increases in 5-HT 
levels are not  expected, [
18F]-MPPF seems a useful ligand to measure 5-
HT1A receptor binding potentials without interference of endogenous 5-HT. Chapter 2 
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Abstract 
[
18F]-MPPF is a selective serotonin-1A (5-HT1A) receptor antagonist and 
may be used to measure changes in the functional levels of serotonin (5-
HT). The technique is based on the assumption that the injected 
radiolabeled ligand competes for the same receptor as the endogenous 
transmitter. Results from studies using serotonergic ligands are not always 
consistent. The aim of the present study was to investigate if [
18F]-MPPF 
binding is decreased after an increase in 5-HT levels. [
18F]-MPPF binding 
was assessed in conscious rats using ex-vivo autoradiography. We studied 
the effect of the 5-HT releasing agent and reuptake inhibitor fenfluramine 
(10 mg/kg i.p.) and of a combination of the selective serotonin reuptake 
inhibitor (SSRI) citalopram (10 μmol/kg, s.c.) with the 5-HT2C antagonist 
ketanserin (100 nmol/kg, s.c). The effect of both treatments on extracellular 
5-HT levels was determined using microdialysis. Fenfluramine treatment 
resulted in a 30-fold increase in extracellular 5-HT levels in the ventral 
hippocampus and induced a significant reduction of [
18F]-MPPF binding in 
the frontal cortex, hypothalamus, amygdala and hippocampus. The 
microdialysis results showed a 10-fold 5-HT increase in the ventral 
hippocampus after combined administration of ketanserin and citalopram. 
The combination, however, did not affect [
18F]-MPPF binding. Our data 
show that [
18F]-MPPF binding in conscious rats is only reduced after 
substantial and therefore non-physiological increases in 5-HT levels. These 
results may imply that the majority of 5-HT1A receptors is in the low affinity 
state, in vivo.  Chapter 3 
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Introduction 
The serotonergic system has been implicated in the pathophysiology and 
treatment of a variety of psychiatric disorders such as depression, anxiety 
and schizophrenia (Blier and de Montigny 1998; den Boer 2000; Kapur and 
Remington 2001; Seeman 2002). Several studies reported the possible 
involvement of the 5-HT1A receptor in these disorders (Bantick et al. 2001; 
Groenink et al. 2003; Hjorth et al. 2000). Differences in receptor densities 
can be quantified using radiolabeled ligands. The selective 5-HT1A receptor 
antagonists [
18F]-MPPF (4-(2'-methoxyphenyl)-1-[2'-(N-2"-pyridinyl)-p-
[
18F]fluorobenzamido]ethylpiperazine) and [
11C]-WAY-100635 ([
11C][O-
methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) 
cyclohexanecarboxamide trihydrochloride) appear to be useful radioligands 
for imaging of the 5-HT1A receptor in human subjects (Andree et al. 2000; 
Passchier et al. 2000; Sargent et al. 2000). 
 
Previous studies have shown that radiolabeled ligands could also be used 
to measure changes in the functional level of neurotransmitters in the brain. 
Abnormalities in 5-HT transmission have been widely studied using 
neuroendocrine challenge studies (Power and Cowen 1992). This method 
however, only reflects functioning of the hypothalamo-hypophysial 
serotonergic system, but does not necessarily assess 5-HT transmission in 
other brain regions. The combined use of radiolabeled ligands with a 
serotonergic challenge may provide information on 5-HT release in specific 
regions of the brain. The approach is based on the assumption that an 
injected radiolabeled ligand competes for the same receptor as the 
endogenous transmitter. So, increases in neurotransmitter release result in 
a decreased binding of the radioligand and decreased neurotransmitter 
release induces an increase in ligand binding. The changes in ligand 
binding are used as a measure of the change in neurotransmitter levels. 
This method has successfully been used for the dopaminergic system 
(Breier et al. 1997; Laruelle 2000). Results from studies using serotonergic 
ligands, however, do not always agree. 
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At present, a few studies have investigated if the binding of serotonergic 
ligands is sensitive to changes in 5-HT levels. These studies have primarily 
used [
11C]-WAY-100635 and [
18F]-MPPF and have been performed in rats 
and human subjects. Hume et al. (2001) reported the effect of the 5-HT 
releasing agent and reuptake inhibitor fenfluramine (10 mg/kg i.p.) on [
11C]-
WAY-100635 binding. They investigated the effect by means of positron 
emission tomography (PET) in anesthetized rats and the ex vivo distribution 
in dissected brain tissues from non-anesthetized rats. The PET results 
showed a 20% decrease in [
11C]-WAY-100635 binding potential in the 
hippocampus but not in the prefrontal cortex or raphe nucleus. The post 
mortem dissection studies did not show a statistically significant effect of 
fenfluramine on [
11C]-WAY-100635 uptake in the majority of tissues 
sampled, probably due to the relative long time interval between 
fenfluramine administration and measurement of radioactivity content. Using 
the same radioligand and comparable methods, Maeda et al. (2001) did not 
find an effect of fenfluramine (10 mg/kg i.p.) in the hippocampus of 
anesthetized rats. Zimmer et al. (2002a) investigated the effect of different 
doses of fenfluramine on [
18F]-MPPF binding in anesthetized rats, using a 
ß
+ radiosensitive probe. The authors reported a dose-related decrease of 
[
18F]-MPPF binding in the hippocampus. In human subjects [
11C]-WAY-
100635 binding in the prefrontal cortex and medial temporal cortex was not 
consistently affected after manipulation of 5-HT levels by means of either 
tryptophan depletion or tryptophan infusion (Rabiner et al. 2002). We have 
studied the effect of changes in 5-HT release on [
18F]-MPPF binding in 
human subjects and did not find a significant difference in [
18F]-MPPF 
binding between a tryptophan depletion and tryptophan infusion condition 
(Udo de Haes et al. 2002). 
 
The lack of effect in the studies that manipulated tryptophan levels may 
have been caused by the fact that intrasynaptic 5-HT levels are not 
sufficiently changed to produce a measurable effect on ligand binding 
(Rabiner et al. 2002; Udo de Haes et al. 2002). The differences in the 
studies using fenfluramine may be related to differences in timing of the 
pharmacological treatment. Another important factor could be the use of 
anesthesia. Previous studies have shown that ligand binding may be 
affected by the use of different anesthetics. The mechanism of these effects Chapter 3 
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is not completely understood but may be related to changes in cerebral 
blood flow or receptor affinity (Ginovart et al. 2002; Harada et al. 2004; 
Hassoun et al. 2003; Seeman and Kapur 2003). The size of 5-HT increase 
may also differ between conscious and anesthetized rats (Mokler et al. 
1998). 
 
In the present study we investigated the effect of fenfluramine (10 mg/kg, 
i.p.) and of a combination of the SSRI citalopram with the 5-HT2C antagonist 
ketanserin. Microdialysis studies in rat have shown that both treatments 
induce marked increases in extracellular 5-HT concentrations. The effect of 
the combined treatment of citalopram with ketanserin may be caused by a 
combination of 5-HT reuptake inhibition and modulation of global or local 
feedback mechanism(s), resulting in increased 5-HT release (Cremers et al. 
2004). Because, as mentioned before, anesthetics may have confounding 
effects on ligand binding, we used conscious rats. The effects on [
18F]-
MPPF binding were investigated using ex-vivo autoradiography. 
Concurrently, the effect of both challenges on extracellular 5-HT 
concentration was studied using similar dosages in microdialysis 
experiments. 
Materials and Methods 
Animals 
Male Wistar rats weighing 250-350 gram (Harlan, Zeist, The Netherlands) 
were used. After surgery (see below), rats were housed individually and 
kept on a 12-h light/dark schedule with food and water ad libitum. 
Microdialysis and ex vivo autoradiography experiments were done in 
separate animal groups. During microdialysis sampling and radioligand 
injection, rats were in conscious condition and able to move freely in their 
cages. All experiments were done during the light period. The study was 
approved by the Animal Care Committee of the University of Groningen. [18F]-MPPF binding in rat brain 
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Synthesis of [
18F]-MPPF 
[
18F]-MPPF was prepared by nucleophilic [
18F] fluorination of the appropriate 
nitro precursor  (see Shiue et al. 1997 for a comparable method). It was 
formulated into a 5% NaCl solution. Levels of nitro precursor were << 1 
mg/L. The radiochemical purity was greater than 95% and the specific 
activity > 10 TBq/mmol at the time of injection. 
Ex vivo autoradiography 
Jugular veins were cannulated 24 to 48 hours prior to radioligand injection 
(for a detailed description of the cannulation method, see Steffens (1969), 
for details on anesthesia during cannulation, see microdialysis 
experiments). Two hours before radioligand injection, the animals were 
deprived of food. Rats were injected with [
18F]-MPPF via the jugular vein 
cannula, in conscious condition. The mean (± SD) injected activity and 
injected mass were 14.4 (± 5.8) MBq and 0.23 (±0.07) nmol respectively 
and did not significantly differ between groups. 30 minutes prior to 
radioligand injection, the animals were treated either with saline (n=7), 
fenfluramine (10 mg/kg, i.p.) (n=7) or a combination of citalopram (10 
μmol/kg, s.c.) with ketanserin (100 nmol/kg, s.c.) (n=5). The animals were 
sacrificed by rapid guillotine decapitation (no anesthesia) 30 minutes after 
[
18F]-MPPF administration. This time point is based on earlier studies which 
showed that 30 minutes after injection, MPPF binding reaches a state of 
transient equilibrium (Plenevaux et al. 2000a; Shiue et al. 1997). The brains 
were removed from the skull, frozen in isopentane (-80 °C), cut into 80 μm 
coronal slices in a cryostat at –10 °C, thaw mounted onto glass slides, 
exposed to a phosphor storage screen (Packard) for at least 10 half-life 
times (18-20 hours) and scanned using the Cyclone storage phosphor 
system. Regions of interest (ROI’s) were drawn around the frontal cortex, 
cingulate cortex, septal nuclei, caudate-putamen (striatum), thalamus, 
hypothalamus, dentate gyrus, interpeduncular nucleus, amygdala, 
hippocampus, dorsal raphe and median raphe, using the Paxinos and 
Watson brain atlas (Paxinos and Watson 1998). For each region, data from 
the 4 sections with the highest activity were averaged, except for the 
amygdala, interpeduncular nucleus and raphe where an average of 2 
sections was used. For quantification, the digital light units (DLU)/mm
2 
values were measured for the different ROI’s. Individual calibration Chapter 3 
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standards with known activity were exposed to the screen simultaneously 
with the brain slices to convert the DLU/mm
2 values to Bq/mm
2. The activity 
of the different regions was converted to % injected dose per gram tissue 
(%ID) by dividing the regional activity by the injected activity and thickness 
of the slice. Specific binding was defined by the activity ratio of the region of 
interest to the cerebellum, a region virtually devoid of 5-HT1A receptors (Hall 
et al. 1997). 
Microdialysis experiments 
Preceding surgery, rats were anesthetized by means of isoflurane 2%, 600 
ml/min O2 and 400 ml/min N2O. Microdialysis probes were inserted in the 
ventral hippocampus (L +4.8 mm, IA: +3.7 mm, V: -8.0 mm) and dorsal 
raphe nucleus (L -1.4 mm, IA: +1.2 mm, V: -7.0 mm angle 10°). Sample 
collection was performed 24 to 48 hours after surgery, in conscious 
condition. The animals were treated either with fenfluramine (10 mg/kg, i.p.) 
(n=4 in the ventral hippocampus) or a combination of citalopram (10 
μmol/kg, s.c.) with ketanserin (100 nmol/kg, s.c.) (n=4 in the ventral 
hippocampus and raphe nucleus). The probes were perfused with artificial 
cerebrospinal fluid containing (in mM): NaCl 147, KCl 3.0, CaCl2 1.2, and 
MgCl2 1.2, at a flow-rate of 1.5 l/m). 15-minute microdialysis samples were 
collected and 5-HT levels were measured by HPLC with electrochemical 
detection. Post mortem, the position of the probe was verified by the track of 
the probe through the brain. Data are expressed as percent baseline. For a 
more detailed description of the microdialysis experiments and serotonin 
analysis, see Cremers et al. (2004). 
Behavioral observation 
The animals were continously observed after injection of the 
pharmacological treatments and effects on body movements or posture 
were scored as
 present if occurring during the observation period. 
Statistics 
The effects of the different treatments on [
18F]-MPPF binding were analyzed 
by an independent samples t-test. The data are presented as mean ratio to [18F]-MPPF binding in rat brain 
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cerebellum (±SD) and % change compared to control rats. Bonferroni 
corrections were used in order to correct for multiple comparisons. 
Drugs 
Citalopram hydrobromide and racemic fenfluramine hydrochloride were 
synthesized at and obtained from Lundbeck A/S (Copenhagen, Denmark). 
Ketanserin was obtained from RBI (Natick, USA). All drugs were dissolved 
in saline. 
Results 
Microdialysis 
Fenfluramine (10 mg/kg, i.p.) administration induced a 25 fold increase in 
the hippocampus at 45 minutes post injection. 5-HT levels were maximal at 
60 minutes after administration. At that time, a 30-fold increase in 5-HT 
levels was observed. After combined administration of citalopram (10 
μmol/kg, s.c.) and ketanserin (100 nmol/kg, s.c.), a 10 fold increase in 5-HT 
was observed in the ventral hippocampus and a 5 fold increase in the raphe 
nucleus. Peak levels were achieved 45 minutes after administration (Figure 
1). 
Ex vivo autoradiography 
[
18F]-MPPF distribution 
After administration of [
18F]-MPPF, the distribution of radioactivity in the 
control group was in agreement with previous results and with known 5-
HT1A  receptor localization, with the highest uptake in the raphe nuclei, 
septum and hippocampus and low uptake in the cerebellum (Ginovart et al. 
2000; Passchier et al. 2000; Plenevaux et al. 2000b; Shiue et al. 1997). 
Region over cerebellum ratios ranged from approximately 1 in the striatum 
to around 10 in the dorsal raphe nucleus. 
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Figure 1: Mean (±SD) extracellular 5-HT levels after fenfluramine (10 mg/kg, 
i.p.) (n=4) (ventral hippocampus) and combined citalopram (10 μmol/kg, s.c.) 
with ketanserin (100 nmol/kg, s.c.) (n=4) (ventral hippocampus and dorsal raphe 
nucleus) administration to conscious rats. HIP: hippocampus. 
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Effect of fenfluramine pretreatment 
Administration of fenfluramine did not significantly affect cerebellar [
18F]-
MPPF binding, compared to control rats. In fenfluramine treated rats mean 
(± SD) radioactivity in the cerebellum was 0.028 (±0.017) %ID, compared to 
0.030 (±0.010) %ID in control rats. Figure 2 depicts an example of a 
phosphor screen image at the level of the hippocampus and cerebellum of a 
control and fenfluramine treated rat, showing that [
18F]-MPPF binding is 
reduced in the fenfluramine treated rat compared to the control rat. In table 
1 and figure 3 the mean [
18F]-MPPF binding values (ratio to cerebellum) of 
control and fenfluramine treated rats are shown. Fenfluramine treatment 
resulted in a significant reduction in [
18F]-MPPF binding in the frontal cortex, 
thalamus, hypothalamus, amygdala, dentate gyrus, hippocampus and raphe 
nuclei. After Bonferroni correction, the reduction was significant in the frontal 
cortex, hypothalamus, amygdala and hippocampus. 
 
 
 
Figure 2: Ex vivo phosphor screen images, 30 minutes after i.v. injection of 
[
18F]-MPPF to conscious rats. Example of coronal sections at the level of the 
hippocampus and cerebellum in saline or fenfluramine (10 mg/kg, i.p.) 
pretreated animals. HIP: hippocampus, IPR: interpeduncular nucleus, CRB: 
cerebellum. Bar: 5 mm. Chapter 3 
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Effect of ketanserin-citalopram pretreatment 
Combined administration of ketanserin with citalopram also did not have a 
significant effect on cerebellar [
18F]-MPPF binding, compared to control rats. 
In the ketanserin with citalopram treated rats mean (± SD) radioactivity in 
the cerebellum was 0.029 (±0.006) %ID, compared to 0.030 (±0.010) %ID in 
control rats. Table 1 and figure 3 show mean [
18F]-MPPF binding values 
(ratio to cerebellum) of control and ketanserin with citalopram treated rats. 
In contrast to the effects of fenfluramine, pretreatment with ketanserin and 
citalopram did not significantly affect [
18F]-MPPF binding, except in the 
dorsal raphe nucleus. After Bonferroni correction, no significant changes 
were found. 
 
Figure 3: Mean (± SD) regional ex-vivo [
18F]-MPPF binding (ratio to 
cerebellum), 30 minutes after i.v. injection of the ligand to conscious rats. [
18F]-
MPPF was administered 30 minutes after saline, fenfluramine (10 mg/kg, i.p.) or 
combined citalopram (10 μmol/kg, s.c.) with ketanserin (100 nmol/kg, s.c.) 
treatment. 
* Indicates significant difference compared to control rats (p < 0.05, two tailed t-
test with Bonferroni correction).** Indicates significant difference compared to 
control rats (p < 0.01, two tailed t-test with Bonferroni correction). FC: Frontal 
cortex, CG: cingulate cortex, SEP: septum, STR: striatum, THA: thalamus, 
HYP: hypothalamus, DG: dentate gyrus, AMG: amygdala, HIP: hippocampus, 
IPR: interpeduncular nucleus, DR: dorsal raphe, MR: median raphe. 
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Effects on behavior 
Fenfluramine administration resulted in hind leg abduction, straub tail, penile 
licking and increased respiration. After administration of ketanserin and 
citalopram, penile erections were observed and an increase in grooming 
and licking behavior. Effects were seen at the time of [
18F]-MPPF injection 
and were still present at the moment of decapitation. 
 
 
 
Table I: Mean (± SD) regional ex-vivo [
18F]-MPPF binding (ratio to cerebellum), 
30 minutes after i.v. injection of the ligand to conscious rats. % change refers to 
drug versus saline treated rats. * Indicates significant difference compared to 
control rats (p < 0.05, two tailed t-test with Bonferroni correction). ** Indicates 
significant difference compared to control rats (p < 0.01, two tailed t-test with 
Bonferroni correction). 
 
 [
18F]-MPPF binding (ratio to cerebellum) 
Region Control 
(n=7) 
Mean ± SD  
Fenfluramine 
(n=7) 
Mean ± SD(% change) 
Ketanserin + citalopram 
(n=5) 
Mean ± SD (% change) 
Frontal ctx  4.0 ± 0.3  3.0 ± 0.3 (-23%) **  4.1 ± 0.4 (+3%) 
Cingulate ctx  3.4 ± 0.5  2.9 ± 0.4 (-12%)  3.5 ± 0.4 (+4%) 
Septum  9.7 ± 1.7  8.4 ± 0.6 (-13%)  10.1 ± 1.5 (+4%) 
Striatum  1.1 ± 0.1  1.0 ± 0.1 (-5%)  1.0 ± 0.1 (-3%) 
Thalamus  1.3 ± 0.1  1.1 ± 0.1 (-14%)  1.3 ± 0.1 (+5%) 
Hypothalamus  2.5 ± 0.4  1.7 ± 0.4 (-33%) *  2.5 ± 0.6 (-1%) 
Dentate gyrus  8.3 ± 1.3  6.7 ± 0.4 (-19%)  8.3 ± 1.0 (-0%) 
Amygdala  4.8 ± 0.3  3.6 ± 0.4 (-24%) **  4.6 ± 0.9 (-3%) 
Hippocampus  8.8 ± 1.0  7.1 ± 0.7 (-20%) *  8.8 ± 1.2 (-0%) 
Interpedunc ncl.  6.2 ± 1.2  5.8 ± 0.4 (-7%)  6.4 ± 1.1 (+3%) 
Dorsal raphe  10.3 ± 1.3  7.8 ± 1.8 (-24%)  8.5 ± 0.7 (-17%) 
Median raphe  3.9 ± 0.6  3.0 ± 0.5 (-23)  3.6 ± 0.6 (-7%) Chapter 3 
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Discussion 
The aim of this study was to investigate if [
18F]-MPPF binding to the 5-HT1A 
receptor is reduced after large increases in extracellular 5-HT. We have 
shown that the administration of fenfluramine resulted in a significant 
reduction of [
18F]-MPPF binding in the frontal cortex, hypothalamus, 
amygdala and hippocampus of conscious rats. [
18F]-MPPF binding was not 
changed after combined administration of ketanserin and citalopram. 
 
Previous ex vivo dissection studies in non-anesthetized and anesthetized 
animals (Hume et al. 2001; Maeda et al. 2001, respectively) did not show a 
significant effect of fenfluramine on the distribution of [
11C]-WAY-100635. 
However, in both studies, a non-significant reduction in radioactivity content 
was seen in several brain areas, comparable to the regions in our study. 
The differences in effect size between our study and their studies may be 
explained by differences in method or timing of the pharmacological 
challenge. In our study, the animals were sacrificed at the time of the peak 
in 5-HT concentration, whereas in the studies of Maeda et al. (2001) and 
Hume et al. (2001), the animals were sacrificed before or after the peak in 
5-HT response, respectively. Using PET, Hume et al. (2001) reported a 20% 
reduction in [
11C]-WAY-100635 binding potential in the hippocampus after 
10 mg/kg fenfluramine, a reduction comparable to that seen in our study. 
Using the same ligand as used in our study, the group of Zimmer studied 
the effect of changes in 5-HT levels by administration of different doses of 
fenfluramine (Zimmer et al. 2002a,b). [
18F]-MPPF binding was studied in 
anesthetized rats using a ß
+ radiosensitive probe. The effect of fenfluramine 
in their study was much larger than the effect as reported in our study. In the 
studies of Zimmer et al. a complete displacement of [
18F]-MPPF was seen 
after an injection of 10 mg/kg fenfluramine. And even after lower doses of 
fenfluramine reductions of 25-60% were seen. Compared to [
11C]-WAY-
100635, [
18F]-MPPF has a much lower affinity for the 5-HT1A receptor (Ki of 
0.8 nM and 3.3 nM, respectively) (Zhuang et al. 1994). According to Zimmer 
et al. (2002a), [
18F]-MPPF may therefore be more suitable for detection of 
changes in endogenous 5-HT. Other investigators, however, state that 
changes in specific binding are not dependent on the affinity of the ligand, if 
the experiment is performed at tracer doses (Abi-Dargham et al. 1999; 
Laruelle 2000). Therefore, it is not certain whether the large displacement of [18F]-MPPF binding in rat brain 
  80 
[
18F]-MPPF in the studies of Zimmer et al. (2002a,b) could be attributed to 
its lower affinity. Although the exact reason for the discrepancies between 
our study and the group of Zimmer is not clear, it may be due to 
methodological factors. The group of Zimmer investigated the effects on 
[
18F]-MPPF binding using a ß
+ radiosensitive probe, which is an invasive 
instrument and also sensitive to methodological errors (Ginovart et al. 
2004). Previous autoradiography and PET studies using dopaminergic 
ligands, have reported reductions in radioligand binding in the same order 
as in our study (for a review see Laruelle 2000). 
 
Before attributing the effects of fenfluramine on [
18F]-MPPF binding to an 
increase in intrasynaptic 5-HT release, we should also consider other 
possibilities to explain our results. The effect of fenfluramine in our study 
could have been caused by direct binding of this drug to the 5-HT1A 
receptor, however, this is not very likely since the affinity of fenfluramine for 
the 5-HT1A receptor is very low (μM range) (Mennini et al. 1991). 
Furthermore, the pharmacological treatments may have affected non-
specific binding. However, this would have caused changes in cerebellar 
activity, which is not significantly affected in our study. Increases in 5-HT 
levels may also have an effect on regional cerebral blood flow (Cohen et al. 
1996) which could have induced a decrease in [18F]-MPPF binding. 
However, if one assumes the reduction in [18F]-MPPF binding to be a 
general effect of increased 5-HT levels on blood flow, one would have 
expected an effect of the combination of ketanserin and citalopram as well, 
since citalopram by itself is already able to significantly change rCBF 
(McBean et al. 1999). Therefore the effect of fenfluramine in our study may 
indeed be explained by a reduced 5-HT1A receptor availability, due to an 
increase in intrasynaptic 5-HT levels. 
 
The binding of [
18F]-MPPF was not affected by combined administration of 
citalopram and ketanserin. After administration of fenfluramine, a 30-fold 
increase in extracellular 5-HT levels was found, whereas administration of 
the combination only resulted in a 10-fold increase in 5-HT levels. Previous 
studies have shown that extracellular levels do not always reflect 
intrasynaptic processes (Tsukada et al. 2000a,b). The 5-HT1A receptors are 
located both within the synapse and extrasynaptically (Azmitia et al. 1996; Chapter 3 
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Riad et al. 2000). In a previous study using [
18F]-MPPF, we concluded that 
changes in the binding of this ligand mainly reflect changes in intrasynaptic 
5-HT levels, since, at least in postsynaptic areas, the proportion of 
extrasynaptic receptors is assumed to be low (Udo de Haes et al. 2002). 
The two treatments used in our study may have differently affected 5-HT 
levels at the intrasynaptic 5-HT1A receptor due to their different regulation of 
5-HT release and reuptake. 
 
If we assume however, that the extracellular 5-HT levels are a reflection of 
the intrasynaptic levels, our results may also be explained by the difference 
in the magnitude of the 5-HT increase. The effect of an increase in 5-HT on 
ligand binding can be calculated using the standard competition formula that 
relates the bound radiotracer (B) to the receptor density (Bmax), the 
radioligand KD, and free radioligand (L) in the precense of a competitor such 
as 5-HT, present at concentration F5-HT and with an affinity Ki (Abi-Dargham 
et al. 1999): 
()
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When the ligand is administered at a tracer dose, L is negligible compared 
to KD. Neglecting L in the denominator, and defining the binding potential 
(BP) before and after the serotonergic challenge as BP1 and BP2, F5-HT1 and 
F5-HT2 as the free 5-HT concentrations before and after the challenge, 
respectively, the relative reduction of BP induced by the challenge can be 
calculated as follows:  
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The relative change in BP induced by the change in F5-HT, will be 
independent of KD, as this factor cancels out. The 5-HT1A receptor can exist 
in a high and low affinity state (Khawaja 1995; Watson et al. 2000). In our 
calculations we used 5-HT Ki values of 5 nM and 250 nM for the high and 
low affinity state respectively (Watson et al. 2000) and a baseline [18F]-MPPF binding in rat brain 
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extracellular 5-HT concentration of 0.9 nM (Cremers et al. 2004). Assuming 
all 5-HT1A receptors to be in the high affinity state, the calculated reduction 
in  BP would be 82% after the 30-fold increase in 5-HT induced by 
fenfluramine and 58% after the 10-fold increase induced by the 
administration of ketanserin with citalopram. If all receptors would have 
been in the low affinity state, the reduction in [
18F]-MPPF binding would 
have been 9% after fenfluramine administration and 3% after the 
combination of ketanserin with citalopram. These data indicate that we 
would have seen an effect after the combination if a large proportion of the 
receptors would have been in the high affinity state. Therefore, based on 
these calculations, we may conclude that the majority of 5-HT1A receptors is 
in the low affinity state. 
 
Without Bonferroni correction, the combination of ketanserin and citalopram 
had a significant effect on [
18F]-MPPF binding in the raphe nucleus, despite 
relatively small increases in 5-HT. This nucleus is very small and therefore 
the reduction may be a methodological artifact. However, other explanations 
are possible as well. In contrast to postsynaptic areas, in the raphe nucleus 
a large proportion of receptors is located extrasynaptically (Kia et al. 1996). 
We expect the major part of extrasynaptic 5-HT1A receptors to be in the 
agonist high affinity state (Udo de Haes et al. 2002), and therefore 5-HT 
may have affected [
18F]-MPPF binding in this nucleus. The reduction in the 
raphe may also be due to internalization of the 5-HT1A receptor after agonist 
stimulation. Riad et al. (2004) has shown that presynaptic receptors are 
internalized after agonist stimulation whereas postsynaptic receptors are 
not. 
 
To summarize, we have shown that the administration of fenfluramine 
resulted in a significant reduction of [
18F]-MPPF binding in several brain 
areas of conscious rats. The combination of ketanserin and citalopram did 
not affect [
18F]-MPPF binding, despite a considerable increase in 
extracellular 5-HT levels. Although possible effects of blood flow can not be 
excluded, our data indicate that [
18F]-MPPF binding is only reduced after 
large and therefore non-physiological increases in 5-HT levels. These 
results may imply that the majority of 5-HT1A receptors is in the low affinity 
state, in vivo. Chapter 3 
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Abstract 
[
18F]-MPPF is a selective and reversible antagonist to the serotonin-1A (5-
HT1A) receptor. The aim of the present study was to investigate if the 
binding of [18F]-MPPF is sensitive to increases in 5-HT levels. We used the 
5-HT releasing agent and reuptake inhibitor fenfluramine (FEN) to increase 
the concentration of 5-HT. [18F]-MPPF binding was assessed using 
positron emission tomography (PET) in conscious monkeys. Possible 
effects of blood flow on ligand binding were excluded by using a bolus-
infusion paradigm. Control scans were obtained to assess the state of 
ligand equilibrium. FEN (5 mg/kg or 10 mg/kg i.v.) was administered 
between 90 and 130 minutes after start of the [
18F]-MPPF infusion. The 
binding potential (BP) was calculated for an early interval (30 minutes 
preceding FEN administration) and late interval (20-50 minutes after 
administration of FEN). Microdialyses results showed a 20-fold and 35-fold 
increase in extracellular 5-HT levels in the prefrontal cortex after injection of 
FEN 5 mg/kg and 10 mg/kg respectively. However, despite these large 
increases in 5-HT levels, the change in BP did not significantly differ 
between the control and FEN scans. These results may imply that the 
majority of 5-HT1A receptors is in the low affinity state, in vivo. Chapter 4 
  91 
Introduction 
The serotonergic system has been implicated in the pathophysiology and 
treatment of a variety of psychiatric disorders such as depression, anxiety 
and schizophrenia (Blier and de Montigny 1998; den Boer 2000; Kapur and 
Remington 2001; Seeman 2002; Tauscher et al. 2001). Using Positron 
Emission Tomography (PET) and a serotonergic receptor ligand it may be 
possible to measure changes in serotonin (5-HT) levels in the living brain. 
The technique is based on the assumption that the injected radiolabeled 
ligand competes with the endogenous neurotransmitter for the same 
receptor. Changes in neurotransmitter release can be detected as changes 
in the binding potential (BP) of the radioligand. This approach has been 
successfully used for the dopaminergic system (Laruelle 2000). Results 
from studies using serotonergic ligands, however, do not always agree, 
possibly due to methodological differences. 
 
At present, only a few studies have investigated the effect of changes in 5-
HT levels on serotonergic ligands. These studies have primarily used [
18F]-
MPPF (4-(2'-methoxyphenyl)-1-[2'-(N-2"-pyridinyl)-p-[
18F]fluorobenzamido] 
ethylpiperazine) and [
11C]-WAY-100635 ([carbonyl-
11C-][O-methyl-3H]-N-(2-
(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexane 
carboxamide. Both ligands are reversible antagonists to the 5-HT1A 
receptor, but differ in their affinity (Ki of 0.8 nM and 3.3 nM for [
11C]-WAY-
100635 and [
18F]-MPPF, respectively) (Zhuang et al. 1994). 
 
Studies in human subjects have shown that changes in 5-HT in the 
physiological range did not affect ligand binding. After changing 5-HT levels 
by means of either tryptophan depletion or tryptophan infusion, [
11C]-WAY-
100635 binding in the prefrontal cortex and medial temporal cortex was not 
consistently affected (Rabiner et al. 2002). We have studied the effect of 
tryptophan manipulation on [
18F]-MPPF binding and did not find significant 
differences between the infusion and depletion condition in the same 
subject (Udo de Haes et al. 2002). 
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In order to investigate the effect of larger increases in 5-HT levels, several 
studies have been performed in rats. In most of these experiments, 5-HT 
levels were increased using the 5-HT releasing agent and reuptake inhibitor 
fenfluramine (FEN). After administration of FEN at a dose of 10 mg/kg, 10-
30 fold increases in extracellular 5-HT levels have been reported (Hume et 
al. 2001; Maeda et al. 2001; Udo de Haes et al. 2005; Zimmer et al. 2002). 
Despite these extensive increases in 5-HT levels, the results of the studies 
were not always consistent. Hume et al. (2001) reported the effect of FEN 
(10 mg/kg i.p.) on [
11C]-WAY-100635 binding. They investigated the effect 
by means of PET in anesthetized rats and the ex vivo distribution in 
dissected brain tissues from non-anesthetized rats. The PET results showed 
a 20% decrease in [
11C]-WAY-100635 binding potential in the hippocampus 
but not in the prefrontal cortex or raphe nucleus. The post mortem 
dissection studies did not show a statistically significant effect of FEN on 
[
11C]-WAY-100635 uptake, except in the medulla. Using the same 
radioligand and comparable methods, Maeda et al. (2001) did not find an 
effect of FEN (10 mg/kg i.p.) in the hippocampus of anesthetized rats. 
Zimmer et al. (2002) investigated the effect of different doses of FEN on 
[
18F]-MPPF binding in anesthetized rats, using a ß
+ radiosensitive probe. 
The authors reported a dose-related decrease of [
18F]-MPPF binding in the 
hippocampus. We studied the effect of FEN (10 mg/kg i.p.) and of a 
combination of the selective serotonin reuptake inhibitor (SSRI) citalopram 
(10 μmol/kg, s.c.) with the 5-HT2C antagonist ketanserin (100 nmol/kg, s.c). 
The effect on [
18F]-MPPF binding was assessed in conscious rats using ex-
vivo autoradiography. FEN treatment resulted in a significant reduction of 
[
18F]-MPPF binding in the frontal cortex, hypothalamus, amygdala and 
hippocampus, whereas administration of the combination did not affect 
[
18F]-MPPF binding (Udo de Haes et al. 2005). 
 
The aim of the current study was to investigate if [
18F]-MPPF binding in the 
conscious monkey brain is decreased after a FEN-induced increase in 5-HT 
levels. We used conscious monkeys since previous studies have shown that 
ligand binding may be affected by the use of anesthetics (Ginovart et al. 
2002; Harada et al. 2004; Hassoun et al. 2003; Momosaki et al. 2004; 
Seeman and Kapur 2003; Tsukada et al. 2002). So far, all studies have 
used bolus injections of the ligand. To exclude possible effects of drug-Chapter 4 
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induced changes in blood flow on ligand binding we used a bolus-infusion 
paradigm in our study. 
Materials and Methods 
Animals 
Five young-adult male rhesus monkeys (Macaca mulatta) (A, B, C, D and E, 
weighing 6.7 ± 0.9 kg) were used for the PET experiments. The 
microdialysis experiments were performed with the same group of monkeys 
(n = 3 per dose). The monkeys were maintained and handled in accordance
 
with the recommendations of the United States National Institutes
 of Health 
and the guidelines of the Central Research Laboratory,
  Hamamatsu 
Photonics. They were trained to sit on a chair twice
 a week over a period of 
more than 3 months. At least 1 month before the PET study, an acrylic 
plate, with
  which the monkey could be fixed to a monkey chair, was 
attached to the
  head under pentobarbital anesthesia as described 
previously (Onoe
  et al. 1994). The monkeys did not receive any 
pharmacological treatment prior to the present study. 
MRI scans 
Magnetic resonance images (MRI)
  of the monkeys were obtained with a 
Toshiba MRT-50A/II (0.5 T)
  under pentobarbital anesthesia. The 
stereotactic coordinates of
  PET and MRI were adjusted based on the 
orbitomeatal (OM) line
 with a specially designed head holder (Takechi et al. 
1994). 
Microdialysis analysis 
A guide cannula was previously implanted during the procedure for 
attachment of the acrylic plate, 35 mm anterior to the intrameatal line and 
lateral 10 mm from the midline (A: 35, L: 10) according to the individual MR 
images and a stereotactic brain
  atlas (Snider and Lee 1961).  The 
microdialysis experiments were performed in the conscious state, while the 
monkey was sitting in the monkey chair. A microdialysis probe with a 
membrane region of 250 µm in diameter and 3 mm in length (Eicom A-I-08-[18F]-MPPF binding in conscious monkeys 
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03, Eicom,
 Tokyo, Japan) was inserted into the frontal cortex of the brain via 
the guide cannula. The probe was perfused with Ringer’s solution (147 mM 
NaCl, 3.4 mM CaCl2 and 4 mM KCl) at a rate of 5 µl/min. 75
 µl samples 
were collected every 15 min, and the content of serotonin was measured by 
HPLC with electrochemical detection. The averaged data obtained from 0 to 
120 min before administration of FEN was used as " baseline" data. FEN 5 
mg/kg or 10 mg/kg was administered 120
 min after the start of sampling. 
Sampling continued during 240 minutes after FEN injection. The frontal 
cortex ECF serotonin level was expressed as percentage
 of
 baseline. To 
verify
 the exact positioning of the probe, 5 µl of China ink was injected
 via 
the guide cannula at the end of the experiments. Animals were
 anesthetized 
with sodium pentobarbital and decapitated. The brains
  were quickly 
removed, coronal sections were cut on a cryostat,
 and the location of the 
probe implantation site was determined
 visually. 
Synthesis of [
18F]-MPPF 
[
18F]-MPPF was prepared by nucleophilic [
18F] fluorination of the appropriate 
nitro precursor  (see Shiue et al. 1997 for a comparable method). It was 
formulated into a NaCl solution. Levels of nitro precursor were << 1 mg/L. 
The radiochemical purity was greater than 95% and the specific activity > 10 
TBq/mmol at the time of injection. 
PET scans 
Data were collected on a high-resolution PET scanner (SHR-7700, 
Hamamatsu Photonics K.K., Hamamatsu, Japan) with a transaxial 
resolution of 2.6 mm full width at half-maximum and a center-to-center
 
distance of 3.6 mm (Watanabe et al. 1997). The PET camera allowed
 31 
slices for imaging to be recorded
 simultaneously. After an overnight fast, the 
animals were fixed to the monkey chair with the stereotaxic coordinates 
aligned parallel to the OM line. A cannula was implanted into the posterior 
tibial vein of the monkey for administration of [
18F]-MPPF, and another 
cannula was put into the posterior tibial vein of the other leg to administer 
FEN. A transmission scan was made for attenuation correction of the 
dynamic PET scan. [
18F]-MPPF (510 MBq) was administered as a bolus 
injection to study the distribution in the monkey brain (monkey A). In this 
study, the following time frames were used: 6 frames of 10 seconds, 6 Chapter 4 
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frames of 30 seconds, 12 frames of 1 minute and 25 frames of 3 minutes. In 
the other experiments [
18F]-MPPF (mean ± SD, 560 ± 430 MBq) was 
administered as a bolus followed by a constant infusion over maximal 180 
minutes. Three monkeys (A, B and C), were used for bolus-infusion 
experiments with the following time frames: 6 frames of 30 seconds, 7 
frames of 1 minute and 34 frames of 5 minutes. The Kbol was 84 min. For 
monkey D and E a “Feedback-controlled infusion system" was used (Ohba 
et al. 2004). The frame duration was 1 minute for these experiments. 
Control scans (without FEN administration) were obtained in monkey A, B 
and C. Monkey A and B both received a FEN dose of 5 mg/kg. A dose of 10 
mg/kg was given to monkey A, C (twice), D and E. FEN was injected 
between 90 and 130 minutes after start of the [
18F]-MPPF infusion, at the 
time of ligand equilibrium (constant ratio between regions of interest and 
cerebellum). Due to the head fixation, there was no detectable head 
movement. Regions of interest (ROIs) were identified according to the MR 
images of each monkey’s brain, for the frontal cortex, hippocampus, 
striatum and cerebellum. The ROI for the raphe nucleus was placed directly 
on the PET image. Time activity curves were obtained and the binding 
potential (BP) was calculated by (Ct-Cref)/Cref, were Ct is the activity in the 
region of interest at equilibrium and Cref is the activity in the reference region 
(Ito et al. 1998). In our study we selected the cerebellum as reference 
region since the cerebellum is virtually devoid of 5-HT1A receptors (Hall et 
al. 1997). BPs were calculated for two intervals, an early interval: BP(T1) 
(mean of the 30 minutes preceding FEN administration) and a late interval: 
BP(T2) (mean of the 20-50 minutes after FEN administration).  
Statistical analysis 
The effect of FEN on BP in the frontal cortex, hippocampus, striatum and 
raphe was calculated using a repeated measures ANOVA with time (BP(T1) 
and BP(T2)) as within subject factor and condition (control, 5 mg/kg and 10 
mg/kg) as between subject factor. The percent change in BP: (BP(T2)- 
BP(T1) / BP(T1))*100 in the different regions was calculated for the control 
and FEN scans. [18F]-MPPF binding in conscious monkeys 
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Drugs 
Racemic (±)-Fenfluramine hydrochloride ((±)-N-Ethyl-alpha-methyl-m-
[trifluoromethyl]phenethylamine hydrochloride) was purchased from Sigma-
Aldrich, Tokyo, Japan and dissolved in saline. 
Results 
Microdialysis 
Administration of FEN 5 mg/kg and 10 mg/kg resulted in a 20-fold and 35-
fold increase in extracellular 5-HT levels respectively, at 15 minutes after 
injection (Figure 1).  
 
 
 
Figure 1: Extracellular 5-HT levels in the prefrontal cortex after fenfluramine 
administration to conscious monkeys (n=3). 
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 [
18F]-MPPF distribution 
After administration of [
18F]-MPPF, the regional uptake of radioactivity was 
in agreement with previous results in non-human primates and with known 
5-HT1A receptor localization, with the highest uptake in the frontal cortex, 
cingulate cortex and hippocampus and low uptake in the cerebellum (Kung 
et al. 1996; Mengod et al. 1996; Plenevaux et al. 2000a; Shiue et al. 1997) 
(Figure 2).  
 
 
 
 
Figure 2: Example of [
18F]-MPPF binding in 2 horizontal sections of the 
conscious monkey brain, at the level of the frontal cortex and hippocampus. Frt 
Ctx: frontal cortex, Cg Ctx: cingulate cortex, Hip: hippocampus, Crb: 
cerebellum, Raphe: raphe nucleus. 
 
After bolus administration of [
18F]-MPPF, the distribution and clearance 
were slower than reported for the anesthetized cynomologus monkey (Shiue 
et al. 1997), and more rapid than for [
11C]-WAY-100635 and analogues 
(Farde et al. 1997; Osman et al. 1998; Pike et al. 1998; Tsukada et al. 2001) 
(Figure 3). The half-life time varied from 27 minutes in the cerebellum to 56 
minutes in the hippocampus. After administration of [
18F]-MPPF as a bolus 
followed by a constant infusion, an equilibrium in [
18F]-MPPF uptake was 
achieved in some of the experiments, while activity gradually increased or 
decreased with time in other experiments. However, the ratio’s of the 
regions of interest to the cerebellum reached stable values approximately [18F]-MPPF binding in conscious monkeys 
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30 minutes preceding FEN administration, assessed by visual inspection of 
the curves. The BP curves in the frontal cortex of the different monkeys are 
shown in figure 4A. The mean (±SD) BPs in the control situation ranged 
from 0.4 (±0.1) in the striatum, 0.5 (±0.2) in the raphe nucleus, 1.1 (±0.2) in 
the frontal cortex to 1.2 (±0.4) in the hippocampus. 
 
 
 
 
Figure 3: Time-activity curves after bolus injection of [
18F]-MPPF (Monkey A). 
Effect of fenfluramine treatment on [
18F]-MPPF binding 
Administration of FEN resulted in variable changes in [
18F]-MPPF binding 
compared to the control situation. Some of the individual time-activity curves 
seem to show short lasting reductions in [
18F]-MPPF binding after FEN 
administration, however, the reductions were not consistent over the 
different monkeys. Figure 4B shows the BP curves in the frontal cortex of 
the different monkeys in the FEN (10 mg/kg) condition. The ANOVA results 
showed that the interaction effects of time*condition and 
time*condition*region were not significant (p=0.82 and p=0.95 respectively), 
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thereby indicating that in none of the regions significant differences between 
the control and FEN conditions were found (Figure 5). 
 
 
 
 
Figure 4: [
18F]-MPPF BP in the frontal cortex of the different monkeys after 
continuous infusion of the ligand, in the control (4A) and fenfluramine (10 
mg/kg) condition (4B). Since FEN was administered at different time-points, the 
time activity curves are relative to FEN administration. 
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Figure 5: Percent change in BP  ((BP(T2)- BP(T1) / BP(T1))*100) for the 
different monkeys in the frontal cortex, hippocampus, striatum and raphe 
nucleus in the control condition (CON) and after administration of fenfluramine 5 
mg/kg or 10 mg/kg. 
Discussion 
The aim of this study was to investigate if [
18F]-MPPF binding to the 5-HT1A 
receptor is decreased after a pharmacologically-induced increase in 5-HT 
levels. We have investigated the effect in conscious animals using a 
constant infusion paradigm. Using this paradigm, a sustained equilibrium in 
ligand binding is achieved. Under this condition, there is no net radiotracer 
transfer across the blood-brain barrier and possible effects of FEN-induced 
changes in blood flow can therefore be excluded (Laruelle 2000). Our study 
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was performed in conscious monkeys, since anesthetics may have an effect 
on ligand binding (Ginovart et al. 2002; Harada et al. 2004; Hassoun et al. 
2003; Momosaki et al. 2004; Seeman and Kapur 2003; Tsukada et al. 
2002). Thus in our study we intended to diminish possible non-specific 
effects on [
18F]-MPPF binding. We have shown that FEN, at the doses as 
used in our study, induced considerable increases in 5-HT levels. After FEN 
administration short lasting changes in [
18F]-MPPF binding were seen in 
some of the individual time-activity curves. However, the effect did not 
significantly differ between the control and FEN conditions. 
 
As mentioned before, previous studies using either [
11C]-WAY-100635 or 
[
18F]-MPPF did not show consistent changes in ligand binding. Physiological 
changes in 5-HT levels did not induce measurable effects in humans 
(Rabiner et al. 2002; Udo de Haes et al. 2002) and studies in rat have 
shown that larger increases in 5-HT levels were not always effective either 
(Hume et al. 2001; Maeda et al. 2001; Udo de Haes et al. 2005). 
 
In contrast to these negative results, some rat studies have shown an effect 
of 5-HT increases on 5-HT1A ligand binding. As mentioned before, Hume et 
al. (2001) reported a 20% reduction in [
11C]-WAY-100635 binding in the 
hippocampus after FEN (10 mg/kg i.p.) administration, using PET in 
anesthetized rats. Zimmer et al. (2002) reported a dose-related decrease of 
[
18F]-MPPF binding in the hippocampus after FEN (1, 2 and 10 mg/kg) 
administration, also in anesthetized rats. Previously we showed that FEN 
treatment resulted in a significant reduction of [
18F]-MPPF binding in several 
regions, using ex-vivo autoradiography in conscious rats (Udo de Haes et 
al. 2005). In addition, in vitro studies have shown that 5-HT is able to 
compete with [
11C]-WAY-100635 or [
18F]-MPPF binding (Gozlan et al. 1995; 
Newman-Tancredi et al. 1996; Watson et al. 2000). 
 
The inconsistencies may be caused by several factors. As mentioned 
before, the two ligands [
18F]-MPPF and [
11C]-WAY-100635 differ with 
respect to their affinity to the 5-HT1A receptor (Ki of 0.8 nM and 3.3 nM for 
[
11C]-WAY-100635 and [
18F]-MPPF, respectively). It has been suggested 
that the lower affinity of [
18F]-MPPF could make it more sensitive to changes 
in 5-HT levels (Plenevaux et al. 2000b). In non-equilibrium situations the [18F]-MPPF binding in conscious monkeys 
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affinity could indeed have an effect on the percent change in ligand binding. 
Under equilibrium conditions however, the affinity of the ligand does not 
influence the percentage change in BP (Laruelle 2000). 
 
In addition, differences in timing (Endres and Carson 1998; Yoder et al. 
2004) or the extent of increases in 5-HT levels may be an explanation for 
the inconsistent results of the studies using 5-HT1A ligands. In our rat study 
(Udo de Haes et al. 2005), the animals were sacrificed at the time of the 
peak in FEN-induced 5-HT increase, whereas in the study of Maeda et al. 
(2001) and the post mortem dissection study of Hume et al. (2001), the 
animals were sacrificed before or after the peak in 5-HT response, 
respectively. In our monkey study, however, 5-HT increases were even 
larger than in the rat studies. Therefore, the lack of effect in our study 
should be explained by other factors. 
 
The effect of a serotonergic challenge on ligand binding, may also be 
influenced by the baseline serotonergic tone. Baseline 5-HT levels may 
differ between species or conditions, or even between individual animals. 
These differences in baseline state have already been shown to play a role 
in the dopaminergic system. The extent of dopamine release, and as a 
result the change in ligand binding, is reported to be dependent on the level 
of anxiety and mood at baseline, probably reflecting baseline dopaminergic 
tone (Volkow et al. 1994). Previous studies have shown that 5-HT levels are 
influenced by subjective effects such as stress or activity status (Amat et al. 
1998; Bland et al. 2003; Kalen et al. 1989). In our study, the monkeys were 
trained for several months to minimize possible effects of stress. However, 
differences in baseline 5-HT levels can not be excluded. 
 
Another important factor is the fact that the 5-HT1A receptor can exist in a 
high and low affinity state (Gozlan et al. 1995; Khawaja 1995; Mongeau et 
al. 1992; Nénonéné et al. 1994; Watson et al. 2000). Antagonists, such as 
[
18F]-MPPF and [
11C]-WAY-100635 will bind with equal affinity to either state 
whereas agonists such as 5-HT will preferentially bind to the high affinity 
state (Gozlan et al. 1995; Khawaja 1995; Mongeau et al. 1992; Nénonéné et 
al. 1994; Watson et al. 2000). It can be argued that changes in 5-HT will 
therefore mainly effect [
18F]-MPPF and [
11C]-WAY-100635 binding at the Chapter 4 
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receptors in the high affinity state. Consequently, changes in binding can 
only be detected when a large enough proportion of 5-HT1A receptors is in 
the high agonist affinity state. The proportion of receptors in the high affinity 
state may depend on the brain area examined (Khawaja 1995) or the 
method used (Richfield et al. 1986). Furthermore, the affinity state of G-
protein coupled receptors may depend on the use of anesthetics (Seeman 
and Kapur 2003) and may differ between species (Klotz et al. 1991). It is 
possible that the proportion of 5-HT1A receptors in the high affinity state 
differed between the various experiments that have investigated the effect 
of 5-HT increases on ligand binding, thereby leading to differences in the 
results. 
 
The relative insensitivity of the 5-HT1A ligands to increases in 5-HT levels 
contrasts with the results from experiments using dopamine D2 ligands. 
Ligand binding at the 5-HT1A receptor is only affected after substantial 
increases in 5-HT levels. In contrast, previous results have shown that D2 
ligand binding is not only affected after pharmacological challenges but also 
by physiological changes in dopamine levels (de la Fuente-Fernandez et al. 
2002; Pruessner et al. 2004; Zald et al. 2004). It is currently unknown how 
these differences can be explained. One of the major differences between 
the serotonergic 5-HT1A and dopaminergic D2 receptor systems, concerns 
the proportion of receptors in the high affinity state. Previous dopaminergic 
studies have calculated that approximately 40% of the receptors is in the 
high affinity state and vulnerable to competition with the endogenous 
neurotransmitter (Cumming et al. 2002; Narendran et al. 2004). In contrast, 
the proportion of 5-HT1A receptors in the high affinity state is probably much 
lower (Nénonéné et al., 1994; Udo de Haes et al. 2005). These data may 
offer an explanation for the differences in sensitivity to changes in 
neurotransmitter concentration. The finding of Bantick et al. (2004) that 
other 5-HT1A agonists than 5-HT affected ligand binding only at relatively 
high doses is in agreement with this concept. 
 
Labeled agonists to the 5-HT1A receptor could possibly be used to show 
effects of 5-HT increases on ligand binding at receptors in the high affinity 
state. This approach has already been used for the dopaminergic system. 
Results from these studies show that the agonist tracer was indeed more [18F]-MPPF binding in conscious monkeys 
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sensitive to changes in dopamine as compared to the antagonist tracer. 
(Cumming et al. 2002; Narendran et al. 2004). In addition, it may be 
interesting to study possible effects of anesthesia and blood flow on 5-HT1A 
ligand binding. 
 
In conclusion, [
18F]-MPPF binding is not significantly affected in conscious 
monkeys, even after relatively large increases in 5-HT levels. These results 
may imply that the majority of 5-HT1A receptors is in the low affinity state, in 
vivo. 
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Abstract 
The dopaminergic system has been implicated in the pathogenesis and 
treatment of a variety of neuropsychiatric disorders. It has been shown that 
information on endogenous dopamine (DA) release can be obtained 
noninvasively, by combining positron emission tomography (PET) with a 
dopaminergic challenge. This approach is based on the assumption that an 
injected radiolabeled ligand competes with the neurotransmitter for the 
same receptor. Increases in DA release will therefore result in a decreased 
binding of the radioligand. We investigated the effect of the DA reuptake 
blocker methylphenidate (MP) (0.25 mg/kg i.v) on the binding of the D2 
receptor ligand [
11C]-raclopride (RAC) in 6 healthy volunteers. RAC was 
administered as a bolus followed by constant infusion and subjective effects 
were assessed using verbal rating scales. Control scans without MP 
administration, showed that the mean RAC binding reached stable values 
approximately 30 minutes after start of the infusion. MP administration 
induced a 24% decrease in RAC binding in the total striatum. Significant 
correlations were found between the MP-induced change in euphoria and 
percent change in binding potential (ΔBP) in the dorsal striatum and 
between baseline anxiety and ΔBP in the dorsal and middle striatum. We 
also found a significant negative correlation between baseline BP in the 
dorsal striatum and change in euphoria. Our results comply with previous 
findings, indicating the feasibility of the bolus infusion design combined with 
a relatively low MP dose to study dopaminergic (dys)function. Chapter 5 
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Introduction 
The dopaminergic system has been implicated in the pathogenesis and 
treatment of a variety of neurological and psychiatric disorders such as 
schizophrenia, Parkinson’s disease, depression and addiction (Kapur and 
Mamo 2003; Leenders 2002; Naranjo et al. 2001; Volkow et al. 2002a). The 
involvement of dopamine (DA) in these disorders may be related to its 
function in reward processing (Kapur 2003; Kunig et al. 2000; Schmidt et al. 
2001). However, the exact role of DA in these processes is not completely 
known yet. In order to study the (dys)function of the dopaminergic system, it 
is important to quantify changes in DA levels in the living brain. 
 
Over the last decade, it has been shown that information on endogenous 
DA release can be obtained noninvasively, by using positron emission 
tomography (PET) or single-photon emission computed tomography 
(SPECT). This approach is based on the assumption that an injected 
radiolabeled ligand competes with the endogenous neurotransmitter for the 
same receptor. Increases in DA release will result in a decreased binding of 
the radioligand and vice versa (Dewey et al. 1993; Laruelle 2000). The 
exact mechanism for these changes in receptor availability is not known. 
The changes may be a result of true competition between DA and the 
injected ligand, but may also be due to DA-induced internalization of the 
receptor (Sun et al. 2003). Nevertheless, it is generally assumed that the 
changes in radioligand binding can be used as a measure for the alterations 
in neurotransmitter release (Laruelle 2000). Using this method, correlations 
between DA function and behavioral or physiological scores have been 
found, providing information on the possible role of this neurotransmitter in 
pathological or physiological processes (Drevets et al. 2001; Laruelle et al. 
1995; Leyton et al. 2002; Martinez et al. 2003; Pruessner et al. 2004; 
Volkow et al. 1994, 1999a, 2003). 
 
Previous studies that investigated changes in DA levels, have primarily 
assessed changes in striatal binding, using D2 receptor antagonists such as 
[
11C]-raclopride (RAC) or [
123I]-IBZM. In most studies a paired bolus protocol 
was used, with two separate scans: a dopaminergic challenge is [11C]-Raclopride binding in human subjects 
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administered during one of the scans while the other scan serves as a 
control. Alternatively, the ligand may be administered as a bolus followed by 
a constant infusion, leading to sustained equilibrium of radioligand levels in 
blood and brain (Carson 2000). A challenge can then be administered 
during the equilibrium period, enabling measurement of baseline and drug-
induced changes in ligand binding in the same experiment. During 
equilibrium, there is no net transfer of the radioligand across the blood-brain 
barrier, thereby minimizing possible effects of changes in drug-induced 
blood flow on ligand binding (Laruelle 2000). This aspect is an important 
advantage of the bolus with infusion paradigm, as compared to the double 
bolus protocols. 
 
Previous studies using RAC as a bolus followed by infusion have used 
amphetamine (AMPH) to assess pharmacologically-induced changes in 
dopaminergic transmission (Breier et al. 1997; Carson et al. 1997; Martinez 
et al. 2003; Tsukada et al. 2002). Since AMPH is not a registered drug in 
the Netherlands, we aimed to investigate the effect of the DA reuptake 
blocker methylphenidate (MP). Microdialysis studies have shown that both 
compounds induce large increases in DA levels (Breier et al. 1997; 
Hernandez et al. 1987; Hurd and Ungerstedt 1989; Kuczenski and Segal 
1997) which resulted in 15-25% reductions in RAC binding in human 
subjects (Breier et al. 1997; Drevets et al. 2001; Martinez et al. 2003; Piccini 
et al. 2003; Volkow et al. 1994). The effect of MP on RAC binding has only 
been investigated using the double bolus method. Using this method, 
Volkow et al. (1999a) studied the effect of a wide range of MP doses and 
found significant changes in specific binding after intravenous doses of 0,25 
mg/kg and 0,5 mg/kg. The effect of MP on RAC binding has not yet been 
investigated using a bolus with constant infusion protocol. In our study we 
used this protocol to investigate the effect of MP in healthy volunteers. In 
future studies we intend to use this method to study the dopaminergic 
system in psychiatric patients. We used a MP dose of 0.25 mg/kg, i.v., since 
in previous studies comparable doses were used in psychiatric patients 
(Janowsky and Davis 1976; Joyce et al. 1986). In order to check the 
equilibrium state of the ligand, we also investigated the protocol without MP 
administration. We assessed the subjective state of the subject before and 
after MP administration, since previous studies reported correlations Chapter 5 
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between subjective effects and changes in ligand binding (Drevets et al. 
2001; Laruelle et al. 1995; Leyton et al. 2002; Martinez et al. 2003; Volkow 
et al. 1994, 1999a). Finally, studies using AMPH have found a larger effect 
on ligand binding in more ventral compared to dorsal regions of the striatum. 
Therefore, we studied the effect of MP in different striatal regions. 
 
The aim of our study was to investigate if the results from the combined use 
of a relatively low dose of MP with a RAC constant infusion protocol comply 
with results from previous studies that used different dopaminergic 
challenges or double bolus injections. 
Materials and Methods 
Subjects 
Six healthy volunteers participated in the study (5 male, 1 female, mean age 
24 year, range 18-32 years). All subjects gave written informed consent 
after written and oral explanation of the study. Suitability to participate in the 
study was determined by an independent physician after a medical 
examination including an ECG and routine blood hematology and 
biochemistry tests. Exclusion criteria were current or past psychiatric, 
neurological or other diseases that could interfere with the study, 
dependence on any substance other than nicotine or caffeine and exposure 
to psychoactive drugs during the past 3 months. The study was approved by 
the Medical Ethics Committee of the University Medical Center Groningen 
(UMCG). 
[
11C]-raclopride synthesis 
The tracer [
11C]-raclopride was prepared from [
11C]-methyl iodide as 
previously described by Ehrin et al. (1987). It was dissolved in a volume of 
20 mL sterile saline, and taken to the subject in the PET scanner. The 
specific radioactivity was >10.000 GBq/mmol at the time of injection. [11C]-Raclopride binding in human subjects 
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PET scan protocol 
The subjects were instructed to refrain from alcohol and caffeine containing 
products during 24 hours prior to each scan. Before the start of the PET 
scan an intravenous catheter was inserted in each arm for blood sampling 
and MP injection and for ligand administration. The volunteers were 
positioned in the camera and their heads were fixed using a head restraint. 
The subjects were scanned in 3D acquisition mode using a Siemens ECAT 
Exact HR+ camera, giving 63 slices with a center to center distance of 
2.425 mm. During the scans, RAC was administered as a fast bolus (1 
minute) followed by a constant infusion over 90 minutes with a bolus to 
infusion rate ratio (Kbol) of 100 minutes. The mean (± SD) activity at the start 
of the experiment was 220 (± 99) MBq). Thirty-six consecutive frames were 
acquired with a duration of 2.5 minutes. Each subject was scanned twice. 
One of the scans served as a control scan to check the equilibrium state of 
the ligand. During the other scan MP 0.25 mg/kg was injected intravenously 
over 1 minute, at 40 minutes after start of the RAC infusion. The two scans 
were performed in random order separated by 2 -7 months. During both 
scans plasma samples were taken for metabolite analysis at 5, 30, 60 and 
90 minutes after the start of the RAC infusion. During the MP scan, 
subjective and behavioral effects were evaluated using a verbal analog 
rating scale, at 10 minutes before and 10 minutes after MP injection. The 
subjects were asked to respond to the following descriptors, using a whole 
number between 0 (no effects) and 10 (maximal effects): Euphoria, anxiety, 
happiness, sexual desire, desire for MP, alertness, annoyance, distrust, loss 
of control, restlessness, depression (Volkow et al. 1999a,b; Wang et al. 
1997). Blood pressure, heart rate and ECG were continuously monitored 
during the MP scans. 
Metabolite analysis 
Plasma samples from only five subjects were analyzed due to sampling 
problems in one of the volunteers. After centrifugation with acetonitrile, the 
liquid phase of the samples was injected into the HPLC system, which 
contained a 300 x 7.9 mm μBondapak C18 semi-preparative column. The 
column was eluted with a mixture of acetonitrile / water / 85% phosphoric 
acid (500:500:1) at a flow rate of 2 ml/min. Fractions of the eluate were 
collected at 0.5 min intervals and radioactivity in the fractions was Chapter 5 
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determined using a gamma counter. The relative contributions of parent and 
metabolites were calculated. 
Image analysis 
Attenuation correction was performed by drawing ellipses on the brain 
images, assuming uniform attenuation. Statistical Parametric Mapping 
(SPM) 99 was used for spatial normalization of the RAC image. A 
summation of the first 10 RAC frames was normalized to the SPM [
15O]-H2O 
template, giving 68 horizontal planes. The normalization parameters were 
thereafter used to normalize the other frames of the RAC scan. A 
predetermined standard region of interest (ROI) template localized in 
stereotactic MNI space was applied to determine the ROIs including left and 
right dorsal, middle and ventral caudate nucleus, dorsal and ventral 
putamen, cerebellum and occipital cortex. For further analyses we defined 
the following three striatal subregions: dorsal (mean of six horizontal slices 
containing the dorsal caudate and putamen), middle (mean of 4 horizontal 
slices containing the middle caudate and ventral putamen) and ventral 
(mean of 3 horizontal slices containing the ventral caudate, including the 
nucleus accumbens). An activity threshold of 30% was used to extract 
stable peak values from the ROIs (Rottenberg et al. 1991).  
 
Time activity curves from striatal and occipital regions were obtained. 
Estimates of the mean BP were calculated with (Ct-Cref)/Cref (Ito et al. 
1998), were Ct is the mean activity over a time interval (T) in the region of 
interest and Cref is the mean activity over T in a reference region. Intervals 
were T1 (32.5-40 minutes) and T2 (65-80 minutes). During T1, RAC binding 
was relatively stable, as assessed by visual inspection of the time-activity 
curves. T2 was chosen as a compromise between effect size and signal to 
noise ratio. In our study we selected the occipital cortex as reference region 
since the activity in the cerebellum was relatively noisy, probably due to low 
injected activity. The density of D2 receptors is negligible in the occipital 
region compared to the striatum (Camps et al. 1989; Lidow et al. 1989), and 
has been used before as a reference region for D2 binding (Booij et al. 
1997; Kegeles et al. 1999; Laruelle et al. 1995; Laruelle et al. 1997). The 
baseline subjective scores and the scores after MP minus baseline score 
were used as outcome measures for the behavioral effects. [11C]-Raclopride binding in human subjects 
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Sttistical analysis 
Differences between BP(T1) and BP(T2) were calculated for the control and 
MP scans, using a paired t-test. Percent change in BP (ΔBP) was calculated 
as follows: (BP(T2) - BP(T1) / BP(T1)) x 100.  ΔBP was assessed for the 
control and MP scans for the total striatum and the striatal subregions 
(dorsal, middle and central) and differences in ΔBP between the control and 
MP condition were calculated using paired t-tests. The effect of MP on the 
subjective scores was assessed using paired t-test. Pearson product 
moment correlations were calculated between the behavioral changes and 
ΔBP (difference between ΔBP in the control and MP condition) in the striatal 
subregions. Based on previous studies we investigated the following 
correlations: ΔBP with MP-induced change in euphoria, anxiety at baseline 
with ΔBP and baseline BP (mean of control and MP scans) with change in 
euphoria (Drevets et al. 2001, Laruelle et al. 1995; Martinez et al. 2003, 
Volkow et al. 1994, 1999a,b, 2002b). The effect of MP on blood pressure 
and heart rate was tested with a paired t-test. The four values measured 
during an interval of 30 minutes before start of the PET scan were 
compared to the six values obtained between four to eighteen minutes after 
MP administration which was the time period when peak effects occurred. 
Drugs 
Methylphenidate was obtained from Fagron farma BV, the Netherlands and 
infusions were prepared and provided by the pharmacy of the UMCG. 
Results 
Metabolite analysis 
As in previous studies, raclopride metabolism was not significantly altered 
by MP (Figure 1) (Drevets et al. 2001; Martinez et al. 2003; Volkow et al. 
1994). 
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Figure 1: Percent unchanged [
11C]raclopride in plasma at 5, 30, 60 and 90 
minutes after start of the [
11C]raclopride infusion in control and methylphenidate 
scans. Methylphenidate (0.25 mg/kg) was injected at 40 minutes after start of 
the infusion. 
Cardiovascular measurements 
MP significantly increased heart rate (p < 0.001) and systolic (p < 0.001) 
and diastolic blood pressure (p < 0.001). Increases ranged from 40-70% 
(heart rate), 20-40% (systolic blood pressure) and 20-30% (diastolic blood 
pressure). The effects on heart rate and blood pressure are in agreement 
with results from previous studies (Volkow et al. 2003). No significant 
changes were observed in the ECG, apart from the increases in heart rate. 
PET measurements 
Mean time-activity curves for the control scans and MP scans (total binding 
and ratio to the occipital cortex) are shown in fig 2. In the control condition, 
the mean RAC BP reached relatively stable values approximately 30 
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minutes after the start of the infusion. MP administration induced a decrease 
in RAC binding in the striatum, whereas binding in the occipital cortex was 
not affected. A paired t-test showed a significant difference between striatal 
BP before (BP(T1)) and after (BP(T2)) MP administration (p< 0.001) whereas 
in the control condition no difference was found between BP(T1)  and BP(T2) 
(p = 0.470). Mean ΔBP in the total striatum after MP injection was -24% 
(range -14 to -40%), whereas the mean ΔBP in the control condition was 0% 
(range +33 to -21%).  
 
Since not all individual time activity curves in the control situation were in 
equilibrium, we used the difference in ΔBP between the MP and control 
scans, for further analyses. The mean difference in ΔBP between the MP 
and control condition was -24% (range 0 to -48%). The difference in ΔBP 
between the control and MP condition was larger in the ventral striatum (-
43%, range +19 to -128%) compared to the middle (-27%, range -1 to -46%) 
and dorsal striatum (-13%, range -5 to -18%). A paired t-test showed a 
significant difference in ΔBP between the control and MP condition in whole 
striatum (p = 0.029), the dorsal (p = 0.001) and middle striatum (p = 0.026) 
but not in the ventral striatum (p = 0.122). 
 
Subjective effects 
MP significantly increased the scores for euphoria (p = 0.01), restlessness 
(p = 0.003), and desire for MP (p < 0.001). The behavioral response differed 
between subjects. Most subjects described the experience as pleasurable, 
only one of the subjects described the effect as partly unpleasurable. 
Significant correlations were found between change in euphoria and ΔBP in 
the dorsal striatum (p = 0.006) and between baseline anxiety and ΔBP in the 
dorsal (p = 0.037) and middle striatum (p = 0.005). We found a significant 
negative correlation between baseline BP in the dorsal striatum and change 
in euphoria (p = 0.037) (Figure 3). 
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Figure 2: A: Mean time-activity curves of total RAC uptake for the control and 
methylphenidate scans. B: Mean (± SD) time-activity curves of the binding ratio 
((Ct-Cref)/Cref) to the occipital cortex for the control scans and methylphenidate 
scans. CON: control. MP: methylphenidate. 
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Figure 3: Correlations between % decrease in BP (MP-CON) and change in 
euphoria (A), % decrease in BP (MP-CON) and baseline anxiety (B) and 
between baseline BP and change in euphoria (C). 
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Discussion 
In the present study we investigated the effect of a relatively low dose of MP 
on RAC binding. This is the first study that investigated the effect of MP 
using a bolus with infusion protocol. The mean RAC BP reached relatively 
stable values approximately 30 minutes after the start of the infusion. 
Immediately after MP administration, a clear reduction in striatal RAC 
binding was seen, suggesting increased DA levels. 
 
Previous human studies have shown that MP or AMPH-induced changes in 
RAC binding usually ranged between 15-25%, in double bolus or bolus with 
infusion studies (Breier et al. 1997; Drevets et al. 2001; Martinez et al. 2003; 
Piccini et al. 2003; Volkow et al. 1994). These studies also reported large 
differences between the individual subjects. Using a double bolus design, 
Volkow et al. (1999a) showed that MP (0.25 mg/kg) induced a change in 
RAC binding that ranged from approximately +5 to -30%. With respect to 
the method of ligand administration, Carson et al. (1997) reported a larger 
drug-induced change in RAC binding using a paired bolus design compared 
to the bolus with infusion method. Although the difference was not 
significant, they suggest that the methods may differ in sensitivity due to 
differences in timing of the drug with respect to tracer delivery. However, in 
another study, the reduction in drug-induced BP did not differ between the 
double bolus or constant infusion method (Marenco et al. 2004). In our 
bolus with infusion study, the MP-induced changes in BP were comparable 
to the changes in the double bolus study by Volkow et al. (1999a). 
 
In our and previous studies, correlations were found between changes in 
DA release and subjective effects. DA release, especially in the striatum, 
has been implicated in the processing of rewarding or reinforcing effects of 
certain stimuli (Ikemoto and Panksepp 1999; McClure et al. 2004; Spanagel 
and Weiss 1999; Ungless 2004; Wise 2004). Data indicate that DA is 
released both after unexpected rewards, during expectation of a reward and 
desire for a reward and also after novel stimuli (Berridge and Robinson 
1998; De la Fuente Fernandez et al. 2002; Leyton et al. 2002; Schultz 
1998). DA increases have been found both in the dorsal and in the ventral 
striatum. The DA release in the different subdivisions in the striatum may 
depend on the nature of the reward and the behavioral response. In our [11C]-Raclopride binding in human subjects 
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study, we have found a correlation between the MP-induced change in 
euphoria and BP change in the dorsal striatum. Previous studies using 
AMPH have found correlations between drug-induced euphoria and BP 
changes in the ventral but not the dorsal striatum (Drevets et al. 2001; 
Martinez et al. 2003). In contrast, Leyton et al. (2002) found that AMPH-
induced  BP change in the ventral striatum correlated more with “drug 
wanting” than with mood elevation. Moreover, studies with placebo 
injections in Parkinson’s patients showed correlations of placebo-induced 
DA release in the ventral striatum during expectation of the reward (De la 
Fuente Fernandez et al. 2002) and dorsal striatum during experience of the 
reward (clinical improvement) (De la Fuente Fernandez et al. 2001). In 
addition, Small et al. (2003) found that BP change in the dorsal striatum 
correlated with meal pleasantness and monetary reward-induced DA 
release has been found in the medial caudate but not in ventral striatum 
(Zald et al. 2004). Pleasurable experience after smoking was associated 
with increased DA release in dorsal striatum (Barrett et al. 2004). Previous 
studies using MP showed that drug-induced euphoria correlated with DA 
increase in the whole striatum, which according to the authors consisted 
mainly of the dorsal striatum (Volkow et al. 1999a). The correlation between 
MP-induced changes in euphoria and BP changes in the dorsal striatum in 
our study, therefore agrees with the findings from previous studies with MP 
and studies using non-drug challenges. 
 
In our study, the reduction in RAC was larger in the ventral striatum 
compared to the dorsal striatum, although not significant. The lack of 
significance may be due to the high variability in this region. Some previous 
studies using AMPH have shown larger changes in the ventral striatum 
(Drevets et al. 2001; Leyton et al. 2002; Martinez et al. 2003) which is in 
agreement with animal studies that have shown that drugs of abuse 
preferentially increase DA release in the nucleus accumbens (Di Chiara and 
Imperato 1988). It is however not known if this also applies to MP. 
 
We found significant correlations between MP-induced BP changes and 
baseline anxiety. Since MP only blocks reuptake, it is dependent on the 
extent of physiologically released DA, and therefore on the subjective state 
of the subject during the experiment (Volkow et al. 1994). Volkow et al. Chapter 5 
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(1994) has also found correlations between baseline anxiety and MP-
induced changes in BP. They postulate that higher anxiety scores may 
reflect a higher responsiveness of the subjects to novel stimuli and/or 
unfamiliar situations, which could be linked with a more responsive DA 
system. In agreement with these findings are studies which show an effect 
of stress and cortisol on MP- and AMPH-induced increases in DA levels 
(Marsteller et al. 2002; Oswald et al. 2005). 
 
In addition, in our study a significant negative correlation between baseline 
BP and change in euphoria was seen. This is also in agreement with studies 
by Volkow et al. (1999b, 2002b). As Volkow et al. suggest, it is possible that 
in subjects with a high D2 receptor density, a smaller dose of MP may have 
been perceived as pleasant (Volkow et al. 2002b). The low D2 density could 
have been caused by high baseline DA levels. However, Volkow et al. 
(2002b) showed that the measurements were stable over different 
experiments suggesting that they were not influenced by differences in DA 
concentration which, in contrast to D2 density, may fluctuate rapidly between 
measurements. 
 
There are several methodological limitations that should be considered for 
this study. Equilibrium was not always achieved in the individual scans, and 
therefore we used the difference between the MP scans and the control 
scans for further analyses. Optimally, the control and drug measurements 
should be made within the same scan. This would need an increase in scan 
duration in order to attain equilibrium before and after drug administration 
and requires higher injected activity. In situations of non-equilibrium the 
estimation of BP may be biased due to effects of ligand distribution or 
clearance (Carson et al. 1993). In addition, ΔBP may be underestimated if 
the equilibrium is not established postchallenge (Slifstein et al. 2004). It is 
currently unknown to what extent these effects may have influenced our 
results. No MRI scans were made in our study, which would have enabled 
individual ROI delineation. Unfortunately, this study was not placebo 
controlled and we did not assess the subjective state during the control 
condition. Therefore we were unable to distinguish expectation-induced 
changes in DA from the experience of MP effects. In future studies it is 
important to control for such variables. In addition, correction for patient [11C]-Raclopride binding in human subjects 
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motion will help to increase the sensitivity of the measurements and 
coregistration with individual MRI scans would enable partial volume 
correction. 
 
Despite these methodological limitations, our results comply with previous 
findings, indicating the feasibility of the bolus infusion design combined with 
a relatively low MP dose to study dopaminergic (dys)function in psychiatric 
patients. 
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Abstract 
The dopaminergic system has been implicated in the pathogenesis and 
treatment of a variety of neuropsychiatric disorders, such as schizophrenia, 
depression and addiction. (Dys)function of the dopaminergic system may be 
studied by combining [
15O]-H2O PET with a dopaminergic drug challenge. 
We investigated the suitability of the dopamine reuptake blocker 
methylphenidate (MP) as a dopaminergic probe. Measurements of regional 
cerebral blood flow (rCBF) were made at 10 and 30 minutes after placebo 
and MP (0.25 mg/kg) injection to 7 healthy volunteers. During scanning, the 
behavioral condition of the subjects was standardized using a continuous 
performance task. Growth hormone levels were assessed and subjective 
ratings were obtained. MP significantly elevated growth hormone levels. 
After receiving MP, the subjective experience varied from neutral to highly 
pleasurable. Ten minutes after MP administration, significant relative 
increases in rCBF were found in the rostral anterior cingulate (AC), temporal 
poles, and the supplementary motor area. Significant reductions were seen 
in the superior temporal gyri, right medial frontal cortex and right inferior 
parietal cortex. At 30 minutes after MP administration, increases were seen 
in the AC, temporal pole and right cerebellum. No changes were observed 
in the striatum. The activation in the right rostral AC was significantly higher 
in the subjects with the highest euphoria scores compared to the subjects 
with minimal MP-induced changes in euphoria. We suggest that the 
combined MP challenge with functional imaging, as described in our study, 
may be a useful tool to study the functional integrity of the dopaminergic 
system in psychiatric disorders. Chapter 6 
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Introduction 
The dopaminergic system has been implicated in the pathogeneses and 
treatment of a variety of neuropsychiatric disorders, such as schizophrenia, 
Parkinson’s disease, depression and addiction (Kapur and Mamo 2003; 
Leenders 2002; Naranjo et al. 2001; Volkow et al. 2002). The involvement of 
dopamine (DA) in these disorders may be related to its function in the 
processing of rewarding or salient stimuli (Kapur 2003; Kunig et al. 2000; 
Schmidt et al. 2001). However, the exact role of DA in these processes is 
not completely known. The (dys)function of the dopaminergic system may 
be studied by combining functional neuroimaging with a dopaminergic drug 
challenge, such as the DA reuptake blocker methylphenidate (MP). With this 
approach, DA-induced changes in regional neural activity can be assessed 
in living subjects. 
 
The dopaminergic neurons are located in the substantia nigra (SN) and 
ventral tegmental area (VTA). The dopaminergic cells in the SN project 
primarily to the dorsal striatum whereas the neurons of the VTA project most 
strongly to the limbic and cortical areas such as the nucleus accumbens, 
septum, amygdala, hippocampus, prefrontal and cingulate cortex (Wise 
2004). Administration of MP has been shown to induce substantial 
increases in DA levels in the projection areas of the dopaminergic system 
(During et al. 1992; Huff and Davies 2002; Kuczenski and Segal 1997) 
accompanied by strong subjective and behavioral effects (Wang et al. 
1999). 
 
Both positron emission tomography (PET) and functional magnetic 
resonance imaging (fMRI) are increasingly used to measure drug-induced 
changes in brain activity. These techniques provide in vivo measures of 
regional cerebral blood flow (rCBF), glucose utilization or blood 
oxygenation, which serve as an index of neural activity (Herscovitch 2001). 
Previous studies that investigated the effects of dopaminergic drugs on 
neural activity have mainly used [
18F]-fluorodeoxyglucose PET (FDG) (Ernst 
et al. 1997; London et al. 1990a; Volkow et al. 1997, 1998; Vollenweider et 
al. 1998; Wolkin et al. 1987). These studies showed that psychostimulants [15O]-H2O PET in human subjects 
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such as amphetamine, cocaine or MP induce changes in cortical, 
subcortical, limbic and cerebellar areas. Both increases and decreases have 
been reported, probably related to the dose administered (Vollenweider et 
al. 1998), the timing of the challenge (Volkow et al. 1998) or whether 
changes in relative or absolute glucose metabolism were measured. Using 
FDG, neuronal glucose metabolism is established in a measurement over a 
period of approximately 30 minutes. Therefore this method it not suitable to 
detect short lasting changes in brain activation. In our study we were 
interested in the effect of MP at the time of the peak in subjective effects, 
which occurs approximately 10 minutes after administration (Volkow et al., 
1999; Wang et al. 1999). In addition we wished to investigate changes in 
neural activation at the time of the peak in DA concentration, approximately 
30 minutes after MP administration (Huff and Davies 2002; Janowsky et al. 
1978). Compared to FDG, the temporal resolution of [
15O]-H2O PET and 
especially fMRI is much higher. The methods used to assess acute drug 
effects on the fMRI signal are currently under development and need further 
validation (Tracey 2001). Therefore we decided to use [
15O]-H2O PET in our 
study. A previous study that investigated the effects of MP using [
15O]-H2O 
PET, focused on the effects of the drug on absolute rCBF (Wang et al. 
1994). In our study we were interested in the effect of MP on relative 
changes in rCBF. 
 
Previous studies have shown that the behavioral state of the subject may 
influence the MP-induced effects on DA release or neuronal activity (Volkow 
et al. 1994, 1998). Therefore we tried to standardize the behavioral 
condition of the subjects during scanning, using a continuous performance 
task (van Leeuwen et al. 1998). The effect of MP on the behavioral state of 
the subjects was examined using verbal rating scales. We also assessed 
the effect of MP on growth hormone levels, as increases in the 
concentration of this hormone are assumed to reflect dopaminergic activity 
(Janowsky et al. 1978). We used a MP dose of 0.25 mg/kg since previous 
studies in psychiatric patient groups have used comparable doses 
(Janowsky and Davis 1976; Joyce et al. 1986). In our study we were 
interested in the MP-induced effects on rCBF in healthy volunteers. If MP 
induces changes in brain regions that are known to be involved in Chapter 6 
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dopaminergic (dys)function, this probe may be used in studies of 
dopaminergic functional abnormalities in psychiatric patients. 
Materials and Methods 
Subjects 
Seven healthy, right-handed, volunteers participated in the study (4 male, 3 
female, mean age  22 year, range 19 - 26 year). All subjects gave written 
informed consent after written and verbal explanation of the study. 
Suitability to participate in the study was determined by an independent 
physician after a medical examination including an ECG and blood 
laboratory tests. Exclusion criteria were current or past psychiatric, 
neurological, cardiovascular or other disease that could interfere with the 
study, dependence on any substance other than caffeine and exposure to 
psychoactive drugs during the past 6 months, excluding alcohol and 
caffeinated products. The study was approved by the Medical Ethical 
Commission of the University Medical Center Groningen (UMCG). 
General design 
The subjects were instructed to refrain from alcohol and caffeine containing 
products during 24 hours prior to each scan. On the day of the experiment, 
a total of four PET scans was made, two after placebo and two after MP 
injection. After placement in the scanner, either placebo or MP, 0.25 mg/kg 
i.v., injected over 1 minute, was administered and scans were made at 10 
and 30 minutes after each injection. These time points were chosen on the 
basis of the expected peak in MP induced subjective effects (at 10 minutes) 
and DA levels (at 30 minutes). In order to avoid carry over effects of MP, 
placebo injections were always administered first. The subjects were blind 
to the drug administered. Between the placebo and MP scans, the subjects 
were allowed to leave the scanner for approximately 30 minutes. Thereafter, 
they were repositioned in the scanner using marks on the face. During 
scanning, the behavioral condition of the subjects was standardized using a 
continuous performance task (CPT). Immediately after each scan, the 
subjective ratings were obtained and blood samples were taken for growth [15O]-H2O PET in human subjects 
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hormone levels. Blood pressure, heart rate and ECG were monitored during 
the experiment. 
Continuous performance task 
The CPT in our study was based on a task used by van Leeuwen et al. 
(1998). A sequence of digits (0-9) appeared on a computer screen and the 
subjects’ task was to click a mouse button with the right index finger 
whenever the target sequence, a 3 followed by a 7, appeared. Stimuli were 
presented for 150 ms in the center of the screen, between two vertical lines 
which were permanently visible. The interstimulus interval was 1500 ms. 
The target digits and non-target digits were pseudo-randomly distributed 
with equal probability (10 % for the target sequence “3 – 7” and non target 
sequence “3 non 7”). The task was initiated 1 minute before bolus injection 
of [
15O]-H2O and continued throughout scan acquisition. The task was 
practiced before scanning. 
Subjective ratings 
The behavioral effects were evaluated using a verbal analog rating scale. 
The subjects were asked to respond to the following descriptors, using a 
whole number between 0 (no effects) and 10 (maximal effects): Euphoria, 
anxiety, happiness, sexual desire, desire for MP, alertness, annoyance, 
distrust, loss of control, restlessness, depression and tiredness (Wang et al. 
1997). The subjects were also asked if they experienced the effects of the 
drug as pleasant or unpleasant. 
Growth hormone 
Plasma growth hormone levels were assessed by radioimmunoassay. 
PET scans 
For administration of the radioligand and MP or placebo, a venous cannula 
was placed in one of the veins in the right lower forearm. A second 
intravenous cannula was placed in the left arm for sampling of hormone 
levels. The subject was placed in the scanner and the head was fixed using 
a head restraint. The subjects were scanned in 3D acquisition mode using a 
Siemens ECAT Exact HR+ camera, giving 63 slices with a center to center Chapter 6 
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distance of 2.425 mm. For each scan, 500 MBq of [
15O]-H2O in saline was 
injected and flushed with saline (total volume 32 ml) at a speed of 8 ml/sec. 
After injection of the radioactive bolus, data were collected for a duration of 
2 min, in one frame.  
Data and image analysis 
Attenuation correction was performed by drawing ellipses on the brain 
images, assuming uniform attenuation. Statistical Parametric Mapping 
(SPM99) (Friston et al. 1995) was used for spatial transformation and 
statistical analysis. The origins were manually set at the anterior 
commissure. Changes in position due to repositioning of the subject, could 
be adequately solved by the realignment routine of SPM. The images were 
normalized to MNI template and smoothed with a Gaussian kernel of 10 mm 
FWHM. The data were analyzed using a multiple-subjects conditions and 
covariates model with covariate 0. Proportional scaling was used to correct 
for MP-induced changes in global blood flow. The images were scaled to a 
mean global activity of 50 ml/100 ml/min. The following contrasts were 
examined: differences between the two placebo scans (to assess the 
reproducibility of the scans), between the first placebo scan and first MP 
scan, and between the second placebo and second MP scan, using paired t 
tests. The initial T-map threshold was set at 3.69 (p <0.001), uncorrected for 
multiple comparisons. Results were considered significant at the 0.05 level, 
corrected for multiple comparisons. Clusters reaching this statistical 
threshold are included in the discussion. The coordinates of maximum 
relative changes were converted from MNI space to Talairach space. To 
investigate the prediction that the anterior cingulate (AC) was differentially 
activated in subjects with either high or low euphoria scores, we conducted 
a (multi-group) region of interest (ROI) analysis using the MARSBAR 
toolbox (Brett et al. 2002). The two groups consisted of the 3 subjects with 
the highest and lowest scores for euphoria respectively. The effect of MP on 
subjective ratings and hormone levels was assessed with paired t-tests. 
 
Drugs 
Methylphenidate was obtained from Fagron farma BV, the Netherlands and 
infusions were prepared and provided by the pharmacy of the UMCG. [15O]-H2O PET in human subjects 
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Results 
Growth hormone 
MP significantly elevated growth hormone levels at 10 minutes after 
administration (p<0.01) and 30 minutes after administration (p<0.01) (Fig 1). 
 
Figure 1: Growth hormone levels at 10 and 30 minutes after methylphenidate 
and placebo administration. 
Subjective effects 
After receiving MP, the subjective experience varied from neutral to highly 
pleasurable. Due to the variability in effects, the change in the different 
subjective ratings was not significant, except for happiness, 10 minutes after 
MP administration (p < 0.05). 
Scan results 
Due to failure of the first MP scan of one of the (female) subjects, we only 
have data for 6 subjects at ten minutes after MP administration. No 
differences were observed  between the two placebo scans, indicating 
reproducibility of the scans. Ten minutes after MP administration, a 
significant relative increase in rCBF was found in the rostral AC, temporal 
poles, and the supplementary motor area. Significant relative reductions 
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were seen in the superior temporal gyri, right medial frontal cortex and right 
inferior parietal cortex. At 30 minutes after MP administration, increases 
were seen in the AC, temporal pole and right cerebellum (table 1 and figure 
2). No changes were observed in the striatum, not even after lowering the 
initial significance threshold to p < 0.01 or after combining the two MP 
scans. At 10 minutes after MP administration, the activation in the right 
rostral AC was significantly higher in the three subjects with the highest 
euphoria scores compared to the subjects with minimal MP-induced 
changes in euphoria (p < 0.01) (Figure 3). At 30 minutes after MP 
administration, no significant differences were found in this region. 
 
 
Table I: Talairach coordinates of maximum relative changes in rCBF at 10 and 
30 minutes after intravenous administration of methylphenidate (0.25 mg/kg). 
Brain region  Talairach coordinates   Cluster size  p 
  x y z    
          
MP > placebo t = 10 min           
Anterior cingulate  -4  37  2  1277  < 0.001 
Right temporal pole  52  0  -39  710  < 0.001 
Left temporal pole  -57  6  -29  652  < 0.001 
Supplementary motor area  -4  26  54  251  0.01 
          
MP > placebo t = 30 min           
Anterior cingulate  2  37  6  220  0.019 
Left temporal pole  -57  6  -29  280  0.006 
Right  cerebellum  40  -71 -22 321  0.003 
          
Placebo > MP t = 10 min           
Right superior temporal gyrus  40  1  -19  687  < 0.001 
Left superior temporal gyrus  -40  -8  -8  202  0.028 
Right medial frontal cortex  30  66  -10  338  0.002 
Right medial frontal cortex  32  50  20  183  0.041 
Right inferior parietal cortex   55  -32  24  209  0.024 
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Figure 2: Glass brains (sagittal, coronal and tranverse projections) showing the 
location of significant relative increases (MP-placebo) and decreases (Placebo-
MP) in rCBF at 10 and 30 minutes after MP administration (p<0.001). AC: 
anterior cingulate, TP: temporal pole, SMA: supplementary motor area, CRB: 
cerebellum, STG: superior temporal gyrus, MFC: medial frontal cortex, IPC: 
inferior parietal cortex. 
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Figure 3: Relative rCBF changes in the right AC in the three subjects with the 
highest euphoria scores and the three subjects with low euphoria scores. P1: 10 
minutes after placebo, P2: 30 minutes after placebo, MP1: 10 minutes after 
methylphenidate, MP2: 30 minutes after methylphenidate. 
Discussion 
In our study we demonstrated a significant, MP-induced relative increase in 
the rCBF in the rostral AC in healthy volunteers. At 10 minutes after MP 
administration, activation in the right rostral AC differed significantly 
between the subjects with the highest euphoria scores compared to the 
subjects with low euphoria scores, suggesting a correlation between the 
magnitude of activation and the level of euphoria. Increases were also seen 
in the temporal poles, the supplementary motor area and cerebellum. MP-
induced decreases were found in the superior temporal gyri, right medial 
frontal cortex and right inferior parietal cortex. [15O]-H2O PET in human subjects 
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Changes in rCBF are coupled to changes in glucose consumption and 
assumed to be an index for changes in neuronal activation (Herscovitch 
2001). Since most changes in brain energy consumption are due to 
changes in glutamatergic signaling (Attwell and Laughlin 2001), the findings 
must be understood in terms of anatomical circuits where dopaminergic 
stimulation induces changes in glutamate release in connected anatomical 
regions. Previous studies have shown that direct vasoactivity of DA is 
unlikely to be the dominant mechanism underlying the rCBF response 
(Schwarz et al. 2004). 
 
The AC is part of the limbic system and includes numerous specialized 
subdivisions with a large range of cognitive, emotional, motor, nociceptive 
and visuospatial functions. Two major subdivisions can be distinguished: the 
dorsal cognitive division and a rostral-ventral affective subdivision (Bush et 
al. 2000; Philips et al. 2003; Pizzagalli et al. 2001). The (euphoria-related) 
increase in rCBF in our study was located in the affective subdivision of the 
AC. This division is primarily involved in assessing the salience of emotional 
and motivational information and the regulation of emotional responses 
(Allman et al. 2001; Bush et al. 2000) and may be activated during efforts to 
cope with or control feelings (Posner and Rothbart 1998). This region has 
extensive connections with other limbic areas such as the striatum and 
amygdala (Devinsky et al. 1995; Kalivas and McFarland 2003). As stated 
above,  the [
15O]-H2O PET signal is mainly due to changes in glutamate 
release. Therefore, the activation in the AC may be interpreted as a result of 
a change in the glutamatergic input from the amygdala (Jackson and 
Moghaddam 2001). 
 
The AC activation in our study is probably not due to the experience of 
euphoria per se. In accordance with the role of the AC, we suggest that the 
activation is related to an increased need for emotional control during MP 
administration. This would agree with results from previous studies that 
reported increased activation of the (right) AC after administration of various 
psychoactive drugs (Gouzoulis et al. 1999; Vollm et al. 2004). In these 
studies, the subjects were also asked to perform a task which may have 
increased the need to control the drug-induced emotional experiences. In Chapter 6 
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addition, studies that specifically asked the subjects to attend to or control 
their emotions have found increased activation of the (right rostral) AC 
(Beauregard et al. 2001; Childress et al. 2004; Lane et al. 1997; Ochsner et 
al. 2004). In a meta analysis by Berthoz and Blair (2002) it is also concluded 
that the AC is a key structure in emotion regulation. The finding that the 
(right) rostral AC is activated during unpleasant emotions is also in 
agreement with the suggested role of the AC in emotional control 
(Boshuisen et al. 2002; Damasio et al. 2000; Zubieta et al. 2003). In these 
studies, the subjects experienced strong negative emotions. The 
experiments were performed in the PET camera, thereby necessitating 
control of the experienced emotions. 
 
Previous studies have shown that differences in AC activation may be 
related to baseline differences between the subjects. Cue-induced activation 
in the rostral AC correlated to baseline striatal D2 occupancy in alcoholic 
subjects (Heinz et al. 2004). And in a study by Volkow et al. (1997), baseline 
striatal D2 correlated with MP-induced changes in metabolism in the frontal 
cortex. Differences in AC activation may also be related to personality (Canli 
et al. 2001; Johnson et al. 1999; Sugiura et al. 2000). Unfortunately, in our 
study we did not measure such parameters. 
 
Results from previous studies have indicated AC abnormalities in 
psychiatric patients. Several studies have found differences in (right rostral) 
AC function between depressed patients and healthy control subjects 
(Drevets 1999; Ebert and Ebmeier 1996; Kumari et al. 2003). Moreover, the 
baseline activity in this region has been found to predict the response to 
antidepressant treatments (Mayberg et al. 1997; Pizzagalli et al. 2001; Wu 
et al. 1999). The (right rostral) AC may also be involved in addiction (Bolla 
et al. 2004; Franklin et al. 2002; Goldstein and Volkow 2002). The AC 
abnormalities in these disorders may be related to the disturbances in 
emotion regulation and motivated behavior, probably due to a dysfunction of 
the dopaminergic system (Drevets 1999; Ebert and Ebmeier 1996; Volkow 
et al. 2002; Wu et al. 1999). 
 
In our study, no changes were found in striatal activation. The striatum, and 
especially the ventral striatum, has been implicated in the processing of [15O]-H2O PET in human subjects 
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rewarding or reinforcing effects of dopaminergic drug stimuli (Ikemoto and 
Panksepp 1999; Spanagel and Weiss 1999; Ungless 2004; Wise 2004). 
Therefore, we expected rCBF changes in this region. A review of the 
literature, however, shows that psychostimulant administration does not 
consistently affect striatal activation. Previous human and animal studies 
have reported activations (Chen at al. 1997; Dixon et al. 2005; Ernst et al. 
1997; Marota et al. 2000; Schwarz et al. 2004), deactivations (Cash et al. 
2003; Volkow et al. 1997) or no changes (Howell et al. 2002; Mehta et al. 
2000; Vollm et al. 2004; Wallace et al. 1996) in relative rCBF or brain 
metabolism. Drug administration also resulted in variable effects on 
absolute rCBF or metabolism. In most studies an increase in absolute brain 
activation was seen (Cash et al. 2003; Howell et al. 2002; Pontieri et al. 
1990; Porrino and Lucignani 1987; Vollenweider et al. 1998), however, 
decreases have also been reported (London et al. 1990a; Volkow et al. 
1998; Wang et al. 1994; Wolkin et al. 1987) and in other studies no 
significant changes were found (Cash et al. 2003; Ernst et al. 1997). These 
differences may be due to differences in the pharmacological challenge 
(Pontieri et al. 1990), dose (Porrino and Lucignani 1987; Vollenweider et al. 
1998), use of anesthesia (Cash et al. 2003), timing of the challenge (Porrino 
1993; Stein and Fuller 1993), route of administration (Porrino 1993), 
immobilization (London et al. 1990b), and the state of cortical excitatory 
modulation (Tschanz et al. 1994). It has been suggested that the effects of 
DA on brain activity may depend on the state of the dopaminergic system 
(Volkow et al. 1997, 1998). As stated previously, changes in rCBF are 
primarily caused by changes in glutamatergic transmission. The striatum 
receives glutamatergic projections from the cerebral cortex (Fonnum et al. 
1981). It has been shown that DA may both enhance or inhibit excitatory 
glutamate release in the striatum (Cepeda et al. 1993). The DA-induced 
glutamate response in the striatum is found to be dependent on the basal 
neuronal activity (Kiyatkin and Rebec 1996). It may be concluded that the 
nature of interaction between the cerebral cortex and striatum is dependent 
on the experimental conditions (Bamford et al. 2004, Morari et al. 1998). 
 
A strong activation was seen in both temporal poles at 10 and 30 minutes 
after MP administration. Since this activation extends outside the brain, 
possible movement artifacts can not be excluded. Nevertheless, the Chapter 6 
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activation is in accordance with a role of the temporal poles in emotional 
processes (Dolan et al. 2000). 
 
We have shown a MP-induced activation of the (pre) supplementary motor 
area (rostral part of BA 6). Activations in this region have been shown 
during response conflict or uncertainty (Hazeltine et al. 2000; Ullsperger and 
Cramon 2003). Possibly, the activation in our study is due to the MP-
induced distracting subjective experiences. 
 
The cerebellar activation in our study is difficult to interpret. Evidence exists 
that the cerebellum is not only involved in motor functions, but also in 
cognitive and emotional processes (Rapoport et al. 2000; Schmahmann 
2004). Increases in (right) cerebellar rCBF have also been reported in 
previous studies using psychoactive drugs (Gamma et al. 2000; Gouzoulis 
et al. 1999; Mehta et al. 2000; Volkow et al. 1997). 
 
In our study (right-sided) relative deactivations were found in the superior 
temporal gyri, medial frontal cortex and inferior parietal cortex. A right sided 
fronto-parietal-temporal network is most often associated with (sustained) 
attention, as assessed during performance of a CPT (Berman and 
Weinberger 1990; Buchsbaum et al. 1990; Corbetta and Shulman 2002; 
Hager et al. 1998; Pardo et al. 1991). The deactivations in our study may 
related to a decrease in attention due to task habituation or allocation of 
attention to the MP-induced emotional effects (Coull et al. 1998). 
 
In conclusion, the most important finding in our study was the euphoria-
related relative increase in right rostral AC activation after administration of 
MP. We suggest that the activation is related to the role of this region in 
emotional control. This finding may be relevant with respect to previous 
studies that have shown the involvement of the (right) rostral AC in the 
pathogenesis of psychiatric disorders such as depression (Drevets 1999; 
Ebert and Ebmeier 1996; Kumari et al. 2003; Mayberg et al. 1997; Pizzagalli 
et al. 2001; Wu et al. 1999) or addiction (Bolla et al. 2004; Franklin et al. 
2002; Goldstein and Volkow 2002). As stated before, previous studies have 
also indicated a role of the dopaminergic system in the AC related 
disturbances in emotion regulation and motivated behavior (Drevets 1999; [15O]-H2O PET in human subjects 
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Ebert and Ebmeier 1996; Volkow et al. 2002; Wu et al. 1999). Therefore, we 
suggest that the combined MP challenge with functional imaging, as 
described in our study, may be a useful tool to study the functional integrity 
of the dopaminergic system in psychiatric disorders. 
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Summary 
One of the aims of this thesis was to investigate if the binding of [
18F]-MPPF 
to the 5-HT1A receptor is sensitive to changes in endogenous 5-HT levels. 
The [
18F]-MPPF study in humans has shown that the binding of this ligand 
was not affected by small changes in 5-HT levels, as induced by tryptophan 
depletion and infusion. In rats, the binding of [
18F]-MPPF was decreased 
after fenfluramine-induced increases in 5-HT levels, whereas the 
combination of citalopram with ketanserin did not induce significant changes 
in ligand binding. Microdialysis studies showed that these treatments 
resulted in 30-fold and 10-fold increases in extracellular 5-HT levels 
respectively. The study in monkeys revealed that fenfluramine-induced 
increases in 5-HT did not affect [
18F]-MPPF binding under equilibrium 
conditions, although the increases were comparable to those in the rat 
study. In contrast, an equilibrium study with the D2 ligand [
11C]-raclopride 
showed that the binding of this ligand was affected by a relatively low dose 
of the DA reuptake blocker methylphenidate. Microdialysis studies indicate 
that the increases in DA levels after this dose were less than 6-fold (Huff 
and Davies 2002). Moreover, the DA-induced changes in [
11C]-raclopride 
binding correlated with subjective experiences. Significant correlations were 
found between the methylphenidate-induced change in euphoria and 
percent change in binding potential (ΔBP) in the dorsal striatum and 
between baseline anxiety and ΔBP in the dorsal and middle striatum. We 
also found a significant negative correlation between baseline BP in the 
dorsal striatum and change in euphoria. The [
15O]-H2O PET study showed 
that methylphenidate induced euphoria-related rCBF increases in the AC, a 
region that is involved in DA-associated disturbances in emotion regulation 
and motivated behavior. When interpreting the results of these studies it is 
important to consider the following issues. Chapter 7 
  161 
Measurement of changes in neurotransmitter 
release 
The results of the serotonergic competition studies showed that [
18F]-MPPF 
binding was not consistently affected after large increases in 5-HT levels, 
despite the fact that in vitro studies have shown that 5-HT is able to 
compete with [
18F]-MPPF binding to the 5-HT1A receptor (Watson et al. 
2000). In contrast, [
11C]-raclopride binding was significantly affected after 
relatively small increases in DA levels. 
Extent and timing of changes in neurotransmitter release 
The results of the [
18F]-MPPF studies indicate that only very large increases 
in 5-HT concentration may possibly affect ligand binding at the 5-HT1A 
receptor. Especially in human subjects, safety issues preclude the use of 
such challenges. With respect to the timing of the challenge, it has been 
shown that in bolus studies the extent of the change in ligand binding may 
theoretically be affected by the timing of the challenge. Optimal changes in 
tissue concentration are predicted if the concentration of the competitor 
follows the peak in free ligand concentration (Endres and Carson 1998; 
Morris 1995; Yoder et al. 2004). This may possibly have affected the 
changes in ligand uptake in our rat studies, where [
18F]-MPPF was 
administered as a bolus injection. It would also imply that if equilibrium is not 
achieved and ligand binding is still increasing, net binding will be little 
affected by increases in neurotransmitter (Gatley et al. 2000). However, in 
equilibrium situations, as used in chapter 4 and 5, the changes in ligand 
binding are insensitive to timing of the challenge. 
Internalization 
A difference between the serotonergic and dopaminergic system concerns 
the internalization of receptors. It has been shown that, in contrast to 
(postsynaptic) 5-HT1A receptors, D2 receptors are internalized after agonist 
stimulation (Riad et al. 2004; Sun et al. 2003). As mentioned in the 
introduction, a few studies reported cholinergic, adrenergic and opioid 
ligands to be sensitive to competition with the endogenous neurotransmitter. 
It is noteworthy that the muscarinic-cholinergic, alpha2-adrenergic and mu-
opioid receptors are also found to be internalized after agonist stimulation General discussion 
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(Keith et al. 1998; Maloteaux and Hermans 1994; Olli-Lahdesmaki et al. 
1999). However, the internalization of agonist-induced receptors may 
explain the duration of reduced ligand binding but not the initial decrease. 
Changes in blood flow 
The drugs that are used in pharmacological challenge studies may induce 
changes in blood flow. Since PET ligands are administered via the blood 
circulation their distribution may theoretically be affected by drug-induced 
changes in blood flow. This could lead to erroneous measurements of BP 
changes. With computer simulations, using the kinetic rate constants of the 
ligand, possible effects of changes in blood flow on ligand binding can be 
predicted. For example, in a simulation study with [
18F]-fallypride, Slifstein et 
al. (2004) calculated that changes in blood flow will have only small effects 
on the binding of this ligand. In case of good dynamic data, kinetic models 
which explicitly incorporate blood flow may also provide information on and 
correct for effects of blood flow changes during the experiment (Logan et al. 
1994). Currently, it is not known to what extent the binding of [
18F]-MPPF is 
affected by changes in blood flow. However, under equilibrium conditions, 
as used in chapter 4 and 5, there is no net radiotracer transfer across the 
blood-brain barrier and possible effects of drug-induced changes in blood 
flow can therefore be excluded. 
Ligand characteristics 
Under equilibrium conditions and using tracer doses, changes in specific 
binding are not dependent on the affinity of the ligand (Abi-Dargham et al, 
1999; Laruelle 2000). However, simulation studies have shown that the 
kinetic properties of the ligand play a role when total uptake of the ligand is 
studied (Endres and Carson 1998). Based on the calculations in the study of 
Endres and Carson, it can be assumed that the relatively low BP of the 
ligands in our studies should enable optimal detection of drug-induced 
signal changes in case of bolus with constant infusion. 
Receptor compartments 
As mentioned before, the 5-HT1A and D2 receptors are located both 
extrasynaptically and intrasynaptically. It is possible that the Chapter 7 
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pharmacological challenges differentially affect neurotransmitter levels in 
these two receptor compartments, depending on their mechanism of action. 
The SERT is mainly located extrasynaptically (Zhou et al. 1998) and the 
striatal DAT both intrasynaptically and extrasynaptically (Sesack et al. 
1998). Blockade of these transporters thus results in either extrasynaptic or 
both extra- and intrasynaptic increases in neurotransmitter levels, 
respectively. A drug-induced stimulation of the release of the transmitter 
may involve exocytotic (synaptic) and transporter mediated (extrasynaptic) 
processes, thereby leading to compartment specific changes in 
neurotransmitter levels. Fenfluramine increases 5-HT levels via both release 
mechanisms, in addition to blockade of its reuptake (Crespi et al. 1997). 
Methylphenidate is shown to block the reuptake of DA through binding to 
the DA transporter. Based on the these data, it can be assumed that both 
fenfluramine and methylphenidate lead to neurotransmitter changes in the 
intrasynaptic and extrasynaptic compartments. 
Effects of anesthesia 
Previous studies have shown that ligand binding may be affected by the use 
of different anesthetics. The mechanism of these effects is not completely 
understood but may be related to changes in cerebral blood flow or receptor 
affinity (Ginovart et al. 2002; Harada et al. 2004; Hassoun et al. 2003; 
Momosaki et al. 2004; Seeman and Kapur 2003; Tsukada et al. 2002). 
Anesthetics may also affect serotonergic transmission (Dringenberg and 
Vanderwolf 1995; Dringenberg et al. 1995; Mokler et al. 1998) and reduce 
agonist binding to the 5-HT1A  receptor (Kalipatnapu and Chattopadhyay 
2004). Because of the possible effects of anesthetics on 5-HT1A binding, we 
have chosen to perform our rat and monkey studies in conscious animals. 
However, previous studies were often performed in anesthetized animals 
(Hume et al. 2001; Maeda et al. 2001; Zimmer et al. 2002). The effects of 
anesthesia may possibly explain some of the discrepancies in results from 
5-HT1A competition studies, such as the large changes in [
18F]-MPPF 
binding after different serotonergic manipulations in the studies of Zimmer et 
al. (2002). General discussion 
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Affinity state of receptors 
The relative insensitivity of serotonergic ligands to changes in 5-HT levels 
may be explained by the large proportion of 5-HT1A receptors in the low 
affinity state, as suggested in the first three chapters of this thesis. In 
contrast, the proportion of D2 receptors in the high affinity state is much 
larger (Cumming et al. 2002; Narendran et al. 2004). As mentioned before, 
muscarinic-cholinergic, alpha2-adrenergic and opioid ligands were found to 
be sensitive to competition with the endogenous neurotransmitter (Carson 
et al. 1998; Nishiyama et al. 2001; Skaddan et al. 2002; Tyacke et al. 2005). 
Previous studies have reported that a large proportion of alpha2 and opioid 
receptors is in the high affinity state (Bunzow et al. 1995; Ribas et al. 2001). 
Most cholinergic receptors are located extrasynaptically, and it can therefore 
be assumed that these receptors are also configured in the high affinity 
state (Descarries et al. 1997; Vizi 2000). These data signify the importance 
of the affinity state of receptors in neurotransmitter competition studies. 
Additionally, it should be noted that the proportion of receptors in the high 
affinity state may depend on the species or the use of anesthetics. 
Baseline neurotransmitter concentration 
The baseline concentration of the neurotransmitter may also play a role in 
the sensitivity of the binding of the ligand to competition. If baseline levels 
are high (closer to the KD of the receptor), ligand binding is more easily 
affected by increases in neurotransmitter concentration. If the concentration 
of the neurotransmitter is high enough, this may even result in competition 
at the receptors in the low affinity state. In this respect it is important to 
realize that the baseline level of 5-HT depends on the activity state of the 
animal: high during active waking and low during sleep. All our experiments 
were performed during daytime, which is the resting period of rats and 
waking period of rhesus monkeys. Microdialysis experiments have shown, 
however, that the baseline concentration of 5-HT was comparable in our 
experiments in rats and monkeys (around 0.9 nM). Compared to the 
relatively low baseline level of 5-HT, the baseline concentration of DA is 
much higher (more than 10-fold) (Westerink and de Vries 1991). This may 
have contributed to the fact that, in contrast to the binding of [
18F]-MPPF, 
[
11C]-raclopride binding was found to be sensitive to increases in 
neurotransmitter levels. Chapter 7 
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Activation studies 
The results of our rCBF study comply with the current knowledge of 
dopamine-induced changes in brain activation. As mentioned before, the 
effects of psychostimulants depend on the nature of the pharmacological 
challenge (Pontieri et al. 1990), the dose (Porrino and Lucignani 1987; 
Vollenweider et al. 1998), the use of anesthesia (Cash et al. 2003), the 
route of administration (Porrino 1993), immobilization (London et al. 1990), 
the baseline state of the subject (Volkow et al. 1997, 1998), the timing of the 
measurement (Porrino 1993; Stein and Fuller 1993), or whether changes in 
relative or absolute rCBF or metabolism are measured. 
 
Interpretation of the results from activation studies is not always 
straightforward. For instance, neurotransmitter-induced effects on blood flow 
via direct interaction with receptors on blood vessels can not be excluded. In 
our study we corrected for global changes, and therefore the observed 
changes in rCBF are largely independent of global effects on blood flow. A 
local cerebrovascular effect can not be controlled for however, and can 
therefore not be excluded. Choi et al. (2003) studied the possible vascular 
effects of DA using fMRI and found that the hemodynamic change induced 
by dopaminergic ligands may be mediated through D1/D5 receptors on the 
vasculature. However, Schwarz et al. (2004) has shown that direct 
vasoactivity of DA is unlikely to be the dominant mechanism underlying the 
rCBF response, since changes in DA did not reflect the temporal profile of 
the rCBF response in their study. In previous studies, the authors have 
speculated on the origin of the regional changes in brain activation after 
drug-induced modulation of neurotransmitter release. Sometimes a 
distinction is made between subjective and neurotransmitter-related rCBF 
changes, in order to explain the results. In other studies, primary effects of 
the neurotransmitter are distinguished from secondary effects (Gamma et 
al. 2000; Grasby et al. 1992, 1993; Mann et al. 1996; Smith et al. 2002). 
However, since changes in brain activation are primarily due to changes in 
glutamatergic signaling (Attwell and Laughlin 2001), all findings must be 
interpreted in terms of anatomical circuits where the challenge induces 
changes in glutamate release in connected anatomical regions. General discussion 
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General issues 
Subject characteristics 
The subjects that were included in the studies in this thesis were all healthy 
controls. It is generally assumed that the variability within a group of normal 
volunteers is small. Evidence exists, however, that brain function may differ 
significantly between subjects. Previous studies have reported individual 
differences in dopaminergic or serotonergic function, such as receptor 
density or neurotransmitter release, which are related to personality, gender 
or aging. As indicated in chapter 5, the outcome of neurobiological 
experiments may partly be explained by these inter-individual differences in 
subject characteristics. In that study, the baseline level of anxiety correlated 
with the extent of methylphenidate-induced increases in DA concentration. 
Personality 
Several studies have found correlations between neurotransmitter function 
and personality traits. With respect to the dopaminergic system, the D2 and 
DAT densities were found to be related to detachment (Breier et al. 1998) 
and dopamine synthesis capacity to anxiety-related traits and irritability 
(Laakso et al. 2003). The extent of dopamine release was shown to be 
related to novelty seeking behavior (Leyton et al. 2002). The serotonergic 
system is also found to be involved in personality traits. The 5-HT1A receptor 
density is reported to be correlated to self-transcendence (Borg et al. 2003), 
anxiety (Tauscher et al. 2001a) and aggression (Parsey et al. 2002), 
although correlations with personality traits were not always found (Rabiner 
et al. 2002). The 5-HT2 receptor density is suggested to play a role in harm 
avoidance behavior (Moresco et al. 2002). In addition, the responsiveness 
of the dopaminergic and serotonergic neurotransmitter systems may be 
related to the individual reaction to stress. (Amat et al. 1998; Bland et al. 
2003; Marsteller et al. 2002; Oswald et al. 2005) and different forms of 
stress may have different effects on neurotransmitter release (Amat et al. 
1998; Bland et al. 2003). Methodological differences between studies could 
therefore affect the study outcome if one condition is more stressful than 
another condition. This may partly explain the different outcome of the 
(freely moving) rat and (immobilized) monkey study. 
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An association between personality traits and biological parameters is also 
seen in brain activation studies. Youn et al. (2002) found that different 
temperament types correspond to different patterns of baseline brain 
metabolism and Keightley et al. (2003) found personality-related differences 
in rCBF under transient emotional stress. As mentioned in chapter 6, the 
differences in AC activation may also be related to personality type (Canli et 
al. 2001, Johnson et al. 1999; Sugiura et al. 2000).  
Gender 
Dopaminergic or serotonergic function may also be related to the gender of 
the subject. So far, no evidence exists for gender-related differences in D2 
or 5-HT2 receptor density (Adams et al. 2004; Farde et al. 1995), but several 
studies have reported differences in 5-HT1A density (Parsey et al. 2002; 
Meltzer et al. 2001) and serotonin synthesis capacity (Chugani et al. 1998; 
Nishizawa et al. 1997; Okazawa et al. 2000). Gender differences were also 
found in studies that investigated resting state brain metabolism or rCBF 
(Andreason et al. 1994; George et al. 1996; Kawachi et al. 2002) and mood-
related changes in rCBF (George et al. 1996).  
Aging 
The density of the DAT and D2 and 5-HT2 receptors is found to decline with 
age (Adams et al. 2004; Kaasinen et al. 2000; Lavalaye et al. 2000). Effects 
of age on 5-HT1A receptor density were found in some studies but not in all 
(Meltzer et al. 2001; Parsey et al. 2002; Rabiner et al. 2002; Tauscher et al. 
2001b). In the study described in chapter 2, we did not find correlations 
between 5-HT1A receptor binding and age. The effects of age on brain 
metabolism were studied by Kawachi et al. (2002). They reported significant 
correlations between aging and glucose metabolism in several brain 
regions. 
 
In the studies described in chapter 5 and 6, both males and females were 
included of different ages, although all relatively young. Because of the 
relatively small number of subjects we did not correct for these differences 
and some of the variability in our studies may be related to gender or age-
related factors. In addition, in none of our studies, we used personality 
scales to assess differences in character or temperament. Due to the 
voluntary basis of participation in these studies, it is possible that the General discussion 
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personality of the included volunteers differed from the average population. 
It can, for instance, be assumed that the percentage of novelty seekers in 
our studies was higher than on average. Studies with a larger number of 
subjects could provide more information on the exact contribution of these 
factors. 
Beyond dopamine and serotonin 
Although drug treatment of psychiatric disorders such as depression and 
schizophrenia has largely focused on the modulation of serotonergic and 
dopaminergic transmission, it is not known if the underlying pathophysiology 
of these disorders is causally related to abnormalities in these systems. 
Current research focuses on interactions between these and other systems 
and evidence exists for the involvement of neurotransmitters such as GABA 
or glutamate. Additionally, an increasing number of studies have implicated 
other factors such as stress, abnormal gene expression, environmental 
effects, disturbed immune function, changes in synaptic function and 
plasticity or intracellular mechanisms in the etiology of psychiatric disorders 
(Bosker et al. 2004; Carlsson et al. 2001; Harrison 1999; Harrison and 
Eastwood 2001; Schiffer et al. 2003; Smith et al. 1997). However, as 
described in this thesis, a large amount of evidence indicates the 
involvement of the dopaminergic and serotonergic systems in (the treatment 
of) psychiatic disorders. 
Conclusions 
Alterations in serotonin levels may theoretically be assessed using ligands 
that are sensitive to changes in the concentration of this neurotransmitter. 
The results of the [
18F]-MPPF study in human subjects showed that the 
binding of this ligand is not significantly affected by physiological changes in 
5-HT levels. This finding indicates that this ligand is not suitable for 
detection of disease or drug-related 5-HT changes in human subjects. In a 
bolus study in rats, the binding of [
18F]-MPPF was found to be decreased 
after considerable increases in 5-HT levels. However, a bolus with constant 
infusion study in monkeys did not show significant changes in ligand binding 
after comparable increases in 5-HT levels. The reason for this discrepancy Chapter 7 
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is yet unknown, but may be related to methodological factors such as drug-
induced changes in blood flow or differences in the proportion of receptors 
in the high affinity state. In contrast to these serotonergic studies, an 
equilibrium study with the D2 ligand [
11C]-raclopride showed significant 
reductions in ligand binding after a relatively low dose of the DA reuptake 
blocker methylphenidate. Two major differences between the serotonergic 
5-HT1A and dopaminergic D2 receptor systems, concern the proportion of 
receptors in the high affinity state and the baseline neurotransmitter 
concentration. Currently, these findings are the most likely explanation for 
the differences in sensitivity between the two systems. The measured 
changes in DA release were also found to be related to subjective effects, 
such as euphoria and baseline anxiety. These results comply with previous 
studies, indicating the feasibility of this design to study dopaminergic 
(dys)function in psychiatric disorders such as depression. The combination 
of methylphenidate with [
15O]-H2O PET also showed euphoria-related 
changes in dopaminergic function and thereby offers another useful design 
to study the functional integrity of the dopaminergic system in future studies. 
Future studies 
The insensitivity of 5-HT1A  ligands to changes in 5-HT levels may be 
explained by the relatively small proportion of receptors in the high affinity 
state in vivo, as stated earlier. Labeled agonists to the 5-HT1A receptor could 
possibly be used to show effects of 5-HT increases on ligand binding at the 
high affinity receptors. Unfortunately, the first attempts to develop such 
ligands were unsuccessful, despite the high affinity of these ligands for the 
5-HT1A receptor (Pike et al. 2001; Zimmer et al. 2003). Possibly the 
proportion of 5-HT1A receptors in the high affinity state is simply too low to 
enable measurable binding with these ligands. Alternatively, attention could 
be focused on other serotonergic sites, such as the SERT. A study by 
Ginovart et al. (2003) showed that the binding of the SERT ligand [
11C]-
DASB was reduced after administration of the MAO inhibitor 
tranylcypromine. With respect to the dopaminergic system, the combination 
of methylphenidate with [
11C]-raclopride constant infusion, may be used to 
improve the knowledge on the function of the dopaminergic system in General discussion 
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psychiatric disorders. Additionally, this method may provide information on 
the mechanism of action of drugs in development. 
 
Our studies have shown that it may be difficult to find suitable ligands to 
measure changes in neurotransmitter levels. Moreover, due to the lack of 
specific ligands, it has not been possible to study the role of a number of 
receptor subtypes. In these cases, functional studies using [
15O]-H2O PET 
or fMRI, possibly in combination with cognitive or emotional tasks, may 
provide information on the effects of psychoactive drug challenges. The 
results of our [
15O]-H2O PET study with methylphenidate indicate the 
potential usefulness of such studies in psychiatric research or drug 
development. 
 
Future studies may also provide insight in the involvement of age, gender 
and personality-related factors in the results of neuroimaging studies. In 
addition, it would be interesting to study the contribution of these subject 
related characteristics to the pathogenesis and treatment of psychiatric 
disorders. These studies may also lead to a greater understanding of the 
neurobiological basis of psychiatric disorders and their treatment. Chapter 7 
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SAMENVATTING 
Inleiding 
Black box? 
Lange tijd werd het brein beschouwd als een zogenaamde “black box” waar 
processen plaatsvinden die we niet kunnen zien of meten. In de loop van de 
vorige eeuw kwam daar echter verandering in. Er werden in die periode 
verschillende technieken ontwikkeld die het mogelijk maken om 
hersenprocessen te bestuderen bij de levende mens. Eén van deze 
technieken is Positron Emission tomography (PET). Gedurende de jaren 70 
werden de eerste PET scans gemaakt en daarna breidden de 
mogelijkheden van deze techniek zich snel uit. Met behulp van PET kunnen 
nu vele biologische processen zoals de hersenactiviteit, receptordichtheid 
en neurotransmitterafgifte worden afgebeeld en gemeten. 
Signaalstoffen in de hersenen 
Neurotransmitters zijn de signaalstoffen van de hersenen. Deze stoffen 
worden afgescheiden door de zenuwcellen (neuronen) die via lange 
uitlopers met elkaar in verbinding staan. De ruimte tussen de uitloper van 
een cel en de doelcel heet synaps. De neurotransmitters worden 
uitgescheiden in deze synaps en binden vervolgens aan specifieke 
receptoren op de doelcel. Op deze manier wordt het signaal doorgegeven 
van de ene cel op de andere. Inmiddels zijn al meer dan 100 
neurotransmitters, en een nog groter aantal receptor subtypes, 
geïdentificeerd in de hersenen. Twee belangrijke neurotransmitters zijn 
dopamine en serotonine. Er is veel onderzoek gedaan naar de functie van 
deze neurotransmitters en hun receptoren. Hieruit is gebleken dat dopamine 
vooral van belang is bij beweging, motivatie, aandacht en 
beloningsmechanismen en dat serotonine een rol speelt bij de regulatie van Samenvatting 
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slaap, seksueel gedrag, eetlust, temperatuur, stress, de stemming en het 
geheugen. Ook is gevonden dat deze neurotransmitters betrokken zijn bij 
het ontstaan en de behandeling van psychiatrische en neurologische 
ziektebeelden zoals depressie, angst, schizofrenie, verslaving en de ziekte 
van Parkinson. Het is echter nog steeds niet bekend wat de precieze rol van 
dopamine en serotonine hierbij is. Met behulp van neuroimaging technieken 
zoals PET is het mogelijk om hierin meer inzicht te krijgen. In eerdere 
studies is bijvoorbeeld gevonden dat er een verband bestaat tussen 
biologische eigenschappen zoals het aantal receptoren of de activiteit in 
een bepaald hersengebied en emoties zoals angst, depressie of euforie. 
Ook zijn er relaties gevonden met mentale processen zoals geheugen en 
aandacht. Dergelijke bevindingen kunnen uiteindelijk meer inzicht geven in 
de hersenprocessen die betrokken zijn bij onze emoties, gedrag en 
denkvermogen, zowel bij gezondheid als bij ziekte. Ook kunnen we hierdoor 
meer te weten komen over het werkingsmechanisme van geneesmiddelen 
die aangrijpen op deze processen. PET kan zo dus een belangrijke rol 
spelen bij het onderzoek naar de oorzaak en behandeling van 
psychiatrische en neurologische ziektebeelden. 
Hoe werkt PET? 
Bij deze techniek neemt een proefpersoon plaats in een camera en wordt 
een kleine hoeveelheid van een radioactief gelabelde stof (radiotracer of 
radioligand in het geval van receptor studies) ingespoten in de arm waarna 
de stof zich verdeelt over het lichaam. Bij het verval van de radioactieve stof 
worden positronen (anti-elektronen) uitgezonden die onmiddellijk fuseren 
met een elektron uit het omringende weefsel. Bij deze fusie komt straling vrij 
die wordt gedetecteerd door de camera. Met behulp van geavanceerde 
elektronica en software wordt deze informatie omgezet in een 
driedimensionaal beeld dat de verdeling van de ingespoten stof over de 
hersenen weergeeft. Verschillende wiskundige modellen maken het 
vervolgens mogelijk om de verkregen informatie te kwantificeren (in getallen 
uit te drukken).  
Het meten van veranderingen in neurotransmitterafgifte 
De afgelopen decennia is gebleken dat PET gebruikt kan worden om 
veranderingen in neurotransmitterafgifte te meten. Deze ontwikkeling heeft Samenvatting 
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ondermeer informatie opgeleverd over verstoringen in 
neurotransmitterafgifte bij psychiatrische patiënten. Het principe van deze 
methode berust op het gegeven dat de binding van een radioligand wordt 
beïnvloed door veranderingen in de neurotransmitterconcentratie. Als het 
radioligand en de neurotransmitter binden aan dezelfde receptor kunnen ze 
met elkaar in competitie gaan. Dit betekent dat een toename van de 
neurotransmitterconcentratie leidt tot een afname in de binding van het 
radioligand en andersom. Het is momenteel nog niet helemaal duidelijk of 
competitie inderdaad het verantwoordelijke mechanisme is voor de 
waargenomen veranderingen in de binding van het radioligand. Het wordt 
echter algemeen aangenomen dat deze veranderingen als maat genomen 
kunnen worden voor veranderingen in neurotransmitterconcentratie. Tot nu 
toe is deze methode voornamelijk toegepast op het dopaminerge systeem. 
Hierbij werd vooral gebruik gemaakt van het radioligand [
11C]-raclopride dat 
specifiek bindt aan de dopamine D2 receptor (een subtype van de dopamine 
receptoren). Studies met dit radioligand hebben ondermeer verstoringen in 
de dopamineafgifte aangetoond bij schizofrenie en verslaving. Het zou erg 
interessant zijn als er een vergelijkbaar radioligand zou bestaan voor het 
serotonerge systeem. Hiermee zou bijvoorbeeld onderzocht kunnen worden 
of er bij depressie inderdaad sprake is van een verminderde afgifte van 
serotonine, een hypothese waar tot nu toe alleen indirecte aanwijzingen 
voor bestaan. Ook zou met deze techniek het effect van medicatie op de 
serotonineafgifte gemeten kunnen worden. Het blijkt echter niet eenvoudig 
te zijn om radioliganden te vinden die gevoelig zijn voor veranderingen in de 
afgifte van deze neurotransmitter. Er zijn verschillende studies gedaan met 
serotonerge radioliganden waarbij gekeken is of de binding werd beïnvloed 
door veranderingen in de serotonineconcentratie. Deze studies zijn 
uitgevoerd bij mensen en bij proefdieren waarbij in de dierstudies vaak 
gebruik is gemaakt van anesthesie. De resultaten van deze studies zijn 
helaas niet erg eenduidig. In sommige studies werden kleine veranderingen 
in de binding van het radioligand waargenomen. In andere studies was er 
echter geen meetbaar effect. Deze inconsistenties zijn mogelijk een gevolg 
van methodologische verschillen tussen de studies. Hierbij kan gedacht 
worden aan verschillen in het gebruikte radioligand, de diersoort of de 
toepassing van anesthesie. Samenvatting 
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Het onderzoek in dit proefschrift 
Meten van veranderingen in de serotonineconcentratie 
Het PET centrum in Groningen beschikt over het radioligand [
18F]-MPPF. 
Deze stof bindt aan een van de serotonine receptor subtypes: de 
serotonine-1A (5-HT1A) receptor. Het doel van de eerste drie studies in dit 
proefschrift was te onderzoeken of de binding van dit radioligand gevoelig is 
voor veranderingen in de serotonineconcentratie. In de eerste studie 
(hoofdstuk 2) werd de binding van [
18F]-MPPF onderzocht bij 6 gezonde 
mannelijke vrijwilligers. Bij deze vrijwilligers werden [
18F]-MPPF scans 
gemaakt in twee verschillende condities. In de ene conditie werd de 
serotonineconcentratie verhoogd door middel van een tryptofaan infusie en 
in de andere werd de concentratie verlaagd door middel van tryptofaan 
depletie (vermindering). Tryptofaan is de precursor van serotonine (de stof 
waaruit serotonine wordt opgebouwd) en veranderingen in de concentratie 
van deze stof leiden tot veranderingen in de mate van aanmaak van 
serotonine. Indien [
18F]-MPPF inderdaad gevoelig zou zijn voor 
veranderingen in de concentratie van serotonine dan zou de binding 
afnemen in de eerste en toenemen in de tweede conditie. Helaas werd in 
deze studie geen verschil gevonden tussen beide condities. Uit voorgaande 
studies is gebleken dat de condities die in deze studie zijn gebruikt leiden 
tot respectievelijk een tweevoudige toename en een halvering van de 
serotonineconcentratie. De conclusie was dat deze relatief kleine 
veranderingen geen meetbaar effect hebben op de binding van [
18F]-MPPF. 
Daarom werd in de volgende studie (hoofdstuk 3) het effect van veel 
grotere veranderingen in de serotonineconcentratie onderzocht. Deze studie 
werd uitgevoerd bij ratten vanwege mogelijk schadelijke bijwerkingen van 
deze hoge serotonineconcentraties bij de mens. De binding van [
18F]-MPPF 
werd bepaald in een controle conditie en na toediening van fenfluramine en 
een combinatie van ketanserine en citalopram. Fenfluramine remt de 
heropname en stimuleert de afgifte van serotonine en veroorzaakte in deze 
studie een 30-voudige verhoging van de serotonine concentratie. De 
combinatie van ketanserine en citalopram leidt eveneens tot een verhoogde 
afgifte en heropnameremming en resulteerde in een 10-voudige verhoging 
van de serotonine concentratie. Dit gedeelte van de studie werd uitgevoerd Samenvatting 
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bij wakkere ratten om eventuele effecten van anesthesie te vermijden. De 
[
18F]-MPPF binding werd vervolgens gemeten met behulp van 
autoradiografie, een methode waarbij het weefsel in plakjes wordt gesneden 
waarna de activiteit in verschillende hersengebieden kan worden bepaald. 
In deze studie zagen we een kleine afname in [
18F]-MPPF binding in een 
aantal hersengebieden na toediening van fenfluramine. Toediening van de 
combinatie van ketanserine en citalopram leidde niet tot veranderingen in 
[
18F]-MPPF binding. De binding van [
18F]-MPPF werd dus alleen beïnvloed 
bij zeer hoge serotonine concentraties. Omdat [
18F]-MPPF in deze studie 
werd toegediend als bolus (een kortdurende injectie), kan echter niet 
volledig worden uitgesloten dat de afname in binding werd veroorzaakt door 
een fenfluramine-geïnduceerde verandering in de doorbloeding. Een 
verandering in de doorbloeding kan dan namelijk effect hebben op de 
verdeling van het radioligand over het weefsel. Daarom werd in de derde 
studie (hoofdstuk 4) een methode gebruikt die ongevoelig is voor 
veranderingen in doorbloeding. [
18F]-MPPF werd hierbij toegediend als een 
bolus gevolgd door een continu infuus. Dit leidt ertoe dat de [
18F]-MPPF 
concentratie een evenwicht bereikt in het bloed en de hersenen waardoor 
mogelijke doorbloedings effecten worden geminimaliseerd. Deze studie 
werd uitgevoerd bij wakkere apen die waren getraind om stil te zitten in de 
PET camera. Ook in deze studie werd de serotonineconcentratie verhoogd 
door middel van fenfluramine waarbij dezelfde dosering werd gebruikt als in 
de vorige studie. Er werden echter geen consistente veranderingen in de 
binding van [
18F]-MPPF waargenomen. Hieruit kan geconcludeerd worden 
dat [
18F]-MPPF geen geschikt radioligand is om veranderingen in de 
serotonineconcentratie te meten. Toekomstig onderzoek zal moeten 
uitwijzen of radioliganden met andere eigenschappen misschien wel 
gevoelig zijn voor veranderingen in serotonine. Het is echter ook mogelijk 
dat het serotonerge systeem bepaalde kenmerken heeft waardoor de 
zogenaamde competitie methode hierbij niet kan worden toegepast. 
Meten van veranderingen in de dopamineconcentratie 
Uit voorgaande studies in andere onderzoekscentra is gebleken dat het wel 
mogelijk is om veranderingen in de dopamineafgifte te meten. Het volgende 
doel was het introduceren van zo’n methode in het PET centrum in 
Groningen. Dit onderzoek werd uitgevoerd bij gezonde vrijwilligers maar in Samenvatting 
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de toekomst zal deze methode mogelijk gebruikt kunnen worden bij 
patiënten met bijvoorbeeld depressie, verslaving of de ziekte van Parkinson. 
In  hoofdstuk 5 is een studie beschreven waarbij deze methode werd 
toegepast in combinatie met de dopamine heropnameremmer 
methylfenidaat, een stof die leidt tot een stijging van de dopamine 
concentratie in de hersenen. Op deze manier kan het functioneren van het 
dopaminerge systeem worden onderzocht. In deze studie werd gebruik 
gemaakt van het radioligand [
11C]-raclopride dat bindt aan de dopamine D2 
receptor. Deze binding is gevoelig voor veranderingen in de 
dopamineconcentratie. In deze studie werd ook weer gebruik gemaakt van 
de zogenaamde bolus-infusie methode waarbij effecten van veranderingen 
in doorbloeding kunnen worden vermeden. Omdat in voorgaande studies 
correlaties zijn gevonden tussen de binding van [
11C]-raclopride en 
subjectieve factoren zoals euforie en angst is daar in deze studie ook naar 
gekeken. Toediening van methylfenidaat leidde in deze studie bij de meeste 
proefpersonen tot een gevoel van euforie, een enkeling had nauwelijks 
effect. Verder lieten de resultaten van de studie een duidelijke afname zien 
van de [
11C]-raclopride binding, duidend op een verhoging van de 
dopamineconcentratie. De mate van euforie bleek gerelateerd te zijn aan de 
afname in [
11C]-raclopride binding in het dorsale striatum. Dit gebied ligt 
diep in de hersenen en is betrokken bij beloningsmechanismen. Ook werd 
een relatie gevonden tussen de mate van angst aan het begin van het 
experiment en de afname van [
11C]-raclopride in het dorsale en midden 
striatum. Bovendien bleek de mate van euforie af te hangen van de 
dopamine D2 receptor dichtheid. Proefpersonen met een lage receptor 
dichtheid rapporteerden een grotere mate van euforie na toediening van 
methylfenidaat dan mensen met een hoge receptor dichtheid. Deze 
resultaten laten zien dat binnen een groep van gezonde proefpersonen 
grote verschillen kunnen bestaan in reactie op bijvoorbeeld het toedienen 
van een geneesmiddel. Deze biologische verschillen kunnen ook een rol 
spelen bij de mate waarin mensen gevoelig zijn voor bepaalde 
psychiatrische aandoeningen. Zo kan de D2 receptor dichtheid mogelijk een 
rol spelen bij de gevoeligheid voor verslaving. Concluderend kunnen we 
zeggen dat uit onze resultaten is gebleken dat deze PET methode 
inderdaad kan worden gebruikt om verschillen in dopamineafgifte te meten. 
In de toekomst kan hiermee onderzoek worden gedaan naar mogelijke Samenvatting 
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verstoringen in de dopamineafgifte bij patiënten met psychiatrische of 
neurologische aandoeningen. Ook kan het effect van potentiële 
geneesmiddelen bij de behandeling van deze ziektebeelden worden 
onderzocht. 
Meten van veranderingen in hersenactiviteit 
De “competitie methode”, beschreven in de voorgaande hoofdstukken, 
maakt het mogelijk om regionale veranderingen in 
neurotransmitterconcentratie te meten. Deze methode geeft echter geen 
informatie over zogenaamde postsynaptishe effecten. Dit zijn de effecten 
die optreden zodra de neurotransmitter aan een receptor bindt. Deze 
binding kan bijvoorbeeld leiden tot een toename of afname in de activiteit 
van de doelcel. Omdat de cellen in de hersenen met elkaar in verbinding 
staan, kan deze binding uiteindelijk leiden tot veranderingen in de activiteit 
van een heel netwerk van hersengebieden. Met behulp van PET kunnen 
deze veranderingen in hersenactiviteit worden gemeten. Dit kan 
bijvoorbeeld door het inspuiten van [
15O]-H2O (radioactief water). Er wordt 
vanuit gegaan dat [
15O]-H2O vrij kan diffunderen (verspreiden) naar alle 
weefsels en dat de mate van opname in de weefsels gerelateerd is aan de 
doorbloeding. De verandering in doorbloeding in een bepaald gebied wordt 
gezien als een maat voor de locale hersenactiviteit. Uit voorgaande studies 
is gebleken dat cognitieve taken (voor het meten van mentale processen) of 
emoties leiden tot een toe- of afname van de activiteit in specifieke 
hersengebieden. Er is niet altijd sprake van een één op één relatie tussen 
dergelijke functies en een bepaald gebied; vooral bij meer complexe 
mentale functies of emoties zijn vaak meerdere gebieden betrokken. Toch is 
met behulp van deze methode veel informatie verkregen over de functie van 
specifieke hersengebieden. Vaak wordt de functie van zo’n gebied mede 
bepaald door de interactie met andere gebieden. Bij patiënten met 
psychiatrische of neurologische aandoeningen zijn regelmatig afwijkingen 
gevonden in dergelijke activatiepatronen. In de laatste studie van dit 
proefschrift, beschreven in hoofdstuk 6, werd onderzocht welk effect een 
verhoging van de dopamineconcentratie heeft op de hersenactiviteit. Deze 
studie werd eveneens uitgevoerd bij gezonde proefpersonen. In de 
toekomst kan deze methode mogelijk worden gebruikt om dopamine-
gerelateerde verstoringen in de hersenactiviteit te onderzoeken bij Samenvatting 
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psychiatrische patiënten. Ook in deze studie werd gebruik gemaakt van de 
dopamine heropnameremmer methylfenidaat. Bij elke persoon werden 
[
15O]-H2O scans gemaakt na placebo en na injectie van methylfenidaat. De 
subjectieve toestand van de proefpersonen werd tijdens het scannen zo 
veel mogelijk gestandaardiseerd door middel van een simpele taak: de 
“continuous performance task”. Dit werd gedaan om de variatie tussen 
proefpersonen te verkleinen. Na de injectie van placebo en methylfenidaat 
werd de subjectieve toestand van de proefpersonen genoteerd. Het effect 
van methylfenidaat varieerde in deze studie van nauwelijks merkbaar tot 
een sterk gevoel van euforie. Het belangrijkste resultaat was een 
methylfenidaat-geïnduceerde (relatieve) toename in activiteit in de “anterior 
cingulate cortex”. Deze toename bleek gerelateerd te zijn aan de mate van 
euforie. Uit de literatuur blijkt dat dit gebied betrokken is bij het controleren 
van de emotionele toestand. Ook zijn er in de “anterior cingulate cortex” 
afwijkingen gerapporteerd bij patiënten met depressie en verslaving. Het 
zou interessant zijn in toekomstige studies het effect van methylfenidaat te 
onderzoeken bij deze patiëntgroepen. Afwijkende activatiepatronen kunnen 
wellicht meer inzicht geven in de oorzaak en mogelijke behandeling van 
deze stoornissen.  
 
Samenvattend kan worden geconcludeerd dat de binding van [
18F]-MPPF 
niet gevoelig is voor (kleine) veranderingen in de concentratie van 
serotonine terwijl [
11C]-raclopride wel geschikt is als ligand voor het meten 
van veranderingen in de dopamineconcentratie. In hoofdstuk 7 worden 
een aantal factoren besproken die van invloed kunnen zijn op de resultaten 
van dergelijke “competitie studies”. Ook worden een aantal mogelijke 
oorzaken naar voren gebracht voor het verschil in toepasbaarheid van de 
“competitie methode” bij deze twee neurotransmittersystemen. Het is 
wellicht van belang dat de basale serotonineconcentratie veel lager is dan 
de basale dopamineconcentratie. Ook zijn er verschillen gevonden in 
affiniteit (geneigdheid tot binding aan de neurotransmitter) tussen de 5-HT1A 
en D2 receptor. Slechts een gedeelte van deze receptoren verkeerd in een 
toestand van hoge affiniteit en dit percentage is voor de D2 receptor veel 
hoger dan voor de 5-HT1A receptor. Uit ons onderzoek bleek ook dat de 
combinatie van [
15O]-H2O PET met methyfenidaat mogelijk geschikt is om 
dopamine-gerelateerde verstoringen in de hersenactiviteit van Samenvatting 
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psychiatrische patiënten te onderzoeken. In hoofdstuk 7 worden een aantal 
factoren besproken die van belang zijn bij de interpretatie van dergelijke 
studies. Als laatste worden een aantal persoonskenmerken genoemd die de 
resultaten van PET studies, zoals beschreven in dit proefschrift, kunnen 
beïnvloeden Zo zijn er aanwijzingen dat de persoonlijkheid van de 
proefpersoon, het geslacht en de leeftijd effect kunnen hebben op de 
uitkomst van deze studies. 
Black box? 
De werking van ons brein blijft in vele opzichten een raadsel. Niettemin is 
onze kennis over het functioneren van de hersenen de laatste decennia 
sterk toegenomen. Mede dankzij beeldvormende technieken zoals PET 
blijkt het steeds beter mogelijk om licht te werpen in de “black box”. Samenvatting 
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